<SEC-DOCUMENT>0001829126-23-003606.txt : 20230519
<SEC-HEADER>0001829126-23-003606.hdr.sgml : 20230519
<ACCEPTANCE-DATETIME>20230519092231
ACCESSION NUMBER:		0001829126-23-003606
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20230519
DATE AS OF CHANGE:		20230519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13341
		FILM NUMBER:		23938066

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>titanpharma_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ttnp="http://titanpharm.com/20221231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_ECD%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_ttnp_titanpharm.com_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20220101_20221231 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000910267 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DDocumentType_DEF 14A -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityCentralIndexKey">0000910267</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:DocumentType">DEF 14A</ix:nonNumeric>
  <ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2021-01-012021-12-31_custom_DavidLazarMember" id="xdx2ixbrl0024" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2021-01-012021-12-31_custom_DavidLazarMember" id="xdx2ixbrl0025" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" id="xdx2ixbrl0042" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" id="xdx2ixbrl0049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" id="xdx2ixbrl0062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" id="xdx2ixbrl0069" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ttnp-20221231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MarcRubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:MarcRubinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DavidLazarMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DavidLazarMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NonpeoNeosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:NonpeoNeosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MarcRubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:MarcRubinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DavidLazarMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DavidLazarMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NonpeoNeosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:NonpeoNeosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrRubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrRubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000910267</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES AND EXCHANGE COMMISSION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington, D.C. 20549</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">SCHEDULE&#160;14A</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Rule&#160;14a-101)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION REQUIRED IN PROXY STATEMENT</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE&#160;14A
INFORMATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: normal">Proxy Statement Pursuant to Section&#160;14(a) of the</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Securities
Exchange Act of 1934</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">(Amendment
No.&#160;&#160;)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by the Registrant &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
by a Party other than the Registrant &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.35in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy
    Statement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential, for Use of the
    Commission Only (as permitted by Rule&#160;14a-6(e)(2))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material under
    &#167;240.14a-12</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20220101__20221231_zn1VLdxlZbu1"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="dei:EntityRegistrantName">Titan
                                            Pharmaceuticals, Inc.</ix:nonNumeric></span></b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of
    Registrant as Specified In Its Charter)</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>&#160;</b></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of
    Persons(s) Filing Proxy Statement, if other than the Registrant)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of Filing Fee (Check all boxes that apply):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.35in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    fee required</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid
    previously with preliminary materials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed
    on table in exhibit required by Item&#160;25(b) per Exchange Act Rules&#160;14a-6(i)(1) and 0-11</span></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TITAN
PHARMACEUTICALS, INC.<br />
400 Oyster Point Boulevard, Suite 505<br />
South San Francisco, California 94080<br />
<br />
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS<br />
To be held June&#160;29, 2023</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders of Titan Pharmaceuticals, Inc.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual meeting of stockholders (the &#8220;Annual Meeting&#8221;) of Titan Pharmaceuticals, Inc. (the &#8220;Company,&#8221; &#8220;Titan,&#8221;
&#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) will be held at the offices of Olshan Frome Wolosky LLP, located at 1325 Avenue
of the Americas, 15th Floor, New York, New York 10019, on Thursday, June&#160;29, 2023 at 9:00 a.m. (EST) for the following purposes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            elect a board of seven (7) directors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            approve the amendment and restatement of our 2015 Omnibus Equity Incentive Plan (the &#8220;2015
                                            Plan&#8221;) to (i) increase the total number of shares authorized for issuance thereunder
                                            from 1,000,000 to 2,500,000 and (ii) increase the number of shares of common stock that may
                                            be granted as awards to any individual in a single year from 150,000 to 200,000 (the &#8220;Amended
                                            and Restated Plan&#8221;);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            consider a non-binding advisory vote on executive compensation;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            ratify the appointment of WithumSmith+Brown, PC (&#8220;Withum&#8221;) as our independent
                                            registered public accounting firm for the fiscal year ending December&#160;31, 2023; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            consider and take action upon such other matters as may properly come before the Annual Meeting
                                            or any adjournment thereof.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
close of business on May&#160;1, 2023 has been fixed as the record date for the determination of stockholders entitled to notice of,
and to vote at, the Annual Meeting or any adjournment thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are cordially invited to attend the Annual Meeting in person. However, to assure your representation at the Annual Meeting, please mark,
sign, date and return your proxy as promptly as possible in the enclosed postage-prepaid envelope (which will be provided to those stockholders
who request to receive paper copies of these materials by mail). If you attend the Annual Meeting you may vote in person, even if you
returned a proxy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Please
note, if your shares are held in street name, your broker, trust, bank or other nominee holder cannot vote your shares on the election
of directors or approval of the Amended and Restated Plan unless you instruct the nominee holder how to vote by marking your form of
proxy and returning it as instructed</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPORTANT
NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON JUNE&#160;29, 2023, AT 9:00 A.M., EASTERN TIME.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
permitted by the &#8220;Notice and Access&#8221; rules of the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Notice
of Annual Stockholder Meeting, our Proxy Statement, a form of the proxy card and our Annual Reports on Form&#160;10-K for the years ended
December&#160;31, 2022 and December&#160;31, 2021 (the &#8220;Annual Reports&#8221;) are available online at https://ir.titanpharm.com/.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or about May&#160;19, 2023, we commenced mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the &#8220;Notice
of Internet Availability&#8221;) that contains instructions on how stockholders may access and review all of the proxy materials and
how to vote. Also on or about May&#160;19, 2023, we began mailing printed copies of the proxy materials to stockholders that previously
requested printed copies. If you received a Notice of Internet Availability by mail, you will not receive a printed copy of the proxy
materials in the mail unless you request a copy. If you received a Notice of Internet Availability by mail and would like to receive
a printed copy of our proxy materials, you should follow the instructions for requesting such materials included in the Notice of Internet
Availability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
stockholders of the Company are cordially invited to attend the Annual Meeting in person. To assure your representation at the Annual
Meeting, however, you are urged to mark, sign and return the proxy as promptly as possible. If you later desire to revoke your proxy
for any reason, you may do so in the manner provided in the Proxy Statement. Your shares of the Company&#8217;s common stock will be
voted in accordance with the instructions you give in your proxy. You will find more instructions on how to vote in the Proxy Statement
and the Notice of Internet Availability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may submit a proxy for your shares by mail, fax, email or via the internet no later than 5:00 p.m., Eastern time, on June&#160;28, 2022
(as directed on the proxy card). If you choose to submit your proxy card by mail, the Company has enclosed an envelope for your use,
which is prepaid if mailed in the United States. If you attend the Annual Meeting and your shares are registered in your name, you may
also vote in person at the Annual Meeting until voting is closed. If your shares are held through a bank, broker or other nominee, because
you are not the stockholder of record, you may not vote your shares in person at the Annual Meeting unless you request and obtain a valid
proxy in your name from your broker, bank or other nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accompanying
this Notice of Annual Meeting to the Company&#8217;s stockholders are (a) the Proxy Statement, and (b) a form of proxy (or a voting instruction
form if you hold shares of common stock through a broker or other intermediary).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>YOUR
VOTE IS IMPORTANT REGARDLESS OF THE NUMBER OF SHARES YOU OWN.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
enclosed materials require the Company&#8217;s stockholders to make important decisions with respect to the Company. Please read carefully
the accompanying Proxy Statement, as these documents contain detailed information relating to, among other things, the dissolution of
the Company. If you are in doubt as to how to make these decisions, please consult your financial, legal or other professional advisors.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEITHER
THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED ANY OF THE
MATTERS TO BE ACTED UPON AT THE ANNUAL MEETING, PASSED UPON THE MERITS OR FAIRNESS OF SUCH MATTERS OR PASSED UPON THE ADEQUACY OR ACCURACY
OF THE DISCLOSURE IN THIS PROXY STATEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you have any questions, or need assistance in voting your shares, please contact our transfer agent, which is assisting us in the solicitation
of proxies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINENTAL
STOCK TRANSFER &amp; TRUST COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1
State Street, 30<sup>th</sup> Floor</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
York, New York 10004</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attn:
Mark Tumulty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
Order of the Board of Directors,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David E. Lazar<br />
<i>Chief Executive Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May&#160;18,
2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TITAN
PHARMACEUTICALS, INC.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400 Oyster Point Boulevard, Suite 505</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South San Francisco, California 94080</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROXY STATEMENT</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNUAL MEETING OF STOCKHOLDERS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are furnishing this proxy statement (&#8220;Proxy Statement&#8221;) to the holders of our common stock in connection with the solicitation
of proxies on behalf of our board of directors (the &#8220;Board&#8221;) for use at our annual meeting of stockholders (the &#8220;Annual
Meeting&#8221;) to be held at the offices of Olshan Frome Wolosky LLP, located at 1325 Avenue of the Americas, 15th Floor, New York,
New York 10019, on Thursday, June&#160;29, 2023 at 9:00 a.m. (EST), and any adjournment thereof. We will bear the cost of soliciting
proxies. In addition to solicitation of proxies by mail, our employees, without extra remuneration, may solicit proxies personally or
by telephone. We will reimburse brokerage firms and other custodians, nominees and fiduciaries for their reasonable out-of-pocket expenses
for forwarding proxy materials to beneficial owners and seeking instruction with respect thereto. We are furnishing proxy materials,
which include this Proxy Statement, to our stockholders over the internet, and providing a Notice of Internet Availability of Proxy Materials
(the &#8220;Notice of Internet Availability&#8221;) by mail. We mailed the Notice of Internet Availability on or about May&#160;19, 2023
to our stockholders of record and beneficial owners as of May&#160;1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
Report on Form&#160;10-K</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 as filed with the SEC (the &#8220;2022 10-K&#8221;) and our
Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 as filed with the SEC are accessible free of charge on our
website at https://ir.titanpharm.com/all-sec-filings. The 2022 10-K contains audited financial statements covering our fiscal years ended
December&#160;31, 2022 and 2021. You can request a copy of the 2022 10-K free of charge by calling 1-650-989-2268 or sending an e-mail
to bcrowley@titanpharm.com. Please include your contact information with the request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL
INFORMATION ABOUT VOTING</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Record
Date</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
the holders of record of our common stock at the close of business on the record date, May&#160;1, 2023 (the &#8220;Record Date&#8221;),
are entitled to notice of and to vote at the Annual Meeting. On the Record Date, there were 15,016,295 shares of our common stock outstanding.
Stockholders are entitled to one vote for each share of common stock held on the Record Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent
with Delaware law and our bylaws, the presence, in person or by proxy, of at least thirty-four percent (34%) of the shares entitled to
vote at the Annual Meeting will constitute a quorum for purposes of voting on a particular matter at the Annual Meeting. Once a share
is represented for any purpose at the Annual Meeting, it is deemed present for quorum purposes for the remainder of the meeting and any
adjournment thereof unless a new record date is set for the adjournment. If a quorum is not present, the Annual Meeting will be adjourned
until a quorum is obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a proxy is properly executed and returned (and not subsequently properly revoked), the shares it represents will be voted in accordance
with the directions indicated thereon, or, if no direction is indicated thereon, it will be voted:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
                                            </b>the election of the seven (7) director nominees identified therein;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
                                            </b>the approval of the amendment and restatement of our Third Amended and Restated 2015
                                            Omnibus Equity Incentive Plan (the &#8220;2015 Plan&#8221;) to (i) increase the total number
                                            of shares authorized for issuance thereunder from 1,000,000 to 2,500,000 and (ii) increase
                                            the number of shares of common stock that may be granted as awards to any individual in a
                                            single year from 150,000 to 200,000 (the &#8220;Amended and Restated Plan&#8221;);</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
                                            </b>the approval, on an advisory basis, of the compensation of the Company&#8217;s named
                                            executive officers;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
                                            </b>the ratification of the appointment of WithumSmith+Brown, PC (&#8220;Withum&#8221;) to
                                            serve as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the discretion of the proxies with respect to any other matters properly brought before the
                                            stockholders at the Annual Meeting.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Votes
Required for Approval</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Proposal
No. 1: Election of Directors.</i> The election of directors will be determined by a plurality of the votes cast. This means that the
seven (7) nominees receiving the highest number of &#8220;FOR&#8221; votes will be elected as directors. Votes may be cast for or withheld
from the directors. In a plurality election, votes may only be cast in favor of or withheld from each nominee; votes that are withheld
will be excluded entirely from the vote and will have no effect on the results of the election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Proposal
No. 2: Approval of the Amended and Restated Plan. </i>To be approved, the proposal to approve the Amended and Restated Plan to (i) increase
the total number of shares authorized for issuance thereunder from 1,000,000 to 2,500,000 and (ii) increase the number of shares of common
stock that may be granted as awards to any individual in a single year from 150,000 to 200,000 must receive an affirmative vote of the
holders of a majority of the common stock having voting power present in person or represented by proxy. Abstentions will have the same
effect as a vote &#8220;AGAINST&#8221; this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Proposal
No. 3: Advisory Vote on Executive Compensation</i>. The advisory (non-binding) approval of the compensation of the Company&#8217;s named
executive officers requires the favorable vote of the holders of a majority of the common stock having voting power present in person
or represented by proxy and entitled to vote thereon. Abstentions will have the same effect as a vote &#8220;AGAINST&#8221; this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Proposal
No. 4: Ratification of Independent Registered Public Accounting Firm.</i> To be approved, the proposal to ratify our selection of an
independent registered public accounting firm must receive an affirmative vote of the holders of a majority of the common stock having
voting power present in person or represented by proxy. Abstentions will have the same effect as a vote &#8220;AGAINST&#8221; this proposal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker
Non-Votes</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;broker non-vote&#8221; occurs when a broker, bank, or other holder of record holding shares for a beneficial owner does not vote
on a particular proposal because that holder (i) has not received instructions from the beneficial owner and (ii) does not have discretionary
voting power for that particular item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are a beneficial owner and you do not give instructions to your broker, bank, or other holder of record, such holder of record will
be entitled to vote the shares with respect to &#8220;routine&#8221; items but will not be permitted to vote the shares with respect
to &#8220;non-routine&#8221; items (those shares are treated as &#8220;broker non-votes&#8221;). If you are a beneficial owner, your
broker, bank, or other holder of record has discretion to vote your shares on the proposal to ratify the appointment of Withum as our
independent registered public accounting firm if the holder of record does not receive voting instructions from you. However, such holder
of record may not vote your shares on the election of directors or the proposal to approve the Amended and Restated Plan without your
voting instructions on such proposals. Accordingly, without your voting instructions on these proposals, a broker non-vote will occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Proposal No. 1 (the election of directors) and Proposal No. 2 (the approval of the Amended and Restated Plan), broker non-votes,
if any, will be disregarded and have no effect on the outcome of the vote. Because Proposal No. 3 (the advisory vote on executive compensation)
and Proposal No. 4 (the ratification of our selection of an independent registered public accounting firm) are routine proposals on which
a broker or other nominee is generally empowered to vote in the absence of voting instructions from the beneficial owner, broker non-votes
are unlikely to result from these proposals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
encourage you to provide instructions to your bank, brokerage firm, or other nominee by voting your proxy. This action ensures that your
shares will be voted in accordance with your wishes at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revocability
of Proxies</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may revoke any proxy given in response to this solicitation by notifying the Company in writing at the above address, attention: Corporate
Secretary by 5:00 p.m. (EST) on June&#160;28, 2023, or by voting a subsequent proxy or in person at the Annual Meeting. Attendance by
a stockholder at the Annual Meeting does not alone serve to revoke a proxy. If a broker, trust, bank or other nominee holds your shares,
please follow the instructions you receive from that person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;Notice
and Access&#8221; Method of Delivery</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are using the SEC&#8217;s Notice and Access model (&#8220;Notice and Access&#8221;), which allows us to deliver proxy materials over
the internet, as the primary means of furnishing proxy materials. We believe Notice and Access provides stockholders with a convenient
method to access the proxy materials and vote, while allowing us to conserve natural resources and reduce the costs of printing and distributing
the proxy materials. On or about May&#160;19, 2023, we began mailing to stockholders a Notice of Internet Availability containing instructions
on how to access our proxy materials on the internet and how to vote online. The Notice of Internet Availability is not a proxy card
and cannot be used to vote your shares. If you received a Notice of Internet Availability this year, you will not receive paper copies
of the proxy materials unless you request the materials by following the instructions on the Notice of Internet Availability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of the Notice of Annual Meeting, Proxy Statement and the 2022 10-K, as well as other materials filed by the Company with the SEC, are
available without charge to stockholders on the Company&#8217;s corporate website at www.titanpharm.com or upon written request to the
Company at Titan Pharmaceuticals, Inc., 400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080. You can elect to
receive future annual reports, proxy statements and other proxy materials electronically by marking the appropriate box on your proxy
card or vote instruction form or by following the instructions provided if you submit a proxy by fax or via the internet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
of Documents to Stockholders Sharing an Address</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that permit companies to deliver a single Notice of Internet Availability or a single copy of proxy materials to
multiple stockholders sharing an address unless a company has received contrary instructions from one or more of the stockholders at
that address. Upon request, we will promptly deliver a separate Notice of Internet Availability or separate copy of proxy materials to
one or more stockholders at a shared address to which a single Notice of Internet Availability or a single copy of proxy materials was
delivered. Stockholders may request a separate Notice of Internet Availability or separate copy of proxy materials by contacting our
Vice President, Finance either by calling 1-650-989-2268 or by mailing a request to 400 Oyster Point Boulevard, Suite 505, South San
Francisco, California 94080.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
at a shared address who receive multiple Notices of Internet Availability or multiple copies of proxy materials may request to receive
a single Notice of Internet Availability or a single copy of proxy materials in the future in the same manner as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE
GOVERNANCE</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Composition</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is currently comprised of eleven (11) directors: Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Katherine Beebe DeVarney,
Ph.D., Eric Greenberg, David E. Lazar, M. David MacFarlane, Ph.D., James R. McNab, Jr., Matthew C. McMurdo, David Natan and Marc Rubin,
M.D. Dr. Rubin and Messrs. Akers, MacFarlane and McNab are not standing for re-election at the Annual Meeting, and their respective current
terms of office as a director will end as of Thursday, June&#160;29, 2023 at 9:00 a.m. (EST), irrespective of quorum or outcome of the
Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independence
of Directors</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following individuals meet the independence requirements and standards currently established by the NASDAQ Stock Market (&#8220;Nasdaq&#8221;):
Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Ph.D., James R. McNab, Jr., Matthew C. McMurdo
and David Natan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Diversity Matrix (As of May&#160;18, 2023)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellspacing="0" cellpadding="3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="5" style="border: Black 1pt solid; text-align: left; background-color: lightgrey; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Size:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Number of Directors </span></td>
    <td colspan="4" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left; width: 52%">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 3.1pt; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Binary </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Did not Disclose Gender </b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; background-color: lightgrey; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Gender:</b></p>

</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #D9D9D9">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Directors who identify in Any of the Categories Below: </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">White </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two or More Races or Ethnicities </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+ </span></td>
    <td colspan="4" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons with Disabilities<span style="color: #4BACC6"><i></i></span></span></td>
    <td colspan="4" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did Not Disclose Demographic Background</span></td>
    <td colspan="4" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Committees</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has established the following three standing committees: audit committee; compensation committee; and nominating and governance
committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee was formed in compliance with Section&#160;3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), and currently consists of Joseph A. Akers, M. David MacFarlane, Ph.D., Matthew C. McMurdo, James R. McNab, Jr. and David
Natan (chair), each of whom meets the independence requirements and standards currently established by Nasdaq and the SEC. In addition,
the Board has determined that each of Joseph A. Akers and David Natan are &#8220;audit committee financial experts&#8221; and &#8220;independent&#8221;
as defined under the relevant rules of the SEC and Nasdaq. The audit committee assists the Board by overseeing the performance of the
independent auditors and the quality and integrity of Titan&#8217;s internal accounting, auditing and financial reporting practices.
The audit committee is responsible for retaining (subject to stockholder ratification) and, as necessary, terminating, the independent
auditors, annually reviewing the qualifications, performance and independence of the independent auditors and the audit plan, fees and
audit results, and pre-approving audit and non-audit services to be performed by the auditors and related fees. The audit committee met
four times during the fiscal year ended December&#160;31, 2021 and four times during the fiscal year ended December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee makes recommendations to the Board concerning salaries and incentive compensation for our officers, including
our principal executive officer, and employees and administers our stock option plans. The compensation committee currently consists
of Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Ph.D., James R. McNab, Jr. and David Natan
(chair), each of whom meets the independence requirements and standards currently established by Nasdaq. The compensation committee met
one time during the fiscal year ended December&#160;31, 2021 and four times during the fiscal year ended December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the nominating and governance committee is to assist the Board in identifying qualified individuals to become Board members,
in determining the composition of the Board and in monitoring the process to assess Board effectiveness. The nominating and governance
committee first considers a candidate&#8217;s management experience and then considers issues of judgment, background, stature, conflicts
of interest, integrity, ethics, and commitment to the goal of maximizing stockholder value when considering director candidates. The
nominating and governance committee also focuses on issues of diversity, such as diversity of gender, race and national origin, education,
professional experience, and differences in viewpoints and skills. The nominating and governance committee does not have a formal policy
with respect to diversity; however, our Board and the nominating and governance committee believe that it is essential that the directors
represent diverse viewpoints. In considering candidates for our Board, the nominating and governance committee considers the entirety
of each candidate&#8217;s credentials in the context of these standards The nominating and governance committee consists of Joseph A.
Akers, Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, M. David MacFarlane, Ph.D., and James R. McNab, Jr. (chair), each of whom meets
the independence requirements and standards currently established by Nasdaq. The nominating and governance committee met one time during
the fiscal year ended December&#160;31, 2021 and did not meet during the fiscal year ended December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
charters for the audit, compensation and nominating and governance committees, which have been adopted by our Board, contain detailed
descriptions of the committees&#8217; duties and responsibilities and are available in the &#8220;About Titan&#8221; section of our website
at <i>www.titanpharm.com.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Leadership Structure</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
chief executive officer and chairman of the Board positions are both held by David E. Lazar. The Board believes this is currently the
most appropriate and effective leadership structure given the size and activities of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Role
of the Board in Risk Oversight</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee is primarily responsible for overseeing our risk management processes on behalf of the full Board. The audit committee
receives reports from management at least quarterly regarding our assessment of risks. In addition, the audit committee reports regularly
to the full Board, which also considers our risk profile. The audit committee and the full Board focus on the most significant risks
we face and our general risk management strategies. While the Board oversees our risk management, our management team is responsible
for day-to-day risk management processes. Our Board expects management to consider risk and risk management in each business decision,
to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk
management strategies adopted by the audit committee and the Board. We believe this division of responsibilities is the most effective
approach for addressing the risks we face and that our Board leadership structure, which also emphasizes the independence of the Board
in its oversight of its business and affairs, supports this approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
Meetings</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business affairs are managed under the direction of our Board, which is currently comprised of eleven (11) members. The primary responsibilities
of the Board are to provide oversight, strategic guidance, counseling and direction to our management. During the fiscal year ended December&#160;31,
2021, the Board met six times and took action by written consent one time. During the fiscal year ended December&#160;31, 2022, the Board
met 32 times and took action by written consent one time. With the exception of Dr. Rubin, who is not standing for re-election at the
Annual Meeting, no director attended fewer than 75% of the meetings of the Board and Board committees of which the director was a member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
Attendance at the Annual Meeting</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not have a formal policy regarding attendance by members of our Board at the Annual Meeting, we encourage all of our directors
to attend. All of our directors attended last year&#8217;s annual meeting, either in-person or telephonically.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
of Ethics</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted a Code of Business Conduct and Ethics (the &#8220;Code of Ethics&#8221;) in February&#160;2013 that applies to all directors,
officers and employees. The Code of Ethics was filed as an exhibit to our Annual Report on Form&#160;10-K for the year ended December&#160;31,
2012 and is available on our website at www.titanpharm.com as part of that report. A copy of the Code of Ethics will also be provided
to any person without charge, upon written request sent to us at our offices located at 400 Oyster Point Blvd, Suite 505, South San Francisco,
California 94080.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading and Hedging Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insider trading policy, which applies to our employees, officers, directors, scientific advisors and consultants, expressly prohibits
purchasing or selling our securities while in possession of material, non-public information, or otherwise using such information for
their personal benefit. This policy also prohibits engaging in short-term or speculative transactions with respect to our securities,
including through the use of certain financial instruments or derivative transactions, trading in derivative securities related to our
securities, which include publicly traded call and put options, engaging in short selling of our common stock, purchasing our common
stock on margin and pledging our shares as collateral for a loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Communications
with the Board</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
can mail communications to the Board, c/o Titan Pharmaceuticals, Inc., 400 Oyster Point Blvd, Suite 505, South San Francisco, California
94080, who will forward the correspondence to each addressee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Officers</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
L. Lazar serves as Chief Executive Officer of the Company and Katherine Beebe DeVarney, Ph.D. serves as President and Chief Operating
Officer of the Company. The full biographical information for Mr. Lazar and Dr. Beebe DeVarney is provided below under the heading &#8220;Directors
Nominated for Re-Election.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of the Audit Committee of the Board of Directors</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of the Company&#8217;s 2022 10-K filing, the audit committee was comprised of Joseph A. Akers, M. David MacFarlane, Ph.D., Matthew
C. McMurdo, James R. McNab, Jr. and David Natan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee has reviewed and discussed the audited financial statements for the fiscal years ended December&#160;31, 2022 and December&#160;31,
2021 with management of the Company. The audit committee has discussed with the independent registered public accounting firm the matters
required to be discussed by Auditing Standard No. 1301, Communications with Audit Committees, as adopted by the Public Company Accounting
Oversight Board (&#8220;PCAOB&#8221;). The audit committee has also received the written disclosures and the letter from the independent
registered public accounting firm required by applicable requirements of the PCAOB regarding the independent accountants&#8217; communications
with the audit committee concerning independence and discussed with the independent registered public accounting firm the accounting
firm&#8217;s independence. Based on the foregoing, the audit committee recommended to the Board that the audited financial statements
be included in the 2022 10-K for filing with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respectfully
submitted by the audit committee,<br />
<br />
Joseph A. Akers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.
David MacFarlane, Ph.D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
C. McMurdo</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
R. McNab, Jr.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Natan, Chair</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth as of the Record Date, the number of shares of our common stock beneficially owned by (i) each person who
is known by us to be the beneficial owner of more than five percent of our common stock; (ii) each current director and director nominee;
(iii) each of the named executive officers; and (iv) all directors and executive officers as a group. As of the Record Date, we had 15,016,295
shares of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
Unless otherwise indicated, the stockholders listed in the table have sole voting and investment power with respect to the shares indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
and Address of Beneficial Owner<sup>(1)</sup></b></span></p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares<br />
Beneficially<br />
Owned<sup>(2)</sup></b></span></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percent
of<br />
Shares<br />
Beneficially<br />
Owned</b></span></p></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph A. Akers<sup>(3)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,504</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Avraham Ben-Tzvi</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Peter L. Chasey</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kate Beebe DeVarney, Ph.D.<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,613</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Eric Greenberg</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David E. Lazar<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,747,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.96</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. David MacFarlane, Ph.D.<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James R. McNab, Jr.<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">89,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Matthew C. McMurdo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">David Natan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc Rubin, M.D.<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All executive officers and directors as a group (11) persons<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,342,921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.9</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than one percent.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, the address of such individual is c/o Titan Pharmaceuticals, Inc., 400 Oyster Point Boulevard, Suite 505, South
San Francisco, California 94080.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
computing the number of shares beneficially owned by a person and the percentage ownership of a person, shares of our common stock subject
to options or warrants held by that person that are currently exercisable or exercisable within 60 days of the Record Date are deemed
outstanding. Such shares, however, are not deemed outstanding for purposes of computing the percentage ownership of each other person.
Except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table
have sole voting and investment power with respect to all shares of common stock.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 35,207 shares issuable upon exercise of outstanding options and (ii) 1,112 shares issuable upon exercise of outstanding warrants.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
206,533 shares issuable upon exercise of outstanding options.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
359,066 shares of Common Stock directly beneficially owned by Activist Investing, LLC. By virtue of his position as the sole member and
Chief Executive Officer of Activist Investing, LLC, Mr. Lazar may be deemed to be the beneficial owner of these shares.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 35,220 shares issuable upon exercise of outstanding options and (ii) 445 shares issuable upon exercise of outstanding warrants.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 35,207 shares issuable upon exercise of outstanding options, (ii) 1,112 shares issuable upon exercise of outstanding warrants and
(iii) 51,021 shares owned by JT Pharma. Mr. McNab is a principal of JT Pharma and has voting and dispositive power with respect to these
shares.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 220,264 shares issuable upon exercise of outstanding options and (ii) 2,223 shares issuable upon exercise of outstanding warrants.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
(i) 532,431 shares issuable upon exercise of outstanding options and (ii) 4,892 shares issuable upon exercise of outstanding warrants
held by our executive officers and directors listed above.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL
NO. 1<br />
<br />
ELECTION OF DIRECTORS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is currently comprised of eleven (11) directors: Joseph A. Akers, Avraham Ben-Tzvi, Peter L. Chasey, Katherine Beebe DeVarney,
Ph.D., Eric Greenberg, David E. Lazar, M. David MacFarlane, Ph.D., James R. McNab, Jr., Matthew C. McMurdo, David Natan and Marc Rubin,
M.D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Annual Meeting, seven (7) directors will be elected by the stockholders to serve until the next annual meeting of stockholders or
until their successors are elected and shall qualify. It is intended that the accompanying proxy will be voted for the election, as directors,
of Avraham Ben-Tzvi, Katherine Beebe DeVarney, Ph.D., Peter L. Chasey, Eric Greenberg, David E. Lazar, Matthew C. McMurdo and David Natan
unless the proxy contains contrary instructions. We have no reason to believe that any of the nominees will not be a candidate or will
be unable to serve. In the event that any of the nominees should become unable or unwilling to serve as a director, however, the persons
named in the proxy have advised that they will vote for the election of such person or persons as shall be designated by the directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Rubin and Messrs. Akers, MacFarlane and McNab are not standing for re-election at the Annual Meeting, and their respective current terms
of office as a director will end as of Thursday, June&#160;29, 2023 at 9:00 a.m. (EST), irrespective of quorum or outcome of the Annual
Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are appointed for a one-year term to hold office until the next annual meeting of our stockholders or until they resign or
are removed from office in accordance with our bylaws. Set forth below are the respective principal occupations or brief employment histories
of our directors, including the seven nominees. There are no family relationships among any of our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
Nominated for Re-Election</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Avraham
Ben-Tzvi, Adv. </i></b>(52) is the Founder of ABZ Law Office, a boutique Israeli law firm specializing in outsourced general counsel
services for publicly traded as well as private companies and corporations, Investments &amp; Securities Laws, Commercial Law &amp; Contracts
and various civil law matters, which he established in January&#160;2017. Mr. Ben-Tzvi served as Chief Legal Officer and General Counsel
of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies
to overcome tumor immune evasion and drug resistance, from November&#160;2015 until April&#160;2020. Prior to that, Mr. Ben-Tzvi served
as General Counsel and Company Secretary at Medigus Ltd. (NASDAQ/TASE: MDGS), a minimally invasive endosurgical tools medical device
and miniaturized imaging equipment company, from April&#160;2014 until November&#160;2015. Prior to that he served as an attorney at
one of Israel&#8217;s leading international law firms where, amongst other corporate and commercial work, he advised companies and underwriters
on various offerings by Israeli companies listing in the US and on various SEC related filings. Prior to becoming a lawyer, Mr. Ben-Tzvi
worked in a number of business development, corporate finance and banking roles at companies in the financial services, lithium battery
manufacturing and software development industries. Mr. Ben-Tzvi holds a B.A., <i>magna cum laude</i>, in Economics from Yeshiva University
in New York and an LL.B., <i>magna cum laude</i> with Honors from Sha&#8217;arei Mishpat College of Law in Hod HaSharon, Israel. Mr.
Ben-Tzvi is a member of the Israel Bar Association, and is also licensed as a Notary by the Israeli Ministry of Justice. Based on Mr.
Ben-Tzvi&#8217;s extensive legal experience and knowledge in the fields of civil-commercial law and corporate and securities law, and
his previous public company and commercial business experience, our Board believes that Mr. Ben-Tzvi has the appropriate set of skills
to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Katherine
Beebe DeVarney, Ph.D</i></b>. (62) joined Titan in February&#160;2007 and currently serves as our President and Chief Operating Officer
since October&#160;2020. She has been a member of the Board since December&#160;2019. During her 15 years with us, she has served in
various scientific and medical research and development capacities, with primary responsibility for oversight of our product research
and development, Regulatory Affairs, and Medical Affairs. Dr. Beebe DeVarney has 24 years of experience as a Neuroscientist in the pharmaceutical
industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics.
Prior to her pharmaceutical career, Dr. Beebe DeVarney was a hospital-based clinician and worked in academic medicine for 10 years. She
received her Ph.D. in Clinical Neuropsychology from George Mason University, and completed a two-year post-doctoral fellowship at Graduate
Hospital and the University of Pennsylvania. Based on Dr. Beebe DeVarney&#8217;s extensive knowledge of the medical, research, and regulatory
requirements of product development programs, our Board believes that Dr. Beebe DeVarney has the appropriate set of skills to serve as
a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Peter
L. Chasey, Esq.</i></b> (49) currently serves as the Owner of Chasey Law Offices, a law practice specializing in personal litigation,
business litigation and commercial law, since founding the practice in 2005. Earlier in his career, Mr. Chasey served as staff counsel
for one of the largest insurance companies in the world defending general claims against insured businesses and also served as a land
surveyor. Mr. Chasey holds a B.S. in Political Science and Government from the University of San Diego and a J.D. from the University
of San Diego School of Law. Based on Mr. Chasey&#8217;s commercial law expertise, coupled with his experience leading his own law firm,
our Board believes that Mr. Chasey has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eric
Greenberg</i></b> (58), has over 40 years of capital markets experience. As a trader and portfolio manager at hedge funds, his areas
of expertise included the development of trading strategies, portfolio management and deal structuring. Mr. Greenberg was Co-Founder
of Blink Charging Co. (NASDAQ: BLNK), a leader in the EV charging infrastructure industry. In addition, Mr. Greenberg provides investor
relation and digital marketing services for companies across a variety of industries, such as life sciences, fintech, internet platforms
and others. Mr. Greenberg holds a B.B.A in Finance from Baruch College and an M.B.A. in Finance from Baruch College Zicklin School of
Business. Based on Mr. Greenberg&#8217;s more than 40 years&#8217; experience in trading, developing strategies, and portfolio management
and public markets experience in the microcap sector, our Board believes that Mr. Greenberg has the appropriate set of skills to serve
as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>David
E. Lazar</i></b> (32) has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed
public companies through custodianship, since February&#160;2018, and Activist Investing LLC, an actively managed investment fund, since
March&#160;2018. Previously, Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm,
from July&#160;2012 to April&#160;2018. In his role as Chief Executive Officer of Custodian Ventures LLC, Mr. Lazar has successfully
served as a custodian to numerous public companies across a wide range of industries, including without limitation, C2E Energy, Inc.
(OTCMKTS: OOGI), China Botanic Pharmaceutical Inc. (OTCMKTS: CBPI), One 4 Art Ltd., Romulus Corp., Moveix, Inc., Arax Holdings Corp.
(OTCMKTS: ARAT), ESP Resources, Inc. (OTCMKTS: ESPIQ), Adorbs, Inc., Exobox Technologies Corp. (OTCMKTS: EXBX), Petrone Worldwide, Inc.
(OTCMKTS: PFWIQ), Superbox, Inc. (OTCMKTS: SBOX), Sino Green Land Corp. (OTCMKTS: SGLA), SIPP International Industries, Inc. (OTCMKTS:
SIPN), Cereplast, Inc. (OTCMKTS: CERPQ), Energy 1 Corp. (OTCMKTS: EGOC), ForU Holdings, Inc. (OTCMKTS: FORU), China Yanyuan Yuhui National
Education Group, Inc. (OTCMKTS: YYYH), Pan Global Corp. (OTCMKTS: PGLO), Shengtang International, Inc. (OTCMKTS: SHNL), Alternaturals,
Inc. (OTCMKTS: ANAS), USA Recycling Industries, Inc. (OTCMKTS: USRI), Tele Group Corp., Xenoics Holdings, Inc. (OTCMKTS: XNNHQ), Richland
Resources International Group, Inc. (OTCMKTS: RIGG), AI Technology Group, Inc., Reliance Global Group, Inc. (NASDAQ: RELI), Melt, Inc.,
Ketdarina Corp., 3D MarkerJet, Inc. (OTCMKTS: MRJT), Lvpai Group Ltd., Gushen, Inc., FHT Future Technology Ltd., Inspired Builders, Inc.,
Houmu Holdings Ltd. (OTCMKTS: HOMU), Born, Inc. (OTCMKTS: BRRN), Changsheng International Group Ltd., Sollensys Corp. (OTCMKTS: SOLS),
Guozi Zhongyu Capital Holdings Co. (OTCMKTS: GZCC) and Cang Bao Tian Xia International Art Trade Center, Inc. Mr. Lazar currently serves
as an Advisor to PROMAX Investments LLC, a position he has held since July&#160;2022, and as an Ambassador at Large for the Arab African
Council for Integration and Development, since March&#160;2022. Based on Mr. Lazar&#8217;s diverse knowledge of financial, legal and
operations management, public company management, accounting, audit preparation, due diligence reviews and SEC regulations, our Board
believes that Mr. Lazar has the appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Matthew
C. McMurdo, Esq.</i></b> (51) currently serves as Managing Member of McMurdo Law Group, LLC, a corporate and securities law practice,
since 2010. Previously, Mr. McMurdo was a Partner at Nannarone &amp; McMurdo, LLP, a boutique law firm, from 2008 to 2010. In addition,
Mr. McMurdo served as General Counsel of Berkley Asset Management LLC, the general partner of a real estate fund focused on opportunistic
and distressed real estate assets, from 2011 to 2013. Mr. McMurdo holds a B.S. in Finance from Lehigh University and a J.D., <i>cum laude,
</i>from Benjamin N. Cardozo School of Law. Based on Mr. McMurdo&#8217;s extensive experience in corporate and securities law and advising
many public companies on federal securities law, our Board believes that Mr. McMurdo has the appropriate set of skills to serve as a
member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>David
Natan</i></b> (69) currently serves as President and Chief Executive Officer of Natan &amp; Associates, LLC, a consulting firm offering
chief financial officer services to public and private companies in a variety of industries, since 2007. In addition, Mr. Natan currently
serves as Executive Vice President and Chief Financial Officer for Airborne Motorworks, Inc., a privately-held aerospace transportation
company, since April&#160;2020. From February&#160;2010 to May&#160;2020, Mr. Natan served as Chief Executive Officer of ForceField Energy,
Inc. (OTCMKTS: FNRG), a company focused on the solar industry and LED lighting products. From February&#160;2002 to November&#160;2007,
Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of PharmaNet Development Group, Inc., a drug development
services company, and, from June&#160;1995 to February&#160;2002, as Chief Financial Officer and Vice President of Global Technovations,
Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to that, Mr. Natan served in
various roles of increasing responsibility with Deloitte &amp; Touche LLP, a global consulting firm. Mr. Natan currently serves as a
member of the Board of Directors and Chair of the Audit Committee of Global Diversified Marketing Group, Inc. (OTCMKTS: GDMK), a manufacturer,
marketer and distributor of food and snack products, since February&#160;2021 and serves as a member of the Board of Directors and Chair
of the Audit Committee of Sunshine Biopharma, Inc. (NASDAQ: SBFM), a pharmaceutical and nutritional supplement company, since February&#160;2022.
Previously, Mr. Natan served as Chairman of the Board of Directors of ForceField Energy, Inc., from April&#160;2015 to May&#160;2020,
and as a member of the Board of Directors of Global Technovations, Inc., from December&#160;1999 to December&#160;2001. Mr. Natan holds
a B.A. in Economics from Boston University. Based on Mr. Natan&#8217;s extensive experience, our Board believes that Mr. Natan has the
appropriate set of skills to serve as a member of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
Not Standing for Re-Election</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Joseph
A. Akers</i></b> (77) was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities until his
retirement in 2008, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive
officer of Bayer Business and Corporate Services from July&#160;2002 through 2003 and executive vice president and chief administrative
and financial officer from 1999 to July&#160;2002. Mr. Akers received a B.S. in marketing and an M.B.A. in finance from the University
of California at Berkeley. Mr. Akers is not standing for re-election as a director at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>M.
David MacFarlane, Ph.D</i></b>. (82) served as Vice President and Responsible Head of Regulatory Affairs of Genentech, Inc. from 1989
until his retirement in August&#160;1999. Prior to joining Genentech, Inc., he served in various positions with Glaxo Inc., last as Vice
President of Regulatory Affairs. Dr. MacFarlane is not standing for re-election as a director at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>James
R. McNab, Jr</i></b>. (78) has served since June&#160;2014 as chief executive officer of JT Pharmaceuticals, Inc., a privately-held drug
discovery company he founded. From 2009 until December&#160;2019, Mr. McNab served as executive chairman of FirstString Research, Inc.,
a privately-held biopharmaceutical company. Mr. McNab has co-founded several privately-held companies, including Sontra Medical Corporation,
a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products.
He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill. Mr. McNab is
not standing for re-election as a director at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marc
Rubin, M.D.</i></b> (67) served as our president and chief executive from October&#160;2007 until December&#160;2008 and was re-engaged
as our executive chairman in May&#160;2009. Until February&#160;2007, Dr. Rubin served as head of global research and development for
Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering
Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June&#160;2006, Dr. Rubin was a member of the Executive Board
of Schering AG since joining the Company in October&#160;2003, as well as chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals,
a division of Schering AG. From 1990 until August&#160;2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of increasing
responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America.
From 2001 through 2003, he was senior vice president of Global Clinical Pharmacology &amp; Discovery Medicine. Dr. Rubin holds an M.D.
from Cornell University Medical College. Dr. Rubin currently serves on the board of directors of Curis Inc. and Galectin Therapeutics.
Dr. Rubin is not standing for re-election as a director at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
indicated above, each of our director nominees has extensive management and operational experience in one or more facets of the pharmaceutical
industry, including research, product development, clinical and regulatory affairs, manufacturing and sales and marketing, providing
the Company with the leadership needed by a biotechnology company in all stages of its development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE ELECTION OF THE DIRECTOR NOMINEES LISTED ABOVE.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTOR
COMPENSATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes compensation that our non-employee directors earned during the fiscal years ended 2021 and 2022 for services
as members of our Board and Board committees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Awards<br />
($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other<br />
Compensation<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 36%; text-align: left">Joseph A. Akers<sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 6%; text-align: center">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">62,500</td><td style="width: 1%; text-align: left"><sup>(3)</sup>&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">8,859</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">71,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,834</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Avraham Ben-Tzvi<sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Peter L. Chasey</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,625</td><td style="text-align: left"><sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,625</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Eric Greenberg</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left"><sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">M. David MacFarlane<sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,250</td><td style="text-align: left"><sup>(3)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,109</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,832</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Matthew C. McMurdo</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left"><sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">James R. McNab, Jr.<sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left"><sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,859</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,359</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,832</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">David Natan</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,438</td><td style="text-align: left"><sup>(4)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,438</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
shown represent the grant date fair value computed in accordance with FASB ASC 718. The assumptions used by us with respect to the valuation
of option grants and stock awards are set forth in the 2022 10-K under Note 8 to the financial statements.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate number of option awards held at December&#160;31, 2022 and December&#160;31, 2021 was 35,207 and 25,207, respectively.</span></td>
</tr>

<tr style="vertical-align: top">
    <td style="width: 0in; font-size: 10pt"></td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Amounts shown do not include legal fees paid by the Company to the law firm operated by Mr. Ben-Tzvi.</span></td></tr>

<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts reported in the &#8220;Fees Earned or Paid in Cash&#8221; column for 2022 represent directors fees earned for 2022 that have
been deferred to 2023 at the director&#8217;s election.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate number of option awards held at December&#160;31, 2022 and December&#160;31, 2021 was 35,220 and 25,251, respectively.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate number of option awards held at December&#160;31, 2022 and December&#160;31, 2021 was 35,207 and 25,207, respectively.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above table does not include options granted to certain directors on August&#160;15, 2022 and September&#160;15, 2022, as these options
are conditioned on the approval by the Company&#8217;s stockholders of an increase in the authorized number of shares available for issuance
under the 2015 Plan under Proposal No. 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no options exercised by members of our Board during 2021 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE
COMPENSATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
Compensation Table</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information concerning the compensation earned for 2021 and 2022 by our named executive officers for
services provided to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Awards<br />
($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards<br />
($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Compensation<br />
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc Rubin, MD<sup>(2)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">204,083</td><td style="width: 1%; text-align: left"><sup>(3)</sup>&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;57,582</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;164,583</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">426,248</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Executive Chairman</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">390,244</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;490,003</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">884,247</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">David Lazar</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">152,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">152,250</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Katherine Beebe DeVarney, Ph.D.</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">308,000</td><td style="text-align: left"><sup>(3)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;54,340</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">362,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">President and Chief Operating Officer</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">383,641</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;490,003</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8199;-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">877,644</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
shown represent the grant date fair value computed in accordance with FASB ASC 718. The assumptions used by us with respect to the valuation
of option grants and stock awards are set forth in the 2022 10-K under Note 8 to the financial statements.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Rubin&#8217;s employment was terminated in August&#160;2022. He will receive severance payments through July&#160;2023. He received approximately
$165,000 related to severance payments during 2022.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June&#160;15, 2022, we implemented a plan to reduce expenses and conserve capital that included a company-wide reduction in salaries
and a scale back of certain operating expenses. The cost-savings measures are being undertaken to enable us to maintain sufficient resources
as it works with its advisors on potential strategic alternatives for maximizing shareholder value. As part of the aforementioned plan,
Dr. Rubin and Dr. Beebe DeVarney each agreed to waive 40% of their base salaries until December&#160;15, 2022.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;14, 2022, we entered into an employment agreement with Mr. Lazar pursuant to which Mr. Lazar was hired to serve as our
Chief Executive Officer, effective August&#160;16, 2022.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
Benefits Plans</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal purpose of our stock incentive plans is to attract, motivate, reward and retain selected employees, consultants and directors
through the granting of stock-based compensation awards. The stock option plans provide for a variety of awards, including non-qualified
stock options, incentive stock options (within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended (the
&#8220;Code&#8221;)), stock appreciation rights, restricted stock awards, performance-based awards and other stock-based awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014
Incentive Plan</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February&#160;2014, we adopted the 2014 Incentive Plan (the &#8220;2014 Plan&#8221;) pursuant to which 2,526 shares of our common stock
were authorized for issuance to employees, directors, officers, consultants and advisors. On the Record Date, options to purchase 1,679
shares of our common stock were outstanding under the 2014 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015
Omnibus Equity Incentive Plan</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June&#160;2015, we adopted the 2015 Plan. The 2015 Plan, as amended, currently authorizes a total of 1,000,000 shares of our common stock
for issuance to employees, directors, officers, consultants and advisors. On the Record Date, options to purchase 910,568 shares of our
common stock were outstanding under the 2015 Plan. Our Board has approved, subject to stockholder approval, the amendment and restatement
of the 2015 Plan to (i) increase the total number of shares authorized under the 2015 Plan from 1,000,000 to 2,500,000 and (ii) increase
the number of shares of common stock that may be granted as awards to any individual in a single year from 150,000 to 200,000. <i>See
</i>&#8220;Proposal No. 2. Approval of Amended and Restated Plan.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
Equity Awards At Fiscal Year-End</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the number of securities underlying plan awards for each named executive officer as of December&#160;31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities Underlying Unexercised Awards (#) Exercisable</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities Underlying Unexercised Awards (#) Unexercisable</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price<br />
($)</b></span></td><td colspan="2" style="font-weight: bold; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration Date</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Marc Rubin, M.D.</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">203</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">594.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2025</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">918.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/14/2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">918.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/02/2026</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">702.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/07/2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/2/2029</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/10/2031</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">65,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/05/2032</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Katherine Beebe DeVarney, Ph.D.</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">594.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/14/2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/13/2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/7/2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/10/2031</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/05/2032</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the number of securities underlying plan awards for each named executive officer as of December&#160;31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td>
    <td colspan="8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities Underlying Unexercised Awards (#) Exercisable</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities Underlying Unexercised Awards (#) Unexercisable</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price<br />
($)</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration Date</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Marc Rubin, M.D.</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">253</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,137.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/3/2022</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">594.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">918.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/14/2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">440</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">918.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/02/2026</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">702.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/13/2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/07/2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/2/2029</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">91,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">58,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/10/2031</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Katherine Beebe DeVarney, Ph.D.</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/3/2022</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">594.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/14/2025</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">223</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/13/2027</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/7/2028</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">91,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">58,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/10/2031</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January&#160;2022, Dr. Rubin and Dr. Beebe DeVarney were granted options to purchase 65,000 and 55,000 shares of common stock, respectively.
The options were to vest over 24 months with 50% of the awarded options vesting on the six-month anniversary of the grant date with the
remaining balance vesting over the remaining eighteen months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;15, 2022, a Special Meeting of Stockholders was held at the request of Activist Investing, LLC, or Activist, to increase
the size of our Board from five members to eleven members and to elect Activist&#8217;s slate of six nominees to serve as directors in
addition to the existing five Board members. As a result of the change of control, all unvested options granted under the 2015 Plan prior
to August&#160;15, 2022, immediately became vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;15, 2022, the Board granted Dr. Beebe DeVarney, subject to the receipt of stockholder approval, options to purchase 100,000
shares of common stock at an exercise price of $1.31 per share, such price being the closing price of our common stock and the fair market
value as defined under the 2015 Plan on the September&#160;15, 2022 grant date. The options vest in twelve equal monthly allotments through
the first anniversary of the grant date. In the event of a change of control (as defined under the 2015 Plan), any outstanding unvested
options will automatically vest and become exercisable on the date of such change of control in accordance with the terms of the 2015
Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no options exercised by our named executive officers during 2021 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pension
Benefits</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not sponsor any qualified or non-qualified defined benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonqualified
Deferred Compensation</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not maintain any non-qualified defined contribution or deferred compensation plans. The compensation committee, which is comprised
solely of &#8220;outside directors&#8221; as defined for purposes of Section&#160;162(m) of the Code, may elect to provide our officers
and other employees with non-qualified defined contribution or deferred compensation benefits if the compensation committee determines
that doing so is in our best interests. We sponsor a tax qualified defined contribution 401(k) plan in which Dr. Rubin and Dr. Beebe
DeVarney participated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
Agreements</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&#160;1, 2019, we entered into an employment agreement with Dr. Rubin providing for a base annual salary of $325,000. The employment
agreement contains the following terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bonuses</i>.
                                            The executive may, at the sole discretion of the board of directors or the compensation committee,
                                            be considered for an annual bonus of up to 50% of his then base salary, payable in cash or
                                            awards under the Company&#8217;s equity incentive plan.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Term;
                                            Termination</i>. The employment agreement has a two-year term but may be terminated by the
                                            Company for any reason at any time. In the event of termination by the Company without Cause
                                            or his resignation for Good Reason, not in connection with a Change of Control (as those
                                            terms are defined in such agreements), the executive is entitled to (i) severance in the
                                            form of continuation of his base salary for 12 months, (ii) a pro rata portion of any annual
                                            bonus, (iii) 12 months of COBRA payments, and (iv) the immediate accelerated vesting of any
                                            unvested restricted shares and stock options. In the event such a termination is within 30
                                            days prior to or six months following a change of control, the executive is entitled to an
                                            additional six months of COBRA payments.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restrictive
                                            Covenants</i>. The employment agreement contains 12-month post-termination noncompetition
                                            and non-solicitation provisions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clawback</i>.
                                            The employment agreement contains a two-year post-termination clawback of bonuses and equity
                                            compensation in the event of a restatement of financial results upon which such benefits
                                            were based.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November&#160;2018, we entered into an employment agreement with Dr. Beebe DeVarney providing for a base annual salary of $365,000. The
employment agreement contains the following terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bonuses</i>.
                                            The executive may, at the sole discretion of the board of directors or the compensation committee,
                                            be considered for an annual bonus of up to 50% of her then base salary, payable in cash or
                                            awards under the Company&#8217;s equity incentive plan.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Term;
                                            Termination</i>. The employment agreement may be terminated by the Company for any reason
                                            at any time. In the event of termination by the Company without Cause or their resignation
                                            for Good Reason, not in connection with a Change of Control (as those terms are defined in
                                            such agreement), the executive is entitled to (i) severance in the form of continuation of
                                            her base salary for 12 months, (ii) a pro rata portion of any annual bonus, (iii) 12 months
                                            of COBRA payments, and (iv) the immediate accelerated vesting of any unvested restricted
                                            shares and stock options.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restrictive
                                            Covenants</i>. The employment agreements contain 12-month post-termination noncompetition
                                            and non-solicitation provisions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February&#160;2021, Dr. Rubin&#8217;s and Dr. Beebe DeVarney&#8217;s employment agreements were amended to provide for annual salaries
of $395,000 and $385,000, respectively, and the term of Dr. Rubin&#8217;s agreement was extended to September&#160;30, 2021. In October&#160;2021,
Dr. Rubin&#8217;s agreement was further extended to December&#160;31, 2022. Dr. Rubin&#8217;s employment was terminated in August&#160;2022.
In March&#160;2023, Dr. Beebe DeVarney&#8217;s employment agreement was amended to provide that her base salary shall accrue until such
time as the Company secured a strategic alternative transaction that provided the Company with sufficient funds to pay the accrued and
unpaid base salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;2, 2022, the compensation committee of the Board implemented a retention plan (the &#8220;Retention Plan&#8221;) in recognition
of the change in the composition of the Board following the special meeting of the Company&#8217;s stockholders (the &#8220;Special Meeting&#8221;)
on August&#160;15, 2022. The purpose of the Retention Plan is to help ensure a smooth transition, including the continuation of service
by the Company&#8217;s current employees and directors following the Special Meeting, while the newly reconstituted Board explores and
evaluates strategic alternatives to maximize the value of the Company&#8217;s assets and enhance stockholder value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Retention Plan, the employment agreements with Dr. Rubin and Dr. Beebe DeVarney were amended to (i) accelerate the vesting
of their options following the reconstitution of the Board; and (ii) remove from the definition of &#8220;Good Reason&#8221; the current
proviso that a change in the executive&#8217;s title would not necessarily constitute Good Reason. The agreement with Dr. Rubin was also
amended to state that the term of his employment shall continue until it is terminated in accordance with the existing provisions of
such agreement. All other agreement terms remained substantially the same. Following the Special Meeting, Mr. Lazar replaced Dr. Rubin
as the Chief Executive Officer of the Company. Dr. Rubin is not standing for re-election as a director at the Annual Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&#160;14, 2022, we entered into an employment agreement with Mr. Lazar providing for a base annual salary of $406,000. The employment
agreement contains the following terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bonuses</i>.
                                            Mr. Lazar will be eligible to receive an annual bonus, with a target of fifty percent (50%)
                                            of his base salary. In addition, Mr. Lazar will be eligible for three performance bonuses
                                            on an annual basis, payable in (i) cash and/or (ii) restricted stock under the Plan, each
                                            equal to fifty percent (50%) of his base salary, which shall be dependent on the achievement
                                            by the Company of certain milestones. Furthermore, in the event of a Change of Control (as
                                            defined in the Mr. Lazar&#8217;s employment agreement), the Company shall pay Mr. Lazar a
                                            bonus equal to three percent (3%) of the increased valuation of the surviving corporation
                                            resulting from such Change of Control.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Term;
                                            Termination</i>. The employment agreement has a three-year term but may be terminated by
                                            the Company for any reason at any time. In the event of termination by the Company without
                                            Cause or his resignation for Good Reason, not in connection with a Change of Control (as
                                            those terms are defined in such agreements), the executive is entitled to (i) severance in
                                            the form of continuation of his base salary for the greater of a period of 12 months or the
                                            remaining term, (ii) payment of executive&#8217;s annual medical and dental reimbursement
                                            for a period of 12 months, (iii) a pro rata portion of any annual or performance bonus, and
                                            (iv) the immediate accelerated vesting of any unvested restricted shares and stock options.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restrictive
                                            Covenants</i>. The employment agreement contains 12-month post-termination noncompetition
                                            and non-solicitation provisions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
Compensation Plan Information</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth aggregate information regarding our equity compensation plans that were in effect as of December&#160;31,
2021 and December&#160;31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Plan category</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options, warrant and rights<br /> (a)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options, warrants and rights<br /> (b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities remaining available for future issuance under equity compensation plans<br /> (c)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">925,738</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">74,262</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2021<sup>(1)</sup></td><td style="text-align: left"><sup></sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">680,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320,296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: center">2022<sup>(2)</sup></td><td style="text-align: left"><sup></sup>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">541.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">2021<sup>(3)</sup></td><td style="text-align: left"><sup></sup>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,272</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">534.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">926,927</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,262</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center">2021</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">681,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">320,936</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January&#160;2021, our stockholders approved an amendment to the 2015 Plan to increase the number of authorized shares to 1,000,000 shares.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
1,189 non-qualified stock options granted to employees, directors and consultants under our 2014 Plan.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
1,272 non-qualified stock options and restricted share awards granted to employees, directors and consultants under our 2014 Plan.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
Versus Performance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation of our principal executive officer, or &#8220;PEO,&#8221; and, on
an average basis, the compensation of our other named executive officers, or &#8220;NEOs,&#8221; for each of the fiscal years ended December&#160;31,
2022 and 2021, as such compensation relates to our financial performance for each such fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ecd:PvpTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_eecd--PvpTableTextBlock_zokMnNwYvDDa" summary="xdx: Disclosure - Pay vs Performance Disclosure" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48F_eecd--PeoTotalCompAmt_hecd--IndividualAxis__custom--MarcRubinMember_zb9PTTugUDMi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48F_eecd--PeoActuallyPaidCompAmt_hecd--IndividualAxis__custom--MarcRubinMember_zyTLWXt8iYr1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_487_eecd--PeoTotalCompAmt_hecd--IndividualAxis__custom--DavidLazarMember_zeQ4Sn5qD5d9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48A_eecd--PeoActuallyPaidCompAmt_hecd--IndividualAxis__custom--DavidLazarMember_zK1VV4ZtkjS" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_489_eecd--NonPeoNeoAvgTotalCompAmt_hecd--IndividualAxis__custom--NonpeoNeosMember_zxmyzcLNq8Vk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_481_eecd--NonPeoNeoAvgCompActuallyPaidAmt_hecd--IndividualAxis__custom--NonpeoNeosMember_zKdB9k1jWSb3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_480_eecd--TotalShareholderRtnAmt_pp1p0_zuUngniIe0O4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48D_eus-gaap--NetIncomeLoss_iN_di_zTaOqkwDPa7a" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Marc Rubin</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">David Lazar</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table Total for PEO<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Actually Paid to PEO<sup>(1)(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table Total for PEO<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Actually Paid to PEO<sup>(1)(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table Total for Non-PEO NEOs<sup>(3)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Actually Paid to Non-PEO NEOs<sup>(3)(4)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value of Initial Fixed $100 Investment Based on Total Shareholder Return<sup>(5)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41C_20220101__20221231_znbrCC8VMLq3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 11%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31_custom_MarcRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,248</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31_custom_MarcRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,495</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31_custom_DavidLazarMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31_custom_DavidLazarMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31_custom_NonpeoNeosMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31_custom_NonpeoNeosMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,412</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitRef="USD">23.80</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,206,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_417_20210101__20211231_zffgTtjGCsR1" style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2021-01-012021-12-31_custom_MarcRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,247</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2021-01-012021-12-31_custom_MarcRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">578,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0024">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0025">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2021-01-012021-12-31_custom_NonpeoNeosMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">877,644</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2021-01-012021-12-31_custom_NonpeoNeosMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">578,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="1" scale="0" unitRef="USD">31.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,776,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td id="xdx_983_eecd--NamedExecutiveOfficersFnTextBlock_c20220101__20221231_zjwT62ngsFXd" style="text-align: justify"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ecd:NamedExecutiveOfficersFnTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, our Chief Executive Officer was Marc Rubin through August&#160;15, 2022, and <span id="xdx_90E_eecd--PeoName_c20220101__20221231_zpyuwU9gIcOc"><ix:nonNumeric contextRef="From2022-01-01to2022-12-31" name="ecd:PeoName">David Lazar</ix:nonNumeric></span> was appointed as our Chief Executive Officer
and PEO effective as of August&#160;15, 2022. During 2021, our PEO was <span id="xdx_901_eecd--PeoName_c20210101__20211231_zEZd6b8XPPO5"><ix:nonNumeric contextRef="From2021-01-012021-12-31" name="ecd:PeoName">Dr. Rubin</ix:nonNumeric></span>.</span></ix:nonNumeric></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
the amount of &#8220;compensation actually paid&#8221; to Dr. Rubin, as computed in accordance with SEC rules and does not reflect the
actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were
made to total compensation determine the compensation actually paid.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ecd:AdjToPeoCompFnTextBlock"><p id="xdx_89C_eecd--AdjToPeoCompFnTextBlock_dU_zl1jCVARzBw1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="color: Black; vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: left">Dr. Rubin</td><td style="font-family: Times New Roman, Times, Serif; text-align: center; color: Black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231__ecd--IndividualAxis__custom--DrRubinMember_zG110hp46Jd2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: center">2022<br />
($)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center"></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; color: Black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__ecd--IndividualAxis__custom--DrRubinMember_zldepVNpw2x5" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: center">2021<br />
($)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_407_eecd--PeoTotalCompAmt_zH5lMcttZHef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; width: 76%">Summary Compensation Table Total</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2022-01-012022-12-31_custom_DrRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,248</ix:nonFraction></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="From2021-01-012021-12-31_custom_DrRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,247</ix:nonFraction></td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_404_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--LessValueOfStockAwardsReportedInSummaryCompensationTableMember_zY4F59RZtUKe" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Less, value of Stock Awards reported in Summary Compensation Table</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,782</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">490,003</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_zgIUbimHVpBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year-end fair value of outstanding and unvested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0042">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_zYTu7ReRvemk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, fair value of outstanding and vested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,514</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,534</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_zVmjFqLtLqla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year over year change in fair value of equity awards granted in prior years that vested in the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,515</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0049">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eecd--PeoActuallyPaidCompAmt_zeRelyPvOOh6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Compensation Actually Paid to Dr. Rubin</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2022-01-012022-12-31_custom_DrRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="From2021-01-012021-12-31_custom_DrRubinMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">578,264</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_znwQKEoVSsBk" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
non-PEO NEO in both the 2022 and 2021 reporting years was Katherine Beebe DeVarney, Ph.D.</span></td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
the amount of &#8220;compensation actually paid&#8221; to Dr. Beebe DeVarney, as computed in accordance with SEC rules and does not reflect
the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments
were made to total compensation determine the compensation actually paid.</span></td>
</tr></table>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ecd:AdjToNonPeoNeoCompFnTextBlock"><p id="xdx_89E_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_zhis3nIMML1h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Dr. Beebe DeVarney</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231__ecd--IndividualAxis__custom--DrBeebeDeVarneyMember_zicVLX58oPB5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231__ecd--IndividualAxis__custom--DrBeebeDeVarneyMember_zCR4hKdeKSia" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eecd--NonPeoNeoAvgTotalCompAmt_zuhcUsHISAjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Summary Compensation Table Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">362,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">877,644</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--LessValueOfStockAwardsReportedInSummaryCompensationTableMember_zGW2SaH2LeI3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Less, value of Stock Awards reported in Summary Compensation Table</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,340</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">490,003</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_zn9jgIw2qh65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year-end fair value of outstanding and unvested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0062">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,486</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_zEa43MqiDtJk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, fair value of outstanding and vested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,534</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_zAIgOQo0ZcW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year over year change in fair value of equity awards granted in prior years that vested in the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,515</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0069">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zBgo2N5WKxE6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Compensation Actually Paid to Dr. Beebe DeVarney</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">361,411</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">571,661</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AC_zDmX73PdQqka" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
Shareholder Return (&#8220;TSR&#8221;) assumes $100 was invested on December&#160;31, 2020.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Analysis
of the Information Presented in the Pay Versus Performance Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in more detail in &#8220;Executive Compensation&#8221; above, our executive compensation program reflects a variable pay-for-performance
philosophy. While we utilize several performance measures to align executive compensation with our performance, all measures are not
presented in the Pay Versus Performance table. Moreover, we generally seek to incentivize long-term performance and, therefore, do not
specifically align our performance measures with compensation that is actually paid (as computed in accordance with SEC rules) for a
particular year. In accordance with SEC rules, we are providing the following descriptions of the relationships between information presented
in the Pay versus Performance table. The following charts set forth the relationship between compensation actually paid and our cumulative
TSR and between compensation actually paid and our net income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock"><p id="xdx_898_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zMcmachOcSRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="img_001.jpg" alt="" style="height: 332px; width: 500px" /></b></span></p>

</ix:nonNumeric><p id="xdx_8A3_zT1XIce1Qwz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-12-31" escape="true" name="ecd:CompActuallyPaidVsNetIncomeTextBlock"><p id="xdx_897_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zhmjZ1zaghXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="img_002.jpg" alt="" style="height: 319px; width: 500px" /></b></span></p>

</ix:nonNumeric><p id="xdx_8A3_zu0Nmeu8IeDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL
NO. 2</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPROVAL
OF THE AMENDED AND RESTATED PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August&#160;2022, the Board adopted, subject to the receipt of stockholder approval, the Amended and Restated Plan to (i) increase the
total number of shares authorized for issuance thereunder from 1,000,000 to 2,500,000 and (ii) increase the number of shares of common
stock that may be granted as awards to any individual in a single year from 150,000 to 200,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;15, 2022, in connection with their election to the Board at the Special Meeting, the Board granted each of Avraham Ben-Tzvi,
Peter L. Chasey, Eric Greenberg, Matthew C. McMurdo and David Natan, subject to the receipt of stockholder approval, options to purchase
25,000 shares of our common stock at an exercise price of $1.52 per share, such price being the closing price of our common stock and
the fair market value as defined under the 2015 Plan on the August&#160;15, 2022 grant date (the &#8220;August Options&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September&#160;15, 2022, the Board granted each of Dr. Beebe DeVarney and Messrs. Akers, McNab, MacFarlane, Ben-Tzvi, Chasey, Greenberg,
McMurdo and Natan, subject to the receipt of stockholder approval, options to purchase 100,000 shares our common stock at an exercise
price of $1.31 per share, such price being the closing price of our common stock and the fair market value as defined under the 2015
Plan on the September&#160;15, 2022 grant date (the &#8220;September Options&#8221; and together with the August Options, the &#8220;Options&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Options vest in twelve equal monthly allotments through the first anniversary of the respective grant dates. In the event of a change
of control (as defined under the 2015 Plan), any outstanding unvested Options will automatically vest and become exercisable on the date
of such change of control in accordance with the terms of the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Options are conditioned only on the approval by the Company&#8217;s stockholders of an increase in the authorized number of shares available
for issuance under the 2015 Plan under this Proposal No. 2. As a result, if Proposal No. 2 is approved, the Options described above will
continue, and if Proposal No. 2 is not approved, the Options will be cancelled and deemed void.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of the Amended and Restated Plan is to assist us in attracting and retaining the key personnel we believe we need to conduct
our research and development activities while maintaining cost-cutting measures necessary to fund our operations with our limited available
capital. The Amended and Restated Plan will only become effective upon our receipt of stockholder approval of this Proposal No. 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Description of the Amended and Restated Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material provisions of the Amended and Restated Plan and is qualified in its entirety by reference to the
complete text of the Amended and Restated Plan, a copy of which is attached to this Proxy Statement as Annex A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration</i>. The
Amended and Restated Plan is administered by the compensation committee of the Board, which consists of three members of the Board, each
of whom is a &#8220;non-employee director&#8221; within the meaning of Rule&#160;16b-3 promulgated under the Exchange Act and an &#8220;outside
director&#8221; within the meaning of Code Section&#160;162(m). Among other things, the compensation committee has complete discretion,
subject to the express limits of the Amended and Restated Plan, to determine the directors, employees and nonemployee consultants to
be granted an award, the type of award to be granted the terms and conditions of the award, the form of payment to be made and/or the
number of shares of common stock subject to each award, the exercise price of each option and base price of each stock appreciation right
(&#8220;SAR&#8221;), the term of each award, the vesting schedule for an award, whether to accelerate vesting, the value of the common
stock underlying the award, and the required withholding, if any. The compensation committee may amend, modify or terminate any outstanding
award, provided that the participant&#8217;s consent to such action is required if the action would impair the participant&#8217;s rights
or entitlements with respect to that award. The compensation committee is also authorized to construe the award agreements, and may prescribe
rules relating to the Amended and Restated Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant
of Awards; Shares Available for Awards</i>. The Amended and Restated Plan provides for the grant of stock options, SARs,
performance share awards, performance unit awards, distribution equivalent right awards, restricted stock awards, restricted stock unit
awards and unrestricted stock awards to non-employee directors, officers, employees and nonemployee consultants of Titan or its affiliates.
We have reserved a total of 1,000,000 shares of common stock for issuance as or under awards to be made under the Amended and Restated
Plan. As of the Record Date, awards covering an aggregate of 910,568 shares of common stock were outstanding under the 2015 Plan. If
any award expires, is cancelled, or terminates unexercised or is forfeited, the number of shares subject thereto is again available for
grant under the 2015 Plan. The number of shares of common stock authorized for issuance under the 2015 Plan is currently 1,000,000, and
the number of shares of common stock for which awards may be granted to a participant who is an employee in any calendar year is currently
limited to 150,000 shares. The Amended and Restated Plan, if approved by our stockholders, will (i) increase total the number of shares
authorized for issuance under the Amended and Restated Plan from 1,000,000 to 2,500,000 and (ii) increase the number of shares of common
stock that may be granted as awards to any individual in a single year from 150,000 to 200,000. All information regarding share numbers
gives effect to a 1-for-30 reverse stock split effected on November&#160;30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the Record Date, there were 13 employees and directors entitled to receive stock options and/or shares of restricted stock under the
Amended and Restated Plan. Future new hires and additional non-employee directors and/or consultants would be eligible to participate
in the Amended and Restated Plan as well. The number of stock options and/or shares of restricted stock to be granted to executives and
directors cannot be determined at this time as the grant of stock options and/or shares of restricted stock is dependent upon various
factors such as hiring requirements and job performance. As of the Record Date, the Company&#8217;s stock price as reported by Nasdaq
was $0.78.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i>. The Amended and Restated Plan provides for either &#8220;incentive stock options&#8221; (&#8220;ISOs&#8221;),
which are intended to meet the requirements for special federal income tax treatment under the Code, or &#8220;nonqualified stock options&#8221;
(&#8220;NQSOs&#8221;). Stock options may be granted on such terms and conditions as the compensation committee may determine; provided,
however, that the per share exercise price under a stock option may not be less than the fair market value of a share of the Company&#8217;s
common stock on the date of grant and the term of the stock option may not exceed 10 years (110% of such value and five years in the
case of an ISO granted to an employee who owns (or is deemed to own) more than 10% of the total combined voting power of all classes
of capital stock of the Company or a parent or subsidiary of the Company). ISOs may only be granted to employees. In addition, the aggregate
fair market value of our common stock covered by one or more ISOs (determined at the time of grant) which are exercisable for the first
time by an employee during any calendar year may not exceed $100,000. Any excess is treated as an NQSO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights</i>. A SAR entitles the participant, upon exercise, to receive an amount, in cash or stock or a
combination thereof, equal to the increase in the fair market value of the underlying common stock between the date of grant and the
date of exercise. SARs may be granted in tandem with, or independently of, stock options granted under the Amended and Restated Plan.
A SAR granted in tandem with a stock option (i) is exercisable only at such times, and to the extent, that the related stock option is
exercisable in accordance with the procedure for exercise of the related stock option; (ii) terminates upon termination or exercise of
the related stock option (likewise, the common stock option granted in tandem with a SAR terminates upon exercise of the SAR); (iii)
is transferable only with the related stock option; and (iv) if the related stock option is an ISO, may be exercised only when the value
of the stock subject to the stock option exceeds the exercise price of the stock option. A SAR that is not granted in tandem with a stock
option is exercisable at such times as the compensation committee may specify.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Shares and Performance Unit Awards</i>. Performance shares and performance unit awards entitle the participant to receive
cash or shares of our common stock upon the attainment of specified performance goals. In the case of performance units, the right to
acquire the units is denominated in cash values.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution
Equivalent Right Awards</i>. A distribution equivalent right award entitles the participant to receive bookkeeping credits,
cash payments and/or common stock distributions equal in amount to the distributions that would have been made to the participant had
the participant held a specified number of shares of our common stock during the period the participant held the distribution equivalent
right. A distribution equivalent right may be awarded as a component of another award under the Amended and Restated Plan, where, if
so awarded, such distribution equivalent right will expire or be forfeited by the participant under the same conditions as under such
other award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards and Restricted Stock Unit Awards</i>. A restricted stock award is a grant or sale of common stock to the
participant, subject to our right to repurchase all or part of the shares at their purchase price (or to require forfeiture of such shares
if issued to the participant at no cost) in the event that conditions specified by the compensation committee in the award are not satisfied
prior to the end of the time period during which the shares subject to the award may be repurchased by or forfeited to us. Our restricted
stock unit entitles the participant to receive a cash payment equal to the fair market value of a share of common stock for each restricted
stock unit subject to such restricted stock unit award, if the participant satisfies the applicable vesting requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrestricted
Stock Awards</i>. An unrestricted stock award is a grant or sale of shares of our common stock to the participant that
is not subject to transfer, forfeiture or other restrictions, in consideration for past services rendered to Titan or an affiliate or
for other valid consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change-in-Control
Provisions</i>. In connection with the grant of an award, the compensation committee may provide that, in the event
of a change in control, such award will become fully vested and immediately exercisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Repricing
Prohibited</i>. Without stockholder approval or as a result of a change in control, the compensation committee does
not have the power or authority to reduce, whether through amendment or otherwise, the exercise price under any outstanding option or
stock appreciation right, or to grant any new award or make any payment of cash in substitution for or upon the cancellation of options
and/or stock appreciation rights previously granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
and Termination</i>. The compensation committee may adopt, amend and rescind rules relating to the administration of
the Amended and Restated Plan, and amend, suspend or terminate the Amended and Restated Plan, but no such amendment or termination will
be made that materially and adversely impairs the rights of any participant with respect to any award received thereby under the Amended
and Restated Plan without the participant&#8217;s consent, other than amendments that are necessary to permit the granting of awards
in compliance with applicable laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Federal Income Tax Consequences of the Amended and Restated Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a general summary of certain federal income tax consequences under current U.S. tax law to Titan and to participants in
the Amended and Restated Plan who are individual citizens or residents of the United States for federal income tax purposes (&#8220;U.S.
Participants&#8221;) of stock options, stock appreciation rights, restricted stock, performance shares, performance units, restricted
stock units, distribution equivalent rights and unrestricted stock. It does not purport to cover all of the special rules including special
rules relating to limitations on the ability of the Company to deduct the amounts for federal income tax purposes of certain compensation,
special rules relating to deferred compensation, golden parachutes, participants subject to Section&#160;16(b) of the Exchange Act or
the exercise of a stock option with previously-acquired shares of the Company&#8217;s common stock. For purposes of this summary it is
assumed that U.S. Participants will hold their shares of the Company&#8217;s common stock received under the Amended and Restated Plan
as capital assets within the meaning of Section&#160;1221 of the Code. In addition, this summary does not address the non-U.S. state
or local income or other tax consequences, or any U.S. federal non-income tax consequences, inherent in the acquisition, ownership, vesting,
exercise, termination or disposition of an award under the Amended and Restated Plan, or shares of the Company&#8217;s common stock issued
pursuant thereto. All participants are urged to consult with their own tax advisors concerning the tax consequences to them of an award
under the Amended and Restated Plan or shares of the Company&#8217;s common stock issued thereunder pursuant to the Amended and Restated
Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NQSOs</i>.
A U.S. Participant generally does not recognize taxable income upon the grant of an NQSO. Upon the exercise of an NQSO, the U.S. Participant
recognizes ordinary income in an amount equal to the excess, if any, of the fair market value of the shares acquired on the date of exercise
over the exercise price paid therefor under the NQSO, and the Company will generally be entitled to a deduction for such amount at that
time. If the U.S. Participant later sells shares acquired pursuant to the exercise of an NQSO, the U.S. Participant recognizes long-term
or short-term capital gain or loss, depending on the period for which the shares were held. Long-term capital gain is generally subject
to more favorable tax treatment than ordinary income or short-term capital gain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>ISOs</i>.
A U.S. Participant does not recognize taxable income upon the grant of an ISO. Upon the exercise of an ISO, the U.S. Participant does
not recognize taxable income (except for purposes of the alternative minimum tax as discussed below). If the U.S. Participant disposes
of the shares acquired pursuant to the exercise of an ISO more than two years after the date of grant and more than one year after the
transfer of the shares to the U.S. Participant, the U.S. Participant recognizes long-term capital gain or loss and the Company will not
be entitled to a deduction. However, if the U.S. Participant disposes of such shares prior to the end of either of the required holding
periods, the U.S. Participant will have ordinary income equal to the excess (if any) of the fair market value of such shares on the date
of exercise (or, if less, the amount realized on the disposition of such shares) over the exercise price paid for such shares, with any
remaining gain or loss being treated as capital gain or capital loss. The Company is generally entitled to deduct such amount that the
U.S. participant recognizes as ordinary income. In addition to the tax consequences described above, a U.S. Participant may be subject
to the alternative minimum tax, which is payable to the extent it exceeds the U.S. Participant&#8217;s regular tax. For this purpose,
upon the exercise of an ISO, the excess of the fair market value of the shares over the exercise price paid therefor under the ISO is
a preference item for alternative minimum taxable income determination purposes. In addition, the U.S. Participant&#8217;s basis in such
shares is increased by such excess for purposes of computing the gain or loss on the disposition of the shares for alternative minimum
tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>SARs</i>.
A U.S. Participant generally does not recognize taxable income upon the grant of an SAR. The U.S. Participant has ordinary compensation
income upon exercise of the SAR equal to the increase in the value of the underlying shares, and the Company will generally be entitled
to a deduction for such amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Shares</i>. A U.S. Participant generally does not recognize taxable income upon the receipt of a performance share award until the shares
are received. At such time, the U.S. Participant recognizes ordinary compensation income equal to the excess, if any, of the fair market
value of the shares over any amount thereby paid for the shares, and the Company will generally be entitled to deduct such amount at
such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Units</i>. A U.S. Participant generally does not recognize taxable income upon the receipt of a performance unit award until a cash payment
is treated as received for income tax purposes. At such time, the U.S. Participant recognizes ordinary compensation income equal to the
amount of cash treated as received, and the Company will generally be entitled to deduct such amount at such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. A U.S. Participant generally does not recognize taxable income upon the receipt of a restricted stock unit award until
a cash payment is treated as received for income tax purposes. At such time, the U.S. Participant recognizes ordinary compensation income
equal to the amount of cash treated as received, and the Company will generally be entitled to deduct such amount at such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution
Equivalent Rights</i>. A U.S. Participant generally does not recognize taxable income upon the receipt of a distribution equivalent right
award until a cash payment is treated as received for income tax purposes. At such time, the U.S. Participant recognizes ordinary compensation
income equal to the amount of cash treated as received, and the Company will generally be entitled to deduct such amount at such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock</i>. A U.S. Participant who receives a grant of restricted stock generally recognizes ordinary compensation income equal to the
excess, if any, of the fair market value of such shares of stock at the time the restriction lapses over any amount paid timely for the
shares. Alternatively, the U.S. Participant may make an election under Section&#160;83(b) of the Code, within 30 days of being granted
an award of restricted stock, to be taxed on the fair market value of such shares at the time of grant. The Company thereby will generally
be entitled to a deduction at the same time and in the same amount as the income required to be included by the U.S. Participant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrestricted
Stock</i>. A U.S. Participant recognizes ordinary compensation income upon receipt of the shares under an unrestricted stock award equal
to the excess, if any, of the fair market value of the shares over any amount paid thereby for the shares, and the Company will generally
be entitled to deduct such amount at such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>



<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Section&#160;409A
of the Code</i>. Certain types of awards under the Amended and Restated Plan may constitute, or provide for, a deferral of compensation
subject to Section&#160;409A of the Code. If an award is subject to, but does not comply with the requirements of, Section&#160;409A
of the Code, the taxable events as described above could apply earlier than described, and could result in the imposition of additional
taxes and penalties. In the event that the compensation committee determines that any award may be subject to Section&#160;409A of the
Code, the Amended and Restated Plan and any applicable awards may be modified to exempt the awards from Section&#160;409A of the Code
or comply with the requirements of Section&#160;409A of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Section&#160;162(m)
of the Code</i>. Section&#160;162(m) of the Code disallows a tax deduction for any publicly held corporation for individual compensation
exceeding $1 million in any taxable year for &#8220;covered employees.&#8221; Prior to the effectiveness of the Tax Cuts and Jobs Act
of 2017 (the &#8220;2017 Tax Act&#8221;), compensation that qualified as &#8220;performance-based&#8221; under Section&#160;162(m) of
the Code was exempt from this deduction limitation. The 2017 Tax Act eliminated this exception for performance-based compensation for
tax years beginning after December&#160;31, 2017. The 2017 Tax Act includes a limited grandfather provision, pursuant to which remuneration
that is provided pursuant to a written binding contract in effect on November&#160;2, 2017, and which has not been modified in any material
respect on or after that date, may remain eligible for the exception for performance-based compensation under Section&#160;162(m) of
the Code (as in effect prior to the 2017 Tax Act). The compensation committee, to the extent available, intends to treat qualified &#8220;performance-based&#8221;
compensation that is grandfathered under the 2017 Tax Act as deductible compensation. However, the compensation committee retains the
discretion and flexibility to award compensation that is not deductible under Section&#160;162(m) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
Plan Benefits</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to determine specific amounts that may be awarded in the future under the Amended and Restated Plan because grants of
awards under the Amended and Restated Plan are at the discretion of the Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE APPROVAL OF THE AMENDED AND RESTATED PLAN.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL
NO. 3</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADVISORY
VOTE ON EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, we are providing our stockholders
with the opportunity to cast an advisory vote on the compensation of our named executive officers as disclosed in this Proxy Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in detail under the heading &#8220;Executive Compensation,&#8221; our executive compensation programs are designed to attract
and retain highly qualified leadership personnel, providing them attractive long-term career opportunities. Our compensation philosophy
is to provide executives with a competitive total compensation package which motivates superior job performance, the achievement of our
business objectives, and the enhancement of shareholder value. Please read the disclosure beginning on page 12
for a detailed description and analysis of our executive compensation programs, including information about the fiscal years 2021 and
2022 compensation of our named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the philosophy of the Board to align the interests of our executive officers and stockholders by integrating the executives&#8217;
compensation opportunities with our long-term corporate strategic and financial objectives. Our general approach to compensating executive
officers is to pay cash salaries which generally are competitive within ranges of salaries paid to executives of other early stage biotechnology
companies, particularly those of similar size and those in our geographic areas. Our compensation committee sets overall compensation
at a level it believes to be fair, based upon an analysis of the individual executive&#8217;s experience and past and potential contributions
to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are asking our stockholders to indicate their support for our named executive officer compensation as described in this Proxy Statement.
This proposal, commonly known as a &#8220;say-on-pay&#8221; proposal, gives our stockholders the opportunity to express their views on
our named executive officers&#8217; compensation. This vote is not intended to address any specific item of compensation, but rather
the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement.
Accordingly, we will ask our stockholders to vote &#8220;FOR&#8221; the following resolution at the Annual Meeting:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;RESOLVED,
that the compensation paid to the Company&#8217;s named executive officers, as disclosed pursuant to Item&#160;402 of Regulation S-K,
including the compensation tables and narrative discussion, is hereby approved.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
this say-on-pay advisory vote is non-binding, the Board and the compensation committee value the opinions of our stockholders and will
review the results of this vote and consider such results when making future decisions related to executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<!-- Field: Split-Segment -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPOSAL
NO. 4<br />
<br />
RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee has selected WithumSmith+Brown, PC (&#8220;Withum&#8221;) to serve as our independent accountants for the year ending December&#160;31, 2023. In July&#160;2021, in connection with Withum&#8217;s acquisition of certain assets
of OUM &amp; Co. LLP (&#8220;OUM&#8221;), OUM provided their resignation as the Company&#8217;s independent registered public accounting
firm and the Company, with the approval of the audit committee, consented to the assignment and assumption of OUM&#8217;s engagement
with the Company to Withum. A representative of Withum is expected to be present by teleconference at the Annual Meeting and will have
an opportunity to make a statement if he or she so desires. The representative also is expected to be available to respond to appropriate
questions from stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selection
of our independent registered public accounting firm is not required to be submitted to a vote of stockholders and, accordingly, the
vote will not be binding on our Board or the Company. However, if stockholders fail to ratify the appointment, the audit committee will
reconsider its appointment of Withum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth the aggregate accounting fees paid by us to Withum or OUM, as applicable, for the past three fiscal years
ended December&#160;31, 2022, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Audit Fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">297,850</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">385,546</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Tax Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">45,720</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">48,850</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">47,560</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">346,799</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">346,700</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">433,106</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Fees</b>&#8201;&#8212;&#8201;This category includes aggregate fees billed by our independent auditors for the audit of our annual financial
statements, audit of management&#8217;s assessment and effectiveness of internal controls over financial reporting, review of financial
statements included in our quarterly reports on Form&#160;10-Q and services that are normally provided by the auditor in connection with
statutory and regulatory filings for those fiscal years, including consents and comfort letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit-Related
Fees</b>&#8201;&#8212;&#8201;This category consists of services by our independent auditors that, including accounting consultations
on transaction related matters, are reasonably related to the performance of the audit or review of our financial statements and are
not reported above under Audit Fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
Fees</b>&#8201;&#8212;&#8201;This category consists of professional services rendered for tax compliance and preparation of our corporate
tax returns and other tax advice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
Other Fees</b> &#8212; During the years ended December&#160;31, 2022, 2021 and 2020, Withum (and by OUM prior to its acquisition by Withum)
did not incur any fees for other professional services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee reviewed and approved all audit and non-audit services provided by Withum (and by OUM prior to its acquisition by Withum)
and concluded that these services were compatible with maintaining its independence. The audit committee approved the provision of all
non-audit services by Withum and OUM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Approval
Policies and Procedures</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the SEC&#8217;s auditor independence rules, the audit committee has established the following policies and procedures
by which it approves in advance any audit or permissible non-audit services to be provided to us by our independent auditor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the engagement of the independent auditors for any fiscal year&#8217;s audit, management submits to the audit committee for approval
lists of recurring audit, audit-related, tax and other services expected to be provided by the independent auditors during that fiscal
year. The audit committee adopts pre-approval schedules describing the recurring services that it has pre-approved, and is informed on
a timely basis, and in any event by the next scheduled meeting, of any such services rendered by the independent auditor and the related
fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fees for any services listed in a pre-approval schedule are budgeted, and the audit committee requires the independent auditor and management
to report actual fees versus the budget periodically throughout the year. The audit committee will require additional pre-approval if
circumstances arise where it becomes necessary to engage the independent auditor for additional services above the amount of fees originally
pre-approved. Any audit or non-audit service not listed in a pre-approval schedule must be separately pre-approved by the audit committee
on a case-by-case basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
request to adopt or amend a pre-approval schedule or to provide services that are not listed in a pre-approval schedule must include
a statement by the independent auditors as to whether, in their view, the request is consistent with the SEC&#8217;s rules on auditor
independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee will not grant approval for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            services prohibited by applicable law or by any rule or regulation of the SEC or other regulatory
                                            body applicable to us;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provision
                                            by the independent auditors to us of strategic consulting services of the type typically
                                            provided by management consulting firms; or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            retention of the independent auditors in connection with a transaction initially recommended
                                            by the independent auditors, the tax treatment of which may not be clear under the Code and
                                            related regulations and which it is reasonable to conclude will be subject to audit procedures
                                            during an audit of our financial statements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
services proposed to be provided by the auditor to any director, officer or employee of Titan who is in an accounting role or financial
reporting oversight role must be approved by the audit committee on a case-by-case basis where such services are to be paid for by us,
and the audit committee will be informed of any services to be provided to such individuals that are not to be paid for by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining whether to grant pre-approval of any non-audit services in the &#8220;all other&#8221; category, the audit committee will
consider all relevant facts and circumstances, including the following four basic guidelines:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the service creates a mutual or conflicting interest between the auditor and us;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the service places the auditor in the position of auditing his or her own work;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the service results in the auditor acting as management or an employee of the Company; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the service places the auditor in a position of being an advocate for the Company.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
BOARD RECOMMENDS A VOTE &#8220;FOR&#8221; THE RATIFICATION OF THE APPOINTMENT OF WITHUM TO SERVE AS OUR INDEPENDENT AUDITORS FOR THE
YEAR ENDING DECEMBER&#160;31, 2023</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2021, there were no related party transactions in which the amount involved exceeded $120,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January&#160;2022, we entered into an agreement with JT Pharmaceuticals, Inc. (&#8220;JT Pharma&#8221;), a company for which James R.
McNab, Jr., a member of our Board, serves as chief executive officer, to clarify certain provisions of the October&#160;2020 Asset Purchase
Agreement (the &#8220;JT Agreement&#8221;), pursuant to which we agreed that the proof-of-concept milestone provided for in the JT Agreement
was achieved, made a payment of $100,000 and issued 51,021 shares of our common stock to JT Pharma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2022, we entered
into an engagement with a law firm operated by Avraham Ben-Tzvi, one of our Board members, for the provision of legal services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is charged with reviewing and approving all potential related party transactions and, in accordance with its charter, the audit
committee reviews and provides oversight of related-person transactions, as required by stock exchange rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DELINQUENT
SECTION&#160;16(a) REPORTS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&#160;16(a)
of the Exchange Act requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of
our equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other
equity securities. Such executive officers, directors, and greater than 10% beneficial owners are required by SEC regulation to furnish
us with copies of all Section&#160;16(a) forms filed by such reporting persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely on our review of such forms furnished to us and written representations from certain reporting persons, we believe that all filing
requirements applicable to our executive officers, directors and greater than 10% beneficial owners were complied with during 2022 and
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GENERAL</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not know of any matters other than those stated in this Proxy Statement that are to be presented for action at the Annual Meeting.
If any other matters should properly come before the Annual Meeting, it is intended that proxies in the accompanying form will be voted
on any such other matters in accordance with the judgment of the persons voting such proxies. Discretionary authority to vote on such
matters is conferred by such proxies upon the persons voting them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will bear the cost of preparing, printing, assembling and mailing the proxy, the Notice of Internet Availability, Proxy Statement and
other material which may be sent to stockholders in connection with this solicitation. It is contemplated that brokerage houses will
forward the proxy materials to beneficial owners at our request. In addition to the solicitation of proxies by use of the mail, officers
and regular employees of Titan may solicit proxies without additional compensation, by telephone or other electronic means. We may reimburse
brokers or other persons holding stock in their names or the names of their nominees for the expenses of forwarding soliciting material
to their principals and obtaining their proxies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE
YOU CAN FIND MORE INFORMATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly and current reports, proxy statements and other documents with the SEC under the Exchange Act. Titan&#8217;s SEC
filings made electronically through the SEC&#8217;s EDGAR system are available to the public at the SEC&#8217;s website at http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will only deliver one Notice of Internet Availability or Proxy Statement to multiple security holders sharing an address unless we have
received contrary instructions from one or more of the security holders. Upon written or oral request, we will promptly deliver a separate
copy of this Proxy Statement and any future annual reports and proxy or information statements to any security holder at a shared address
to which a single copy of this Proxy Statement was delivered, or deliver a single copy of this Proxy Statement and any future annual
reports and proxy or information statements to any security holder or holders sharing an address to which multiple copies are now delivered.
You should direct any such requests to the Company at following address: 400 Oyster Point Boulevard, Suite 505, South San Francisco,
California 94080.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDER
PROPOSALS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
proposals intended for inclusion in the Proxy Statement for the next Annual Meeting of Stockholders (the &#8220;Next Annual Meeting&#8221;)
(pursuant to Rule&#160;14a-8 promulgated under the Exchange Act) must be directed to the Corporate Secretary, Titan Pharmaceuticals,
Inc., 400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080 and must be received by January&#160;19, 2024. Stockholder
proposals must comply with the requirements as to form and substance established by the SEC for such proposals in order to be included
in the Proxy Statement. As to any proposal submitted for presentation at the Next Annual Meeting outside the processes of Rule&#160;14a-8,
the proxies named in the form of proxy for the Next Annual Meeting will be entitled to exercise discretionary authority on that proposal
unless we receive notice of the matter on or before April&#160;3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the notice and information requirements contained in our bylaws, to comply with the universal proxy rules, stockholders who
intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information
required by Rule&#160;14a-19 under the Exchange Act no later than April&#160;30, 2024 (the 60th day prior to the first anniversary of
the annual meeting for the preceding year&#8217;s annual meeting).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%">&#160;</td>
  <td style="width: 50%">By
Order of the Board of Directors</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">/s/ David E. Lazar</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>David E. Lazar</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Chief Executive Officer</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
May&#160;18, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS<br />
<br />
PROXY<br />
FOR THE ANNUAL MEETING OF STOCKHOLDERS OF TITAN<br />
PHARMACEUTICALS, INC.<br />
TO BE HELD ON JUNE&#160;29, 2023</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned appoints David E. Lazar and Katherine Beebe DeVarney, Ph.D., and each of them, attorneys and agents with full power of substitution,
is hereby authorized to vote all of the shares of common stock of Titan Pharmaceuticals, Inc. (the &#8220;Company&#8221;) which the undersigned
would be entitled to vote, if personally present, at the upcoming Annual Meeting of Stockholders of the Company scheduled to be held
at the offices of Olshan Frome Wolosky LLP, located at 1325 Avenue of the Americas, 15th Floor, New York, New York 10019 on Thursday,
June&#160;29, 2023 at 9:00 a.m. (EST) (including any adjournments or postponements thereof and any meeting called in lieu thereof, the
&#8220;Annual Meeting&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby revokes any proxy or proxies heretofore given and acknowledges receipt of a copy of the Notice of Meeting and Proxy
Statement and a copy of the Company&#8217;s Annual Report on Form&#160;10-K (without exhibits) for the fiscal year ended December&#160;31,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IF
NO DIRECTION IS INDICATED WITH RESPECT TO THE PROPOSALS ON THE REVERSE, THIS PROXY WILL BE VOTED &#8220;FOR ALL NOMINEES&#8221; WITH
RESPECT TO PROPOSAL 1 AND &#8220;FOR&#8221; PROPOSALS 2, 3 AND 4.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMPORTANT:
PLEASE SIGN, DATE AND MAIL THIS PROXY CARD PROMPTLY!</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONTINUED
AND TO BE SIGNED ON REVERSE SIDE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
board of directors recommends a vote <span style="text-decoration: underline">FOR</span> Proposals 1, 2, 3 and 4</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ELECTION
                                            OF DIRECTORS</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR all nominees listed below <br />
(except
    as marked to the contrary below)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITHHOLD AUTHORITY to <br />
vote for all
    nominees listed below</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 1in">Nominees:</td>
  <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avraham
Ben-Tzvi<br />
Katherine Beebe DeVarney, Ph.D.<br />
Peter L. Chasey<br />
Eric Greenberg<br />
David E. Lazar<br />
Matthew C. McMurdo<br />
David Natan</span></p>

</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSTRUCTION:
To withhold authority to vote for any nominee, write the nominee&#8217;s name in the space provided below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPROVAL
                                            of the AMENDED AND RESTATED 2015 PLAN</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAINST</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABSTAIN</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>approval
                                            of our executive compensation (say-on-pay)</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAINST</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABSTAIN</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RATIFICATION
                                            OF WITHUMSMITH+BROWN, PC AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE FISCAL
                                            YEAR ENDING DECEMBER&#160;31, 2023</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGAINST</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABSTAIN</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign exactly as your name appears below. When shares are held by joint tenants, each should sign. When signing as attorney, executor,
administrator, trustee, guardian, corporate officer, or partner, please give full title as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
_________________, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature if held jointly</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PLEASE
MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY USING THE ENCLOSED ENVELOPE</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex
A</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TITAN
PHARMACEUTICALS, INC.<br />
FORM OF</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOURTH
AMENDED AND RESTATED<br />
2015 OMNIBUS EQUITY INCENTIVE PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
Amended [&#9679;], 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
I<br />
<b>PURPOSE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of this Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan (the &#8220;<span style="text-decoration: underline">Plan</span>&#8221;) is to benefit Titan Pharmaceuticals,
Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) and its stockholders, by assisting the Company to attract, retain and
provide incentives to key employees and directors of, and consultants to, the Company and its Affiliates, and to align the interests
of such service providers with those of the Company&#8217;s stockholders. Accordingly, the Plan provides for the granting of Non-qualified
Stock Options, Incentive Stock Options, Restricted Stock Awards, Restricted Stock Unit Awards, Stock Appreciation Rights, Performance
Stock Awards, Performance Unit Awards, Unrestricted Stock Awards, Distribution Equivalent Rights or any combination of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
II<br />
<b>DEFINITIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following definitions shall be applicable throughout the Plan unless the context otherwise requires:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1 &#8220;<span style="text-decoration: underline">Affiliate</span>&#8221;
shall mean any corporation which, with respect to the Company, is a &#8220;subsidiary corporation&#8221; within the meaning of Section&#160;424(f)
of the Code or other entity in which the Company has a controlling interest in such entity or another entity which is part of a chain
of entities in which the Company or each entity has a controlling interest in another entity in the unbroken chain of entities ending
with the applicable entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2 &#8220;<span style="text-decoration: underline">Award</span>&#8221;
shall mean, individually or collectively, any Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Award, Performance
Unit Award, Stock Appreciation Right, Distribution Equivalent Right or Unrestricted Stock Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3 &#8220;<span style="text-decoration: underline">Award
Agreement</span>&#8221; shall mean a written agreement between the Company and the Holder with respect to an Award, setting forth the terms
and conditions of the Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4 &#8220;<span style="text-decoration: underline">Board</span>&#8221;
shall mean the Board of Directors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 &#8220;<span style="text-decoration: underline">Base
Value</span>&#8221; shall have the meaning given to such term in Section&#160;14.2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6 &#8220;<span style="text-decoration: underline">Cause</span>&#8221;
shall mean (i) if the Holder is a party to an employment or service agreement with the Company or an Affiliate which agreement defines
&#8220;Cause&#8221; (or a similar term), &#8220;<span style="text-decoration: underline">Cause</span>&#8221; shall have the same meaning as provided for in such agreement, or
(ii) for a Holder who is not a party to such an agreement, &#8220;<span style="text-decoration: underline">Cause</span>&#8221; shall mean termination by the Company or an Affiliate
of the employment (or other service relationship) of the Holder by reason of the Holder&#8217;s (A) intentional failure to perform reasonably
assigned duties, (B) dishonesty or willful misconduct in the performance of the Holder&#8217;s duties, (C) involvement in a transaction
which is materially adverse to the Company or an Affiliate, (D) breach of fiduciary duty involving personal profit, (E) willful violation
of any law, rule, regulation or court order (other than misdemeanor traffic violations and misdemeanors not involving misuse or misappropriation
of money or property), (F) commission of an act of fraud or intentional misappropriation or conversion of any asset or opportunity of
the Company or an Affiliate, or (G) material breach of any provision of the Plan or the Holder&#8217;s Award Agreement or any other written
agreement between the Holder and the Company or an Affiliate, in each case as determined in good faith by the Board, the determination
of which shall be final, conclusive and binding on all parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7 &#8220;<span style="text-decoration: underline">Change
of Control</span>&#8221; shall mean: (i) for a Holder who is a party to an employment or consulting agreement with the Company or an Affiliate
which agreement defines &#8220;Change of Control&#8221; (or a similar term), &#8220;<span style="text-decoration: underline">Change of Control</span>&#8221; shall have the same
meaning as provided for in such agreement, or (ii) for a Holder who is not a party to such an agreement, &#8220;<span style="text-decoration: underline">Change of Control</span>&#8221;
shall mean the satisfaction of any one or more of the following conditions (and the &#8220;Change of Control&#8221; shall be deemed to
have occurred as of the first day that any one or more of the following conditions shall have been satisfied):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Any
person (as such term is used in paragraphs 13(d) and 14(d)(2) of the Exchange Act, hereinafter in this definition, &#8220;<span style="text-decoration: underline">Person</span>&#8221;),
other than the Company or an Affiliate or an employee benefit plan of the Company or an Affiliate, becomes the beneficial owner (as defined
in Rule&#160;13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent
(50%) of the combined voting power of the Company&#8217;s then outstanding securities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
closing of a merger, consolidation or other business combination (a &#8220;<span style="text-decoration: underline">Business Combination</span>&#8221;) other than a Business
Combination in which holders of the Shares immediately prior to the Business Combination have substantially the same proportionate ownership
of the common stock of the surviving corporation immediately after the Business Combination as immediately before;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
closing of an agreement for the sale or disposition of all or substantially all of the Company&#8217;s assets to any entity that is not
an Affiliate;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
approval by the holders of shares of Shares of a plan of complete liquidation of the Company, other than a merger of the Company into
any subsidiary or a liquidation as a result of which persons who were stockholders of the Company immediately prior to such liquidation
have substantially the same proportionate ownership of shares of common stock of the surviving corporation immediately after such liquidation
as immediately before; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) Within
any twenty-four (24) month period, the Incumbent Directors shall cease to constitute at least a majority of the Board or the board of
directors of any successor to the Company; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that any director elected to the Board, or nominated for
election, by a majority of the Incumbent Directors then still in office, shall be deemed to be an Incumbent Director for purposes of
this paragraph (e), but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of either
an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation
of proxies or consents by or on behalf of an individual, entity or &#8220;group&#8221; other than the Board (including, but not limited
to, any such assumption that results from paragraphs (a), (b), (c), or (d) of this definition).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8 &#8220;<span style="text-decoration: underline">Code</span>&#8221;
shall mean the Internal Revenue Code of 1986, as amended. Reference in the Plan to any section of the Code shall be deemed to include
any amendments or successor provisions to any section and any regulation under such section.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9 &#8220;<span style="text-decoration: underline">Committee</span>&#8221;
shall mean a committee comprised of two (2) or more members of the Board who are selected by the Board as provided in Section&#160;4.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10 &#8220;<span style="text-decoration: underline">Company</span>&#8221;
shall have the meaning given to such term in the introductory paragraph, including any successor thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11 &#8220;<span style="text-decoration: underline">Consultant</span>&#8221;
shall mean any non-Employee (individual or entity) advisor to the Company or an Affiliate who or which has contracted directly with the
Company or an Affiliate to render bona fide consulting or advisory services thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12 &#8220;<span style="text-decoration: underline">Director</span>&#8221;
shall mean a member of the Board or a member of the board of directors of an Affiliate, in either case, who is not an Employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13 &#8220;<span style="text-decoration: underline">Distribution
Equivalent Right</span>&#8221; shall mean an Award granted under Article XIII of the Plan which entitles the Holder to receive bookkeeping
credits, cash payments and/or Share distributions equal in amount to the distributions that would have been made to the Holder had the
Holder held a specified number of Shares during the period the Holder held the Distribution Equivalent Right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14 &#8220;<span style="text-decoration: underline">Distribution
Equivalent Right Award Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to a Distribution
Equivalent Right Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15 &#8220;<span style="text-decoration: underline">Effective
Date</span>&#8221; shall mean August&#160;24, 2015 or such later date that the Plan is approved by the stockholders of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16 &#8220;<span style="text-decoration: underline">Employee</span>&#8221;
shall mean any employee, including any officer, of the Company or an Affiliate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17 &#8220;<span style="text-decoration: underline">Exchange
Act</span>&#8221; shall mean the Securities Exchange Act of 1934, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18 &#8220;<span style="text-decoration: underline">Fair
Market Value</span>&#8221; shall mean, as of any specified date, the closing sales price of the Shares for such date (or, in the event that
the Shares are not traded on such date, on the immediately preceding trading date) on the NASDAQ Stock Market (&#8220;NASDAQ&#8221;),
as reported by NASDAQ, or such other domestic or foreign national securities exchange on which the Shares may be listed. If the Shares
are not listed on NASDAQ or on a national securities exchange, but are quoted on the OTC Bulletin Board or by the National Quotation
Bureau, the Fair Market Value of the Shares shall be the mean of the highest bid and lowest asked prices per Share for such date. If
the Shares are not quoted or listed as set forth above, Fair Market Value shall be determined by the Board in good faith by any fair
and reasonable means (which means may be set forth with greater specificity in the applicable Award Agreement). The Fair Market Value
of property other than Shares shall be determined by the Board in good faith by any fair and reasonable means consistent with the requirements
of applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19 &#8220;<span style="text-decoration: underline">Family
Member</span>&#8221; of an individual shall mean any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece,
nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, including adoptive relationships,
any person sharing the Holder&#8217;s household (other than a tenant or employee of the Holder), a trust in which such persons have more
than fifty percent (50%) of the beneficial interest, a foundation in which such persons (or the Holder) control the management of assets,
and any other entity in which such persons (or the Holder) own more than fifty percent (50%) of the voting interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20 &#8220;<span style="text-decoration: underline">Holder</span>&#8221;
shall mean an Employee, Director or Consultant who has been granted an Award or any such individual&#8217;s beneficiary, estate or representative,
who has acquired such Award in accordance with the terms of the Plan, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.21 &#8220;<span style="text-decoration: underline">Incentive
Stock Option</span>&#8221; shall mean an Option which is intended by the Committee to constitute an &#8220;incentive stock option&#8221;
and conforms to the applicable provisions of Section&#160;422 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.22 &#8220;<span style="text-decoration: underline">Incumbent
Director</span>&#8221; shall mean, with respect to any period of time specified under the Plan for purposes of determining whether or not
a Change of Control has occurred, the individuals who were members of the Board at the beginning of such period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23 &#8220;<span style="text-decoration: underline">Non-qualified
Stock Option</span>&#8221; shall mean an Option which is not an Incentive Stock Option or which is designated as an Incentive Stock Option
but does not meet the applicable requirements of Section&#160;422 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24 &#8220;<span style="text-decoration: underline">Option</span>&#8221;
shall mean an Award granted under Article VII of the Plan of an option to purchase Shares and shall include both Incentive Stock Options
and Non-qualified Stock Options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25 &#8220;<span style="text-decoration: underline">Option
Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to an Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.26 &#8220;<span style="text-decoration: underline">Performance
Criteria</span>&#8221; shall mean the criteria selected by the Committee for purposes of establishing the Performance Goal(s) for a Holder
for a Performance Period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27 &#8220;<span style="text-decoration: underline">Performance
Goals</span>&#8221; shall mean, for a Performance Period, the written goal or goals established by the Committee for the Performance Period
based upon the Performance Criteria, which may be related to the performance of the Holder, the Company or an Affiliate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28 &#8220;<span style="text-decoration: underline">Performance
Period</span>&#8221; shall mean one or more periods of time, which may be of varying and overlapping durations, selected by the Committee,
over which the attainment of the Performance Goals shall be measured for purposes of determining a Holder&#8217;s right to, and the payment
of, a Qualified Performance-Based Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29 &#8220;<span style="text-decoration: underline">Performance
Stock Award</span>&#8221; or &#8220;<span style="text-decoration: underline">Performance Stock</span>&#8221; shall mean an Award granted under Article XII of the Plan under which,
upon the satisfaction of predetermined Performance Goals, Shares are paid to the Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30 &#8220;<span style="text-decoration: underline">Performance
Stock Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to a Performance Stock Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31 &#8220;<span style="text-decoration: underline">Performance
Unit</span>&#8221; shall mean a Unit awarded to a Holder pursuant to a Performance Unit Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32 &#8220;<span style="text-decoration: underline">Performance
Unit Award</span>&#8221; shall mean an Award granted under Article XI of the Plan under which, upon the satisfaction of predetermined Performance
Goals, a cash payment shall be made to the Holder, based on the number of Units awarded to the Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.33 &#8220;<span style="text-decoration: underline">Performance
Unit Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to a Performance Unit Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.34 &#8220;<span style="text-decoration: underline">Plan</span>&#8221;
shall mean this Titan Pharmaceuticals 2015 Omnibus Equity Incentive Plan, as amended from time to time, together with each of the Award
Agreements utilized hereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.35 &#8220;<span style="text-decoration: underline">Qualified
Performance-Based Award</span>&#8221; shall mean an Award that is intended to qualify as &#8220;performance-based&#8221; compensation under
Section&#160;162(m) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.36 &#8220;<span style="text-decoration: underline">Restricted
Stock Award</span>&#8221; and &#8220;<span style="text-decoration: underline">Restricted Stock</span>&#8221; shall mean an Award granted under Article VIII of the Plan of Shares,
the transferability of which by the Holder is subject to Restrictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37 &#8220;<span style="text-decoration: underline">Restricted
Stock Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to a Restricted Stock Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.38 &#8220;<span style="text-decoration: underline">Restricted
Stock Unit Award</span>&#8221; and &#8220;<span style="text-decoration: underline">RSUs</span>&#8221; shall refer to an Award granted under Article X of the Plan under which, upon
the satisfaction of predetermined individual service-related vesting requirements, a cash payment shall be made to the Holder, based
on the number of Units awarded to the Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.39 &#8220;<span style="text-decoration: underline">Restricted
Stock Unit Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to a Restricted Stock Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.40 &#8220;<span style="text-decoration: underline">Restriction
Period</span>&#8221; shall mean the period of time for which Shares subject to a Restricted Stock Award shall be subject to Restrictions,
as set forth in the applicable Restricted Stock Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.41 &#8220;<span style="text-decoration: underline">Restrictions</span>&#8221;
shall mean the forfeiture, transfer and/or other restrictions applicable to Shares awarded to an Employee, Director or Consultant under
the Plan pursuant to a Restricted Stock Award and set forth in a Restricted Stock Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.42 &#8220;<span style="text-decoration: underline">Rule&#160;16b-3</span>&#8221;
shall mean Rule&#160;16b-3 promulgated by the Securities and Exchange Commission under the Exchange Act, as such may be amended from
time to time, and any successor rule, regulation or statute fulfilling the same or a substantially similar function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.43 &#8220;<span style="text-decoration: underline">Shares</span>&#8221;
or &#8220;<span style="text-decoration: underline">Stock</span>&#8221; shall mean the common stock of the Company, par value $0.001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.44 &#8220;<span style="text-decoration: underline">Stock
Appreciation Right</span>&#8221; or &#8220;<span style="text-decoration: underline">SAR</span>&#8221; shall mean an Award granted under Article XIV of the Plan of a right, granted
alone or in connection with a related Option, to receive a payment equal to the increase in value of a specified number of Shares between
the date of Award and the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.45 &#8220;<span style="text-decoration: underline">Stock
Appreciation Right Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to a Stock Appreciation
Right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.46 &#8220;<span style="text-decoration: underline">Tandem
Stock Appreciation Right</span>&#8221; shall mean a Stock Appreciation Right granted in connection with a related Option, the exercise of
some or all of which results in termination of the entitlement to purchase some or all of the Shares under the related Option, all as
set forth in Article XIV.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.47 &#8220;<span style="text-decoration: underline">Ten
Percent Stockholder</span>&#8221; shall mean an Employee who, at the time an Option is granted to him or her, owns shares possessing more
than ten percent (10%) of the total combined voting power of all classes of shares of the Company or of any parent corporation or subsidiary
corporation thereof (both as defined in Section&#160;424 of the Code), within the meaning of Section&#160;422(b)(6) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48 &#8220;<span style="text-decoration: underline">Termination
of Service</span>&#8221; shall mean a termination of a Holder&#8217;s employment with, or status as a Director or Consultant of, the Company
or an Affiliate, as applicable, for any reason, including, without limitation, Total and Permanent Disability or death, except as provided
in Section&#160;6.4. In the event Termination of Service shall constitute a payment event with respect to any Award subject to Code Section&#160;409A,
Termination of Service shall only be deemed to occur upon a &#8220;separation from service&#8221; as such term is defined under Code
Section&#160;409A and applicable authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.49 &#8220;<span style="text-decoration: underline">Total
and Permanent Disability</span>&#8221; of an individual shall mean the inability of such individual to engage in any substantial gainful
activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has
lasted or can be expected to last for a continuous period of not less than twelve (12) months, within the meaning of Section&#160;22(e)(3)
of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.50 &#8220;<span style="text-decoration: underline">Unit</span>&#8221;
shall mean a bookkeeping unit, which represents such monetary amount as shall be designated by the Committee in each Performance Unit
Agreement, or represents one Share for purposes of each Restricted Stock Unit Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.51 &#8220;<span style="text-decoration: underline">Unrestricted
Stock Award</span>&#8221; shall mean an Award granted under Article IX of the Plan of Shares which are not subject to Restrictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.52 &#8220;<span style="text-decoration: underline">Unrestricted
Stock Agreement</span>&#8221; shall mean a written agreement between the Company and a Holder with respect to an Unrestricted Stock Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
III<br />
<b>EFFECTIVE DATE OF PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan shall be effective as of the Effective Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IV<br />
<b>ADMINISTRATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1 <span style="text-decoration: underline">Composition
of Committee</span>. The Plan shall be administered by the Committee, which shall be appointed by the Board. If necessary, in the Board&#8217;s
discretion, to comply with Rule&#160;16b-3 under the Exchange Act and Section&#160;162(m) of the Code, the Committee shall consist solely
of two (2) or more Directors who are each (i) &#8220;outside directors&#8221; within the meaning of Section&#160;162(m) of the Code (&#8220;<span style="text-decoration: underline">Outside
Directors</span>&#8221;), (ii) &#8220;non-employee directors&#8221; within the meaning of Rule&#160;16b-3 (&#8220;<span style="text-decoration: underline">Non-Employee Directors</span>&#8221;)
and (iii) &#8220;independent&#8221; for purposes of any applicable listing requirements; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that the Board
or the Committee may delegate to a committee of one or more members of the Board who are not (x) Outside Directors, the authority to
grant Awards to eligible persons who are not (A) then &#8220;covered employees&#8221; within the meaning of Section&#160;162(m) of the
Code and are not expected to be &#8220;covered employees&#8221; at the time of recognition of income resulting from such Award, or (B)
persons with respect to whom the Company wishes to comply with the requirements of Section&#160;162(m) of the Code, and/or (y) Non-Employee
Directors, the authority to grant Awards to eligible persons who are not then subject to the requirements of Section&#160;16 of the Exchange
Act. If a member of the Committee shall be eligible to receive an Award under the Plan, such Committee member shall have no authority
hereunder with respect to his or her own Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2 <span style="text-decoration: underline">Powers</span>.
Subject to the other provisions of the Plan, the Committee shall have the sole authority, in its discretion, to make all determinations
under the Plan, including but not limited to (i) determining which Employees, Directors or Consultants shall receive an Award, (ii) the
time or times when an Award shall be made (the date of grant of an Award shall be the date on which the Award is awarded by the Committee),
(iii) what type of Award shall be granted, (iv) the term of an Award, (v) the date or dates on which an Award vests (including acceleration
of vesting), (vi) the form of any payment to be made pursuant to an Award, (vii) the terms and conditions of an Award (including the
forfeiture of the Award, and/or any financial gain, if the Holder of the Award violates any applicable restrictive covenant thereof),
(viii) the Restrictions under a Restricted Stock Award, (ix) the number of Shares which may be issued under an Award, (x) Performance
Goals applicable to any Award and certification of the achievement of such goals, and (xi) the waiver of any Restrictions or Performance
Goals, subject in all cases to compliance with applicable laws. In making such determinations the Committee may take into account the
nature of the services rendered by the respective Employees, Directors and Consultants, their present and potential contribution to the
Company&#8217;s (or the Affiliate&#8217;s) success and such other factors as the Committee in its discretion may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3 <span style="text-decoration: underline">Additional
Powers</span>. The Committee shall have such additional powers as are delegated to it under the other provisions of the Plan. Subject to
the express provisions of the Plan, the Committee is authorized to construe the Plan and the respective Award Agreements executed hereunder,
to prescribe such rules and regulations relating to the Plan as it may deem advisable to carry out the intent of the Plan, to determine
the terms, restrictions and provisions of each Award and to make all other determinations necessary or advisable for administering the
Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in any Award Agreement in the manner
and to the extent the Committee shall deem necessary, appropriate or expedient to carry it into effect. The determinations of the Committee
on the matters referred to in this Article IV shall be conclusive and binding on the Company and all Holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4 <span style="text-decoration: underline">Committee
Action</span>. Subject to compliance with all applicable laws, action by the Committee shall require the consent of a majority of the members
of the Committee, expressed either orally at a meeting of the Committee or in writing in the absence of a meeting. No member of the Committee
shall have any liability for any good faith action, inaction or determination in connection with the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
V<br />
<b>SHARES SUBJECT TO PLAN AND LIMITATIONS THEREON</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1 <span style="text-decoration: underline">Authorized
Shares and Award Limits</span>. The Committee may from time to time grant Awards to one or more Employees, Directors and/or
Consultants determined by it to be eligible for participation in the Plan in accordance with the provisions of Article VI. Subject to
Article XV, the aggregate number of Shares that may be issued under the Plan shall not exceed Two Million Five Hundred Thousand (2,500,000)
Shares. Shares shall be deemed to have been issued under the Plan solely to the extent actually issued and delivered pursuant to an Award.
To the extent that an Award lapses, expires, is canceled, is terminated unexercised or ceases to be exercisable for any reason, or the
rights of its Holder terminate, any Shares subject to such Award shall again be available for the grant of a new Award. Notwithstanding
any provision in the Plan to the contrary, the maximum number of Shares that may be subject to Awards granted to any one person during
any calendar year, shall be Two Hundred Thousand (200,000) Shares (subject to adjustment in the same manner as provided in Article XV
with respect to Shares subject to Awards then outstanding). The limitation set forth in the preceding sentence shall be applied in a
manner which shall permit compensation generated in connection with the exercise of Options or Stock Appreciation Rights to constitute
&#8220;performance-based&#8221; compensation for purposes of Section&#160;162(m) of the Code, including, but not limited to, counting
against such maximum number of Shares, to the extent required under Section&#160;162(m) of the Code, any Shares subject to Options or
Stock Appreciation Rights that are canceled or re-priced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2 <span style="text-decoration: underline">Types
of Shares</span>. The Shares to be issued pursuant to the grant or exercise of an Award may consist of authorized but unissued Shares,
Shares purchased on the open market or Shares previously issued and outstanding and reacquired by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VI<br />
<b>ELIGIBILITY AND TERMINATION OF SERVICE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1 <span style="text-decoration: underline">Eligibility</span>.
Awards made under the Plan may be granted solely to individuals or entities who, at the time of grant, are Employees, Directors or Consultants.
An Award may be granted on more than one occasion to the same Employee, Director or Consultant, and, subject to the limitations set forth
in the Plan, such Award may include, a Non-qualified Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, an Unrestricted
Stock Award, a Distribution Equivalent Right Award, a Performance Stock Award, a Performance Unit Award, a Stock Appreciation Right,
a Tandem Stock Appreciation Right, or any combination thereof, and solely for Employees, an Incentive Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 <span style="text-decoration: underline">Termination
of Service</span>. Except to the extent inconsistent with the terms of the applicable Award Agreement and/or the provisions of Section&#160;6.3
or 6.4, the following terms and conditions shall apply with respect to a Holder&#8217;s Termination of Service with the Company or an
Affiliate, as applicable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Holder&#8217;s rights, if any, to exercise any then exercisable Options and/or Stock Appreciation Rights shall terminate:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) If
such termination is for a reason other than the Holder&#8217;s Total and Permanent Disability or death, ninety (90) days after the date
of such Termination of Service;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) If
such termination is on account of the Holder&#8217;s Total and Permanent Disability, one (1) year after the date of such Termination
of Service; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) If
such termination is on account of the Holder&#8217;s death, one (1) year after the date of the Holder&#8217;s death. Upon such applicable
date the Holder (and such Holder&#8217;s estate, designated beneficiary or other legal representative) shall forfeit any rights or interests
in or with respect to any such Options and Stock Appreciation Rights. Notwithstanding the foregoing, the Committee, in its sole discretion,
may provide for a different time period in the Award Agreement, or may extend the time period, following a Termination of Service, during
which the Holder has the right to exercise any vested Non-qualified Stock Option or Stock Appreciation Right, which time period may not
extend beyond the expiration date of the Award term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) In
the event of a Holder&#8217;s Termination of Service for any reason prior to the actual or deemed satisfaction and/or lapse of the Restrictions,
vesting requirements, terms and conditions applicable to a Restricted Stock Award and/or Restricted Stock Unit Award, such Restricted
Stock and/or RSUs shall immediately be canceled, and the Holder (and such Holder&#8217;s estate, designated beneficiary or other legal
representative) shall forfeit any rights or interests in and with respect to any such Restricted Stock and/or RSUs. Notwithstanding the
immediately preceding sentence, the Committee, in its sole discretion, may determine, prior to or within thirty (30) days after the date
of such Termination of Service that all or a portion of any such Holder&#8217;s Restricted Stock and/or RSUs shall not be so canceled
and forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3 <span style="text-decoration: underline">Special
Termination Rule</span>. Except to the extent inconsistent with the terms of the applicable Award Agreement, and notwithstanding anything
to the contrary contained in this Article VI, if a Holder&#8217;s employment with, or status as a Director of, the Company or an Affiliate
shall terminate, and if, within ninety (90) days of such termination, such Holder shall become a Consultant, such Holder&#8217;s rights
with respect to any Award or portion thereof granted thereto prior to the date of such termination may be preserved, if and to the extent
determined by the Committee in its sole discretion, as if such Holder had been a Consultant for the entire period during which such Award
or portion thereof had been outstanding. Should the Committee effect such determination with respect to such Holder, for all purposes
of the Plan, such Holder shall not be treated as if his or her employment or Director status had terminated until such time as his or
her Consultant status shall terminate, in which case his or her Award, as it may have been reduced in connection with the Holder&#8217;s
becoming a Consultant, shall be treated pursuant to the provisions of Section&#160;6.2, provided, however, that any such Award which
is intended to be an Incentive Stock Option shall, upon the Holder&#8217;s no longer being an Employee, automatically convert to a Non-qualified
Stock Option. Should a Holder&#8217;s status as a Consultant terminate, and if, within ninety (90) days of such termination, such Holder
shall become an Employee or a Director, such Holder&#8217;s rights with respect to any Award or portion thereof granted thereto prior
to the date of such termination may be preserved, if and to the extent determined by the Committee in its sole discretion, as if such
Holder had been an Employee or a Director, as applicable, for the entire period during which such Award or portion thereof had been outstanding,
and, should the Committee effect such determination with respect to such Holder, for all purposes of the Plan, such Holder shall not
be treated as if his or her Consultant status had terminated until such time as his or her employment with the Company or an Affiliate,
or his or her Director status, as applicable, shall terminate, in which case his or her Award shall be treated pursuant to the provisions
of Section&#160;6.2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4 <span style="text-decoration: underline">Termination
of Service for Cause</span>. Notwithstanding anything in this Article VI or elsewhere in the Plan to the contrary, and unless a Holder&#8217;s
Award Agreement specifically provides otherwise, in the event of a Holder&#8217;s Termination of Service for Cause, all of such Holder&#8217;s
then outstanding Awards shall expire immediately and be forfeited in their entirety upon such Termination of Service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VII<br />
<b>OPTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1 <span style="text-decoration: underline">Option
Period</span>. The term of each Option shall be as specified in the Option Agreement; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that except as set
forth in Section&#160;7.3, no Option shall be exercisable after the expiration of ten (10) years from the date of its grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2 <span style="text-decoration: underline">Limitations
on Exercise of Option</span>. An Option shall be exercisable in whole or in such installments and at such times as specified in the Option
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3 <span style="text-decoration: underline">Special
Limitations on Incentive Stock Options</span>. To the extent that the aggregate Fair Market Value (determined at the time the respective
Incentive Stock Option is granted) of Shares with respect to which Incentive Stock Options are exercisable for the first time by an individual
during any calendar year under all plans of the Company and any parent corporation or subsidiary corporation thereof (both as defined
in Section&#160;424 of the Code) which provide for the grant of Incentive Stock Options exceeds One Hundred Thousand Dollars ($100,000)
(or such other individual limit as may be in effect under the Code on the date of grant), the portion of such Incentive Stock Options
that exceeds such threshold shall be treated as Non-qualified Stock Options. The Committee shall determine, in accordance with applicable
provisions of the Code, Treasury Regulations and other administrative pronouncements, which of a Holder&#8217;s Options, which were intended
by the Committee to be Incentive Stock Options when granted to the Holder, will not constitute Incentive Stock Options because of such
limitation, and shall notify the Holder of such determination as soon as practicable after such determination. No Incentive Stock Option
shall be granted to an Employee if, at the time the Incentive Stock Option is granted, such Employee is a Ten Percent Stockholder, unless
(i) at the time such Incentive Stock Option is granted the Option price is at least one hundred ten percent (110%) of the Fair Market
Value of the Shares subject to the Incentive Stock Option, and (ii) such Incentive Stock Option by its terms is not exercisable after
the expiration of five (5) years from the date of grant. No Incentive Stock Option shall be granted more than ten (10) years from the
Effective Date. The designation by the Committee of an Option as an Incentive Stock Option shall not guarantee the Holder that the Option
will satisfy the applicable requirements for &#8220;incentive stock option&#8221; status under Section&#160;422 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4 <span style="text-decoration: underline">Option
Agreement</span>. Each Option shall be evidenced by an Option Agreement in such form and containing such provisions not inconsistent with
the other provisions of the Plan as the Committee from time to time shall approve, including, but not limited to, provisions intended
to qualify an Option as an Incentive Stock Option. An Option Agreement may provide for the payment of the Option price, in whole or in
part, by the delivery of a number of Shares (plus cash if necessary) that have been owned by the Holder for at least six (6) months and
having a Fair Market Value equal to such Option price, or such other forms or methods as the Committee may determine from time to time,
in each case, subject to such rules and regulations as may be adopted by the Committee. Each Option Agreement shall, solely to the extent
inconsistent with the provisions of Sections&#160;6.2, 6.3, and 6.4, as applicable, specify the effect of Termination of Service on the
exercisability of the Option. Moreover, without limiting the generality of the foregoing, a Non-qualified Stock Option Agreement may
provide for a &#8220;cashless exercise&#8221; of the Option, in whole or in part, by (a) establishing procedures whereby the Holder,
by a properly-executed written notice, directs (i) an immediate market sale or margin loan as to all or a part of Shares to which he
is entitled to receive upon exercise of the Option, pursuant to an extension of credit by the Company to the Holder of the Option price,
(ii) the delivery of the Shares from the Company directly to a brokerage firm and (iii) the delivery of the Option price from sale or
margin loan proceeds from the brokerage firm directly to the Company, or (b) reducing the number of Shares to be issued upon exercise
of the Option by the number of such Shares having an aggregate Fair Market Value equal to the Option price (or portion thereof to be
so paid) as of the date of the Option&#8217;s exercise. An Option Agreement may also include provisions relating to: (i) subject to the
provisions hereof, accelerated vesting of Options, including but not limited to, upon the occurrence of a Change of Control, (ii) tax
matters (including provisions covering any applicable Employee wage withholding requirements) and (iii) any other matters not inconsistent
with the terms and provisions of the Plan that the Committee shall in its sole discretion determine. The terms and conditions of the
respective Option Agreements need not be identical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5 <span style="text-decoration: underline">Option
Price and Payment</span>. The price at which an Share may be purchased upon exercise of an Option shall be determined by the Committee;
<span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that such Option price (i) shall not be less than the Fair Market Value of an Share on the date such
Option is granted (or 110% of Fair Market Value for an Incentive Stock Option held by Ten Percent Stockholder, as provided in Section&#160;7.3),
and (ii) shall be subject to adjustment as provided in Article XV. The Option or portion thereof may be exercised by delivery of an irrevocable
notice of exercise to the Company. The Option price for the Option or portion thereof shall be paid in full in the manner prescribed
by the Committee as set forth in the Plan and the applicable Option Agreement, which manner, with the consent of the Committee, may include
the withholding of Shares otherwise issuable in connection with the exercise of the Option. Separate share certificates shall be issued
by the Company for those Shares acquired pursuant to the exercise of an Incentive Stock Option and for those Shares acquired pursuant
to the exercise of a Non-qualified Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6 <span style="text-decoration: underline">Stockholder
Rights and Privileges</span>. The Holder of an Option shall be entitled to all the privileges and rights of a stockholder of the Company
solely with respect to such Shares as have been purchased under the Option and for which share certificates have been registered in the
Holder&#8217;s name.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7 <span style="text-decoration: underline">Options
and Rights in Substitution for Stock or Options Granted by Other Corporations</span>. Options may be granted under the Plan from time to
time in substitution for stock options held by individuals employed by entities who become Employees, Directors or Consultants as a result
of a merger or consolidation of the employing entity with the Company or any Affiliate, or the acquisition by the Company or an Affiliate
of the assets of the employing entity, or the acquisition by the Company or an Affiliate of stock or shares of the employing entity with
the result that such employing entity becomes an Affiliate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8 <span style="text-decoration: underline">Prohibition
Against Re-Pricing</span>. Except to the extent (i) approved in advance by holders of a majority of the shares of the Company entitled to
vote generally in the election of directors, or (ii) as a result of any Change of Control or any adjustment as provided in Article XV,
the Committee shall not have the power or authority to reduce, whether through amendment or otherwise, the exercise price under any outstanding
Option or Stock Appreciation Right, or to grant any new Award or make any payment of cash in substitution for or upon the cancellation
of Options and/or Stock Appreciation Rights previously granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
VIII<br />
<b>RESTRICTED STOCK AWARDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1 <span style="text-decoration: underline">Award</span>.
A Restricted Stock Award shall constitute an Award of Shares to the Holder as of the date of the Award which are subject to a &#8220;substantial
risk of forfeiture&#8221; as defined under Section&#160;83 of the Code during the specified Restriction Period. At the time a Restricted
Stock Award is made, the Committee shall establish the Restriction Period applicable to such Award. Each Restricted Stock Award may have
a different Restriction Period, in the discretion of the Committee. The Restriction Period applicable to a particular Restricted Stock
Award shall not be changed except as permitted by Section&#160;8.2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2 <span style="text-decoration: underline">Terms
and Conditions</span>. At the time any Award is made under this Article VIII, the Company and the Holder shall enter into a Restricted Stock
Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to be appropriate.
Shares awarded pursuant to a Restricted Stock Award shall be represented by a share certificate registered in the name of the Holder
of such Restricted Stock Award. If provided for under the Restricted Stock Agreement, the Holder shall have the right to vote Shares
subject thereto and to enjoy all other stockholder rights, including the entitlement to receive dividends on the Shares during the Restriction
Period, except that (i) the Holder shall not be entitled to delivery of the share certificate until the Restriction Period shall have
expired, (ii) the Company shall retain custody of the share certificate during the Restriction Period (with a share power endorsed by
the Holder in blank), (iii) the Holder may not sell, transfer, pledge, exchange, hypothecate or otherwise dispose of the Shares during
the Restriction Period and (iv) a breach of the terms and conditions established by the Committee pursuant to the Restricted Stock Agreement
shall cause a forfeiture of the Restricted Stock Award. At the time of such Award, the Committee may, in its sole discretion, prescribe
additional terms and conditions or restrictions relating to Restricted Stock Awards, including, but not limited to, rules pertaining
to the effect of Termination of Service prior to expiration of the Restriction Period. Such additional terms, conditions or restrictions
shall, to the extent inconsistent with the provisions of Sections&#160;6.2, 6.3 and 6.4, as applicable, be set forth in a Restricted
Stock Agreement made in conjunction with the Award. Such Restricted Stock Agreement may also include provisions relating to: (i) subject
to the provisions hereof, accelerated vesting of Awards, including but not limited to accelerated vesting upon the occurrence of a Change
of Control, (ii) tax matters (including provisions covering any applicable Employee wage withholding requirements) and (iii) any other
matters not inconsistent with the terms and provisions of the Plan that the Committee shall in its sole discretion determine. The terms
and conditions of the respective Restricted Stock Agreements need not be identical. All Shares delivered to a Holder as part of a Restricted
Stock Award shall be delivered and reported by the Company or the Affiliate, as applicable, to the Holder at the time of vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3 <span style="text-decoration: underline">Payment
for Restricted Stock</span>. The Committee shall determine the amount and form of any payment from a Holder for Shares received pursuant
to a Restricted Stock Award, if any, provided that in the absence of such a determination, a Holder shall not be required to make any
payment for Shares received pursuant to a Restricted Stock Award, except to the extent otherwise required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
IX<br />
<b>UNRESTRICTED STOCK AWARDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1 <span style="text-decoration: underline">Award</span>.
Shares may be awarded (or sold) to Employees, Directors or Consultants under the Plan which are not subject to Restrictions of any kind,
in consideration for past services rendered thereby to the Company or an Affiliate or for other valid consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2 <span style="text-decoration: underline">Terms
and Conditions</span>. At the time any Award is made under this Article IX, the Company and the Holder shall enter into an Unrestricted
Stock Agreement setting forth each of the matters contemplated hereby and such other matters as the Committee may determine to be appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3 <span style="text-decoration: underline">Payment
for Unrestricted Stock</span>. The Committee shall determine the amount and form of any payment from a Holder for Shares received pursuant
to an Unrestricted Stock Award, if any, provided that in the absence of such a determination, a Holder shall not be required to make
any payment for Shares received pursuant to an Unrestricted Stock Award, except to the extent otherwise required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
X<br />
<b>RESTRICTED STOCK UNIT AWARDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1 <span style="text-decoration: underline">Award</span>.
A Restricted Stock Unit Award shall constitute a promise to grant Shares (or cash equal to the Fair Market Value of Shares) to the Holder
at the end of a specified Restriction Period. At the time a Restricted Stock Unit Award is made, the Committee shall establish the Restriction
Period applicable to such Award. Each Restricted Stock Unit Award may have a different Restriction Period, in the discretion of the Committee.
A Restricted Stock Unit shall not constitute an equity interest in the Company and shall not entitle the Holder to voting rights, dividends
or any other rights associated with ownership of Shares prior to the time the Holder shall receive a distribution of Shares pursuant
to Section&#160;10.3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2 <span style="text-decoration: underline">Terms
and Conditions</span>. At the time any Award is made under this Article X, the Company and the Holder shall enter into a Restricted Stock
Unit Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to be appropriate.
The Restricted Stock Unit Agreement shall set forth the individual service-based vesting requirement which the Holder would be required
to satisfy before the Holder would become entitled to distribution pursuant to Section&#160;10.3 and the number of Units awarded to the
Holder. Such conditions shall be sufficient to constitute a &#8220;substantial risk of forfeiture&#8221; as such term is defined under
Section&#160;409A of the Code. At the time of such Award, the Committee may, in its sole discretion, prescribe additional terms and conditions
or restrictions relating to Restricted Stock Unit Awards in the Restricted Stock Unit Agreement, including, but not limited to, rules
pertaining to the effect of Termination of Service prior to expiration of the applicable vesting period. The terms and conditions of
the respective Restricted Stock Unit Agreements need not be identical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3 <span style="text-decoration: underline">Distributions
of Shares</span>. The Holder of a Restricted Stock Unit shall be entitled to receive a cash payment equal to the Fair Market Value of an
Share, or one Share, as determined in the sole discretion of the Committee and as set forth in the Restricted Stock Unit Agreement, for
each Restricted Stock Unit subject to such Restricted Stock Unit Award, if the Holder satisfies the applicable vesting requirement. Such
distribution shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar month next following the end of the
calendar year in which the Restricted Stock Unit first becomes vested (i.e., no longer subject to a &#8220;substantial risk of forfeiture&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
XI<br />
<b>PERFORMANCE UNIT AWARDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1 <span style="text-decoration: underline">Award</span>.
A Performance Unit Award shall constitute an Award under which, upon the satisfaction of predetermined individual and/or Company (and/or
Affiliate) Performance Goals based on selected Performance Criteria, a cash payment shall be made to the Holder, based on the number
of Units awarded to the Holder. At the time a Performance Unit Award is made, the Committee shall establish the Performance Period and
applicable Performance Goals. Each Performance Unit Award may have different Performance Goals, in the discretion of the Committee. A
Performance Unit Award shall not constitute an equity interest in the Company and shall not entitle the Holder to voting rights, dividends
or any other rights associated with ownership of Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2 <span style="text-decoration: underline">Terms
and Conditions</span>. At the time any Award is made under this Article XI, the Company and the Holder shall enter into a Performance Unit
Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to be appropriate.
The Committee shall set forth in the applicable Performance Unit Agreement the Performance Period, Performance Criteria and Performance
Goals which the Holder and/or the Company would be required to satisfy before the Holder would become entitled to payment pursuant to
Section&#160;11.3, the number of Units awarded to the Holder and the dollar value or formula assigned to each such Unit. Such payment
shall be subject to a &#8220;substantial risk of forfeiture&#8221; under Section&#160;409A of the Code. At the time of such Award, the
Committee may, in its sole discretion, prescribe additional terms and conditions or restrictions relating to Performance Unit Awards,
including, but not limited to, rules pertaining to the effect of Termination of Service prior to expiration of the applicable performance
period. The terms and conditions of the respective Performance Unit Agreements need not be identical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3 <span style="text-decoration: underline">Payments</span>.
The Holder of a Performance Unit shall be entitled to receive a cash payment equal to the dollar value assigned to such Unit under the
applicable Performance Unit Agreement if the Holder and/or the Company satisfy (or partially satisfy, if applicable under the applicable
Performance Unit Agreement) the Performance Goals set forth in such Performance Unit Agreement. If necessary to satisfy the requirements
of Code Section&#160;162(m), if applicable, the achievement of such Performance Goals shall be certified in writing by the Committee
prior to any payment. All payments shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar month next following
the end of the Company&#8217;s fiscal year to which such performance goals and objectives relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
XII<br />
<b>PERFORMANCE STOCK AWARDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1 <span style="text-decoration: underline">Award</span>.
A Performance Stock Award shall constitute a promise to grant Shares (or cash equal to the Fair Market Value of Shares) to the Holder
at the end of a specified Performance Period subject to achievement of specified Performance Goals. At the time a Performance Stock Award
is made, the Committee shall establish the Performance Period and applicable Performance Goals based on selected Performance Criteria.
Each Performance Stock Award may have different Performance Goals, in the discretion of the Committee. A Performance Stock Award shall
not constitute an equity interest in the Company and shall not entitle the Holder to voting rights, dividends or any other rights associated
with ownership of Shares unless and until the Holder shall receive a distribution of Shares pursuant to Section&#160;11.3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2 <span style="text-decoration: underline">Terms
and Conditions</span>. At the time any Award is made under this Article XII, the Company and the Holder shall enter into a Performance Stock
Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to be appropriate.
The Committee shall set forth in the applicable Performance Stock Agreement the Performance Period, selected Performance Criteria and
Performance Goals which the Holder and/or the Company would be required to satisfy before the Holder would become entitled to the receipt
of Shares pursuant to such Holder&#8217;s Performance Stock Award and the number of Shares subject to such Performance Stock Award. Such
distribution shall be subject to a &#8220;substantial risk of forfeiture&#8221; under Section&#160;409A of the Code. If such Performance
Goals are achieved, the distribution of Shares (or the payment of cash, as determined in the sole discretion of the Committee), shall
be made no later than by the fifteenth (15th) day of the third (3rd) calendar month next following the end of the Company&#8217;s fiscal
year to which such goals and objectives relate. At the time of such Award, the Committee may, in its sole discretion, prescribe additional
terms and conditions or restrictions relating to Performance Stock Awards, including, but not limited to, rules pertaining to the effect
of the Holder&#8217;s Termination of Service prior to the expiration of the applicable performance period. The terms and conditions of
the respective Performance Stock Agreements need not be identical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3 <span style="text-decoration: underline">Distributions
of Shares</span>. The Holder of a Performance Stock Award shall be entitled to receive a cash payment equal to the Fair Market Value of
a Share, or one Share, as determined in the sole discretion of the Committee, for each Performance Stock Award subject to such Performance
Stock Agreement, if the Holder satisfies the applicable vesting requirement. If necessary to satisfy the requirements of Code Section&#160;162(m),
if applicable, the achievement of such Performance Goals shall be certified in writing by the Committee prior to any payment. Such distribution
shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar month next following the end of the Company&#8217;s
fiscal year to which such performance goals and objectives relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
XIII<br />
<b>DISTRIBUTION EQUIVALENT RIGHTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1 <span style="text-decoration: underline">Award</span>.
A Distribution Equivalent Right shall entitle the Holder to receive bookkeeping credits, cash payments and/or Share distributions equal
in amount to the distributions that would have been made to the Holder had the Holder held a specified number of Shares during the specified
period of the Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2 <span style="text-decoration: underline">Terms
and Conditions</span>. At the time any Award is made under this Article XIII, the Company and the Holder shall enter into a Distribution
Equivalent Rights Award Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may
determine to be appropriate. The Committee shall set forth in the applicable Distribution Equivalent Rights Award Agreement the terms
and conditions, if any, including whether the Holder is to receive credits currently in cash, is to have such credits reinvested (at
Fair Market Value determined as of the date of reinvestment) in additional Shares or is to be entitled to choose among such alternatives.
Such receipt shall be subject to a &#8220;substantial risk of forfeiture&#8221; under Section&#160;409A of the Code and, if such Award
becomes vested, the distribution of such cash or Shares shall be made no later than by the fifteenth (15th) day of the third (3rd) calendar
month next following the end of the Company&#8217;s fiscal year in which the Holder&#8217;s interest in the Award vests. Distribution
Equivalent Rights Awards may be settled in cash or in Shares, as set forth in the applicable Distribution Equivalent Rights Award Agreement.
A Distribution Equivalent Rights Award may, but need not be, awarded in tandem with another Award (other than an Option or a SAR), whereby,
if so awarded, such Distribution Equivalent Rights Award shall expire, terminate or be forfeited by the Holder, as applicable, under
the same conditions as under such other Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3 <span style="text-decoration: underline">Interest
Equivalents</span>. The Distribution Equivalent Rights Award Agreement for a Distribution Equivalent Rights Award may provide for the crediting
of interest on a Distribution Rights Award to be settled in cash at a future date (but in no event later than by the fifteenth (15th)
day of the third (3rd) calendar month next following the end of the Company&#8217;s fiscal year in which such interest is credited and
vested), at a rate set forth in the applicable Distribution Equivalent Rights Award Agreement, on the amount of cash payable thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
XIV<br />
<b>STOCK APPRECIATION RIGHTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1 <span style="text-decoration: underline">Award</span>.
A Stock Appreciation Right shall constitute a right, granted alone or in connection with a related Option, to receive a payment equal
to the increase in value of a specified number of Shares between the date of Award and the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2 <span style="text-decoration: underline">Terms
and Conditions</span>. At the time any Award is made under this Article XIV, the Company and the Holder shall enter into a Stock Appreciation
Right Agreement setting forth each of the matters contemplated thereby and such other matters as the Committee may determine to be appropriate.
The Committee shall set forth in the applicable Stock Appreciation Right Agreement the terms and conditions of the Stock Appreciation
Right, including (i) the base value (the &#8220;<span style="text-decoration: underline">Base Value</span>&#8221;) for the Stock Appreciation Right, which shall be not less than
the Fair Market Value of a Share on the date of grant of the Stock Appreciation Right, (ii) the number of Shares subject to the Stock
Appreciation Right, (iii) the period during which the Stock Appreciation Right may be exercised; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that
no Stock Appreciation Right shall be exercisable after the expiration of ten (10) years from the date of its grant, and (iv) any other
special rules and/or requirements which the Committee imposes upon the Stock Appreciation Right. Upon the exercise of some or all of
the portion of a Stock Appreciation Right, the Holder shall receive a payment from the Company, in cash or in the form of Shares having
an equivalent Fair Market Value or in a combination of both, as determined in the sole discretion of the Committee, equal to the product
of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
excess of (i) the Fair Market Value of an Share on the date of exercise, over (ii) the Base Value, multiplied by, (b)The number of Shares
with respect to which the Stock Appreciation Right is exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3 <span style="text-decoration: underline">Tandem
Stock Appreciation Rights</span>. If the Committee grants a Stock Appreciation Right which is intended to be a Tandem Stock Appreciation
Right, the Tandem Stock Appreciation Right shall be granted at the same time as the related Option, and the following special rules shall
apply:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Base Value shall be equal to or greater than the per Share exercise price under the related Option;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Tandem Stock Appreciation Right may be exercised for all or part of the Shares which are subject to the related Option, but solely upon
the surrender by the Holder of the Holder&#8217;s right to exercise the equivalent portion of the related Option (and when a Share is
purchased under the related Option, an equivalent portion of the related Tandem Stock Appreciation Right shall be canceled);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Tandem Stock Appreciation Right shall expire no later than the date of the expiration of the related Option;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
value of the payment with respect to the Tandem Stock Appreciation Right may be no more than one hundred percent (100%) of the difference
between the per Share exercise price under the related Option and the Fair Market Value of the Shares subject to the related Option at
the time the Tandem Stock Appreciation Right is exercised, multiplied by the number of the Shares with respect to which the Tandem Stock
Appreciation Right is exercised; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
Tandem Stock Appreciation Right may be exercised solely when the Fair Market Value of the Shares subject to the related Option exceeds
the per Share exercise price under the related Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
XV<br />
<b>RECAPITALIZATION OR REORGANIZATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1 <span style="text-decoration: underline">Adjustments
to Shares</span>. The shares with respect to which Awards may be granted under the Plan are Shares as presently constituted; <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that if, and whenever, prior to the expiration or distribution to the Holder of Shares underlying an Award theretofore
granted, the Company shall effect a subdivision or consolidation of the Shares or the payment of an Share dividend on Shares without
receipt of consideration by the Company, the number of Shares with respect to which such Award may thereafter be exercised or satisfied,
as applicable, (i) in the event of an increase in the number of outstanding Shares, shall be proportionately increased, and the purchase
price per Share shall be proportionately reduced, and (ii) in the event of a reduction in the number of outstanding Shares, shall be
proportionately reduced, and the purchase price per Share shall be proportionately increased. Notwithstanding the foregoing or any other
provision of this Article XV, any adjustment made with respect to an Award (x) which is an Incentive Stock Option, shall comply with
the requirements of Section&#160;424(a) of the Code, and in no event shall any adjustment be made which would render any Incentive Stock
Option granted under the Plan to be other than an &#8220;incentive stock option&#8221; for purposes of Section&#160;422 of the Code,
and (y) which is a Non-qualified Stock Option, shall comply with the requirements of Section&#160;409A of the Code, and in no event shall
any adjustment be made which would render any Non-qualified Stock Option granted under the Plan to become subject to Section&#160;409A
of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2 <span style="text-decoration: underline">Recapitalization</span>.
If the Company recapitalizes or otherwise changes its capital structure, thereafter upon any exercise or satisfaction, as applicable,
of a previously granted Award, the Holder shall be entitled to receive (or entitled to purchase, if applicable) under such Award, in
lieu of the number of Shares then covered by such Award, the number and class of shares and securities to which the Holder would have
been entitled pursuant to the terms of the recapitalization if, immediately prior to such recapitalization, the Holder had been the holder
of record of the number of Shares then covered by such Award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3 <span style="text-decoration: underline">Other
Events</span>. In the event of changes to the outstanding Shares by reason of an extraordinary cash dividend, reorganization, merger, consolidation,
combination, split-up, spin-off, exchange or other relevant change in capitalization occurring after the date of the grant of any Award
and not otherwise provided for under this Article XV, any outstanding Awards and any Award Agreements evidencing such Awards shall be
adjusted by the Board in its discretion in such manner as the Board shall deem equitable or appropriate taking into consideration the
applicable accounting and tax consequences, as to the number and price of Shares or other consideration subject to such Awards. In the
event of any adjustment pursuant to Sections&#160;15.1, 15.2 or this Section&#160;15.3, the aggregate number of Shares available under
the Plan pursuant to Section&#160;5.1 (and the Code Section&#160;162(m) limit set forth therein) may be appropriately adjusted by the
Board, the determination of which shall be conclusive. In addition, the Committee may make provision for a cash payment to a Holder or
a person who has an outstanding Award. The number of Shares subject to any Award shall be rounded to the nearest whole number.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4 <span style="text-decoration: underline">Powers
Not Affected</span>. The existence of the Plan and the Awards granted hereunder shall not affect in any way the right or power of the Board
or of the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change of the Company&#8217;s
capital structure or business, any merger or consolidation of the Company, any issue of debt or equity securities ahead of or affecting
Shares or the rights thereof, the dissolution or liquidation of the Company or any sale, lease, exchange or other disposition of all
or any part of its assets or business or any other corporate act or proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5 <span style="text-decoration: underline">No
Adjustment for Certain Awards</span>. Except as hereinabove expressly provided, the issuance by the Company of shares of any class or securities
convertible into shares of any class, for cash, property, labor or services, upon direct sale, upon the exercise of rights or warrants
to subscribe therefor or upon conversion of shares or obligations of the Company convertible into such shares or other securities, and
in any case whether or not for fair value, shall not affect previously granted Awards, and no adjustment by reason thereof shall be made
with respect to the number of Shares subject to Awards theretofore granted or the purchase price per Share, if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
XVI<br />
<b>AMENDMENT AND TERMINATION OF PLAN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan shall continue in effect, unless sooner terminated pursuant to this Article XVI, until the tenth (10th) anniversary of the date
on which it is adopted by the Board (except as to Awards outstanding on that date). The Board in its discretion may terminate the Plan
at any time with respect to any shares for which Awards have not theretofore been granted; <span style="text-decoration: underline">provided</span>, <span style="text-decoration: underline">however</span>, that the
Plan&#8217;s termination shall not materially and adversely impair the rights of a Holder with respect to any Award theretofore granted
without the consent of the Holder. The Board shall have the right to alter or amend the Plan or any part hereof from time to time; <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that without the approval by a majority of the votes cast at a meeting of stockholders at which a quorum representing
a majority of the shares of the Company entitled to vote generally in the election of directors is present in person or by proxy, no
amendment or modification of the Plan may (i) materially increase the benefits accruing to Holders, (ii) except as otherwise expressly
provided in Article XV, materially increase the number of Shares subject to the Plan or the individual Award Agreements specified in
Article V, (iii) materially modify the requirements for participation in the Plan, or (iv) amend, modify or suspend Section&#160;7.7
(re-pricing prohibitions) or this Article XVI. In addition, no change in any Award theretofore granted may be made which would materially
and adversely impair the rights of a Holder with respect to such Award without the consent of the Holder (unless such change is required
in order to cause the benefits under the Plan to qualify as &#8220;performance-based&#8221; compensation within the meaning of Section&#160;162(m)
of the Code or to exempt the Plan or any Award from Section&#160;409A of the Code).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
XVII<br />
<b>MISCELLANEOUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.1 <span style="text-decoration: underline">No
Right to Award</span>. Neither the adoption of the Plan by the Company nor any action of the Board or the Committee shall be deemed to give
an Employee, Director or Consultant any right to an Award except as may be evidenced by an Award Agreement duly executed on behalf of
the Company, and then solely to the extent and on the terms and conditions expressly set forth therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.2 <span style="text-decoration: underline">No
Rights Conferred</span>. Nothing contained in the Plan shall (i) confer upon any Employee any right with respect to continuation of employment
with the Company or any Affiliate, (ii) interfere in any way with any right of the Company or any Affiliate to terminate the employment
of an Employee at any time, (iii) confer upon any Director any right with respect to continuation of such Director&#8217;s membership
on the Board, (iv) interfere in any way with any right of the Company or an Affiliate to terminate a Director&#8217;s membership on the
Board at any time, (v) confer upon any Consultant any right with respect to continuation of his or her consulting engagement with the
Company or any Affiliate, or (vi) interfere in any way with any right of the Company or an Affiliate to terminate a Consultant&#8217;s
consulting engagement with the Company or an Affiliate at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.3 <span style="text-decoration: underline">Other
Laws; No Fractional Shares; Withholding</span>. The Company shall not be obligated by virtue of any provision of the Plan to recognize the
exercise of any Award or to otherwise sell or issue Shares in violation of any laws, rules or regulations, and any postponement of the
exercise or settlement of any Award under this provision shall not extend the term of such Award. Neither the Company nor its directors
or officers shall have any obligation or liability to a Holder with respect to any Award (or Shares issuable thereunder) (i) that shall
lapse because of such postponement, or (ii) for any failure to comply with the requirements of any applicable law, rules or regulations,
including but not limited to any failure to comply with the requirements of Section&#160;409A of this Code. No fractional Shares shall
be delivered, nor shall any cash in lieu of fractional Shares be paid. The Company shall have the right to deduct in cash (whether under
this Plan or otherwise) in connection with all Awards any taxes required by law to be withheld and to require any payments required to
enable it to satisfy its withholding obligations. In the case of any Award satisfied in the form of Shares, no Shares shall be issued
unless and until arrangements satisfactory to the Company shall have been made to satisfy any tax withholding obligations applicable
with respect to such Award. Subject to such terms and conditions as the Committee may impose, the Company shall have the right to retain,
or the Committee may, subject to such terms and conditions as it may establish from time to time, permit Holders to elect to tender,
Shares (including Shares issuable in respect of an Award) to satisfy, in whole or in part, the amount required to be withheld.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.4 <span style="text-decoration: underline">No
Restriction on Corporate Action</span>. Nothing contained in the Plan shall be construed to prevent the Company or any Affiliate from taking
any corporate action which is deemed by the Company or such Affiliate to be appropriate or in its best interest, whether or not such
action would have an adverse effect on the Plan or any Award made under the Plan. No Employee, Director, Consultant, beneficiary or other
person shall have any claim against the Company or any Affiliate as a result of any such action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.5 <span style="text-decoration: underline">Restrictions
on Transfer</span>. No Award under the Plan or any Award Agreement and no rights or interests herein or therein, shall or may be assigned,
transferred, sold, exchanged, encumbered, pledged or otherwise hypothecated or disposed of by a Holder except by will or by the laws
of descent and distribution. An Award may be exercisable during the lifetime of the Holder only by such Holder or by the Holder&#8217;s
guardian or legal representative.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.6 <span style="text-decoration: underline">Beneficiary
Designations</span>. Each Holder may, from time to time, name a beneficiary or beneficiaries (who may be contingent or successive beneficiaries)
for purposes of receiving any amount which is payable in connection with an Award under the Plan upon or subsequent to the Holder&#8217;s
death. Each such beneficiary designation shall serve to revoke all prior beneficiary designations, be in a form prescribed by the Company
and be effective solely when filed by the Holder in writing with the Company during the Holder&#8217;s lifetime. In the absence of any
such written beneficiary designation, for purposes of the Plan, a Holder&#8217;s beneficiary shall be the Holder&#8217;s estate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.7 <span style="text-decoration: underline">Rule&#160;16b-3</span>.
It is intended that the Plan and any Award made to a person subject to Section&#160;16 of the Exchange Act shall meet all of the requirements
of Rule&#160;16b-3. If any provision of the Plan or of any such Award would disqualify the Plan or such Award under, or would otherwise
not comply with the requirements of, Rule&#160;16b-3, such provision or Award shall be construed or deemed to have been amended as necessary
to conform to the requirements of Rule&#160;16b-3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>



<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.8 <span style="text-decoration: underline">Section&#160;162(m)</span>.
The following conditions shall apply if it is intended that the requirements of Section&#160;162(m) of the Code be satisfied such that
Awards under the Plan which are made to Holders who are &#8220;covered employees&#8221; (as defined in Section&#160;162(m) of the Code)
shall constitute &#8220;performance-based&#8221; compensation within the meaning of Section&#160;162(m) of the Code: Any Performance
Goal(s) applicable to Qualified Performance-Based Awards shall be objective, shall be established not later than ninety (90) days after
the beginning of any applicable Performance Period (or at such other date as may be required or permitted for &#8220;performance-based&#8221;
compensation under Section&#160;162(m) of the Code) and shall otherwise meet the requirements of Section&#160;162(m) of the Code, including
the requirement that the outcome of the Performance Goal or Goals be substantially uncertain (as defined in the regulations under Section&#160;162(m)
of the Code) at the time established. The Performance Criteria to be utilized under the Plan to establish Performance Goals shall consist
of objective tests based on one or more of the following: earnings or earnings per share, cash flow or cash flow per share, operating
cash flow or operating cash flow per share revenue growth, product revenue growth, financial return ratios (such as return on equity,
return on investment and/or return on assets), share price performance, stockholder return, equity and/or value, operating income, operating
margins, earnings before interest, taxes, depreciation and amortization, earnings, pre- or post-tax income, economic value added (or
an equivalent metric), profit returns and margins, credit quality, sales growth, market share, working capital levels, comparisons with
various share market indices, year-end cash, debt reduction, assets under management, operating efficiencies, strategic partnerships
or transactions (including co-development, co-marketing, profit sharing, joint venture or other similar arrangements), and/or financing
and other capital raising transaction. Performance criteria may be established on a Company-wide basis or with respect to one or more
Company business units or divisions or subsidiaries; and either in absolute terms, relative to the performance of one or more similarly
situated companies, or relative to the performance of an index covering a peer group of companies. When establishing Performance Goals
for the applicable Performance Period, the Committee may exclude any or all &#8220;extraordinary items&#8221; as determined under U.S.
generally accepted accounting principles including, without limitation, the charges or costs associated with restructurings of the Company,
discontinued operations, other unusual or non-recurring items, and the cumulative effects of accounting changes, and as identified in
the Company&#8217;s financial statements, notes to the Company&#8217;s financial statements or management&#8217;s discussion and analysis
of financial condition and results of operations contained in the Company&#8217;s most recent annual report filed with the U.S. Securities
and Exchange Commission pursuant to the Exchange Act. Holders who are &#8220;covered employees&#8221; (as defined in Section&#160;162(m)
of the Code) shall be eligible to receive payment under a Qualified Performance-Based Award which is subject to achievement of a Performance
Goal or Goals only if the applicable Performance Goal or Goals are achieved within the applicable Performance Period, as determined by
the Committee. If any provision of the Plan would disqualify the Plan or would not otherwise permit the Plan to comply with Section&#160;162(m)
of the Code as so intended, such provision shall be construed or deemed amended to conform to the requirements or provisions of Section&#160;162(m)
of the Code. The Committee may postpone the exercising of Awards, the issuance or delivery of Shares under any Award or any action permitted
under the Plan to prevent the Company or any subsidiary from being denied a federal income tax deduction, provided that such deferral
satisfies the requirements of Section&#160;409A of the Code. For purposes of the requirements of Treasury Regulation Section&#160;1.162-27(e)(4)(i),
the maximum aggregate amount that may be paid in cash during any calendar year to any one person (measured from the date of any payment)
with respect to one or more Awards payable in cash shall be Ten Million Dollars ($10,000,000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.9 <span style="text-decoration: underline">Section&#160;409A</span>.
Notwithstanding any other provision of the Plan, the Committee shall have no authority to issue an Award under the Plan with terms and/or
conditions which would cause such Award to constitute non-qualified &#8220;deferred compensation&#8221; under Section&#160;409A of the
Code unless such Award shall be structured to be exempt from or comply with all requirements of Code Section&#160;409A. The Plan and
all Award Agreements are intended to comply with the requirements of Section&#160;409A of the Code (or to be exempt therefrom) and shall
be so interpreted and construed and no amount shall be paid or distributed from the Plan unless and until such payment complies with
all requirements of Code Section&#160;409A. It is the intent of the Company that the provisions of this Agreement and all other plans
and programs sponsored by the Company be interpreted to comply in all respects with Code Section&#160;409A, however, the Company shall
have no liability to the Holder, or any successor or beneficiary thereof, in the event taxes, penalties or excise taxes may ultimately
be determined to be applicable to any payment or benefit received by the Holder or any successor or beneficiary thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.10 <span style="text-decoration: underline">Indemnification</span>.
Each person who is or shall have been a member of the Committee or of the Board shall be indemnified and held harmless by the Company
against and from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred thereby in connection with or
resulting from any claim, action, suit, or proceeding to which such person may be made a party or may be involved by reason of any action
taken or failure to act under the Plan and against and from any and all amounts paid thereby in settlement thereof, with the Company&#8217;s
approval, or paid thereby in satisfaction of any judgment in any such action, suit, or proceeding against such person; <span style="text-decoration: underline">provided</span>,
<span style="text-decoration: underline">however</span>, that such person shall give the Company an opportunity, at its own expense, to handle and defend the same before he or
she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive and shall
be independent of any other rights of indemnification to which such persons may be entitled under the Company&#8217;s Articles of Incorporation
or By-laws, by contract, as a matter of law, or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.11 <span style="text-decoration: underline">Other
Benefit Plans</span>. No Award, payment or amount received hereunder shall be taken into account in computing an Employee&#8217;s salary
or compensation for the purposes of determining any benefits under any pension, retirement, life insurance or other benefit plan of the
Company or any Affiliate, unless such other plan specifically provides for the inclusion of such Award, payment or amount received. Nothing
in the Plan shall be construed to limit the right of the Company to establish other plans or to pay compensation to its employees, in
cash or property, in a manner which is not expressly authorized under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.12 <span style="text-decoration: underline">Limits
of Liability</span>. Any liability of the Company with respect to an Award shall be based solely upon the contractual obligations created
under the Plan and the Award Agreement. None of the Company, any member of the Board nor any member of the Committee shall have any liability
to any party for any action taken or not taken, in good faith, in connection with or under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.13 <span style="text-decoration: underline">Governing
Law</span>. Except as otherwise provided herein, the Plan shall be construed in accordance with the laws of the State of Delaware, without
regard to principles of conflicts of law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.14 <span style="text-decoration: underline">Severability
of Provisions</span>. If any provision of the Plan is held invalid or unenforceable, such invalidity or unenforceability shall not affect
any other provision of the Plan, and the Plan shall be construed and enforced as if such invalid or unenforceable provision had not been
included in the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.15 <span style="text-decoration: underline">No
Funding</span>. The Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other
segregation of funds or assets to ensure the payment of any Award. Prior to receipt of Shares or a cash distribution pursuant to the
terms of an Award, such Award shall represent an unfunded unsecured contractual obligation of the Company and the Holder shall have no
greater claim to the Shares underlying such Award or any other assets of the Company or Affiliate than any other unsecured general creditor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.16 <span style="text-decoration: underline">Headings</span>.
Headings used throughout the Plan are for convenience only and shall not be given legal significance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Annex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>

    <!-- Field: /Page -->


</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>2
<FILENAME>ttnp-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" xlink:label="loc_ttnpLessValueOfStockAwardsReportedInSummaryCompensationTableMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpLessValueOfStockAwardsReportedInSummaryCompensationTableMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:label="loc_ttnpPlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpPlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" xlink:label="loc_ttnpPlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpPlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:label="loc_ttnpPlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpPlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MarcRubinMember" xlink:label="loc_ttnpMarcRubinMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpMarcRubinMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DavidLazarMember" xlink:label="loc_ttnpDavidLazarMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpDavidLazarMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_NonpeoNeosMember" xlink:label="loc_ttnpNonpeoNeosMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpNonpeoNeosMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DrRubinMember" xlink:label="loc_ttnpDrRubinMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpDrRubinMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DrBeebeDeVarneyMember" xlink:label="loc_ttnpDrBeebeDeVarneyMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpDrBeebeDeVarneyMember" xlink:type="arc" order="40" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>ttnp-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MarcRubinMember" xlink:label="ttnp_MarcRubinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_MarcRubinMember" xlink:to="ttnp_MarcRubinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_MarcRubinMember_lbl" xml:lang="en-US">Marc Rubin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DavidLazarMember" xlink:label="ttnp_DavidLazarMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DavidLazarMember" xlink:to="ttnp_DavidLazarMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DavidLazarMember_lbl" xml:lang="en-US">David Lazar [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_NonpeoNeosMember" xlink:label="ttnp_NonpeoNeosMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_NonpeoNeosMember" xlink:to="ttnp_NonpeoNeosMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_NonpeoNeosMember_lbl" xml:lang="en-US">Non-PEO NEOs</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DrRubinMember" xlink:label="ttnp_DrRubinMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DrRubinMember" xlink:to="ttnp_DrRubinMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DrRubinMember_lbl" xml:lang="en-US">Dr. Rubin [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" xlink:label="ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" xlink:to="ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember_lbl" xml:lang="en-US">Less, value of Stock Awards reported in Summary Compensation Table [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:label="ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:to="ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_lbl" xml:lang="en-US">Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" xlink:label="ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" xlink:to="ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_lbl" xml:lang="en-US">Plus, fair value of outstanding and vested equity awards granted in the year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:label="ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:to="ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_lbl" xml:lang="en-US">Plus, year over year change in fair value of equity awards granted in prior years that vested in the year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DrBeebeDeVarneyMember" xlink:label="ttnp_DrBeebeDeVarneyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ttnp_DrBeebeDeVarneyMember" xlink:to="ttnp_DrBeebeDeVarneyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ttnp_DrBeebeDeVarneyMember_lbl" xml:lang="en-US">Dr. Beebe De Varney [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid to Dr. Beebe DeVarney</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Award Underlying Securities Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Award Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Award Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>ttnp-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://titanpharm.com/role/Cover" xlink:href="ttnp-20221231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://titanpharm.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_MarcRubinMember" xlink:label="loc_ttnpMarcRubinMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpMarcRubinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DavidLazarMember" xlink:label="loc_ttnpDavidLazarMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpDavidLazarMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_NonpeoNeosMember" xlink:label="loc_ttnpNonpeoNeosMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpNonpeoNeosMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DrRubinMember" xlink:label="loc_ttnpDrRubinMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpDrRubinMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_DrBeebeDeVarneyMember" xlink:label="loc_ttnpDrBeebeDeVarneyMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllIndividualsMember" xlink:to="loc_ttnpDrBeebeDeVarneyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" xlink:label="loc_ttnpLessValueOfStockAwardsReportedInSummaryCompensationTableMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpLessValueOfStockAwardsReportedInSummaryCompensationTableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:label="loc_ttnpPlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpPlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" xlink:label="loc_ttnpPlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpPlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ttnp-20221231.xsd#ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:label="loc_ttnpPlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAllAdjToCompMember" xlink:to="loc_ttnpPlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ttnp-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Qpo7xRiXgOn8uPaXcsSaiEqbP9xpJ72ZkhtGl9fRnKDyosfAmf5SK3F/fGUXQA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ttnp="http://titanpharm.com/20221231" elementFormDefault="qualified" targetNamespace="http://titanpharm.com/20221231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://titanpharm.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ttnp-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="ttnp_MarcRubinMember" name="MarcRubinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DavidLazarMember" name="DavidLazarMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_NonpeoNeosMember" name="NonpeoNeosMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DrRubinMember" name="DrRubinMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember" name="LessValueOfStockAwardsReportedInSummaryCompensationTableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" name="PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" name="PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" name="PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ttnp_DrBeebeDeVarneyMember" name="DrBeebeDeVarneyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )\ [\# 2(  A$! Q$!_\0
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M+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C5FB@"M_9]K_SR_\
M'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K_P \O_'C_C5FB@"M
M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/+_QX_P"-']GVO_/+
M_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:* *W]GVO_/+_ ,>/
M^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\ C5FB@"M_
M9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V?:_\\O\
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M_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\
MC5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V
M?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH K?V?:_\
M/+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C
M5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K
M_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/
M+_QX_P"-']GVO_/+_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:
M* *W]GVO_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\
MSR_\>/\ C5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_
M !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH
MK?V?:_\ /+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_S
MR_\ 'C_C5FB@"M_9]K_SR_\ 'C_C52_MH;>!7B7:V[&<GT-:E4=5_P"/5?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH*0)5@*IGM\FXG_Q[\JY#3? -[I7B*36;36X8Y9&8R0K9$1D,<E<>9D#\>U
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MC_'^9JS5;3_^/&/\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56O["WU.SDM+
MI7:"08=4D9-P]"5(./:K-% &1I'AG2=!=VTRWD@W_>47$C*?<J6(S[XS6O11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M].__ (]0!9HJM_IW_3O_ ./4?Z=_T[_^/4 6:*K?Z=_T[_\ CU'^G?\ 3O\
M^/4 6:*K?Z=_T[_^/4?Z=_T[_P#CU %FBJW^G?\ 3O\ ^/4?Z=_T[_\ CU %
MFBJW^G?]._\ X]1_IW_3O_X]0!9HJM_IW_3O_P"/4?Z=_P!._P#X]0!9HJM_
MIW_3O_X]1_IW_3O_ ./4 6:*K?Z=_P!._P#X]1_IW_3O_P"/4 6:*K?Z=_T[
M_P#CU'^G?].__CU %FBJW^G?].__ (]1_IW_ $[_ /CU %FBJW^G?].__CU'
M^G?]._\ X]0!9HJM_IW_ $[_ /CU'^G?].__ (]0!9HJM_IW_3O_ ./4?Z=_
MT[_^/4 6:*K?Z=_T[_\ CU'^G?\ 3O\ ^/4 6:*K?Z=_T[_^/4?Z=_T[_P#C
MU %FBJW^G?\ 3O\ ^/4?Z=_T[_\ CU %FBJW^G?]._\ X]1_IW_3O_X]0!9H
MJM_IW_3O_P"/4?Z=_P!._P#X]0!9HJM_IW_3O_X]1_IW_3O_ ./4 6:*K?Z=
M_P!._P#X]1_IW_3O_P"/4 6:*K?Z=_T[_P#CU'^G?].__CU %FBJW^G?].__
M (]1_IW_ $[_ /CU %FBJW^G?].__CU'^G?]._\ X]0!9HJM_IW_ $[_ /CU
M'^G?].__ (]0!9HJM_IW_3O_ ./587=M&[&['..F: %K+O\ Q#IVG7B6D\LA
MF;[PCB9Q&,$@N0#M&%/7Z] 2-2N1UJUNM,UZ/5K#;=+-./M%F6"G>L+C<K=C
ML['KQR* -^\UFPL;9+F:9C"R[P\4;2C;UW'8#A?<\58>\MX[)KUID^S+'YIE
M!RNW&<Y],5DSI)J/A:-]!DAMUFMU\LS1DYCV\+G/R]>O..?K3(;.#Q'X,M(%
M,^GP3P1D+;N T8&"%!(/'% %[1]>TS7X9)M,N?/CC;:[>6RX/7'S 5I5B>'1
MJ5O]LT_4;G[8UK(HBNBNTR*R@X;W'^%;= !1110 4444 %4=5_X]5_WQ_(U>
MJCJO_'JO^^/Y&@"73_\ CQC_ !_F:LU6T_\ X\8_Q_F:LT %%%% !1110 5G
M:EH=EJK*]P)DD7;^\@F:-B%;< 2I&1GUZ9R,'FM&B@"HFF64>F_V=';JEIMV
M>4N0,=^GKW]:L2PQ3PO#-&LD3J59&&0P/4$4^B@"G9:79Z?YAMXV#28#M)(T
MC$#H,L2<#)P.@S3+/1K#3YS-;0;'V[%R[,$7.=J DA!G'"X' J_10!E1:!8K
M)?EX!LO9!)*GF,P+ \.,GY6Z=,8P*N6>GVUA"T5O&0KL6<NY=G8]V9B23P!R
M>U6:* *%GHUAI\YFMH-C[=BY=F"+G.U 20@SCA<#@41Z-I\-]]L2WQ,&9Q\[
M%%9OO,J9VACDY(&3DU?HH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "LK4/#FFZG<">XCE#;LNL<SHLORE?G (!
MX./7''3BM6B@#-FT#39YTF:W962(0@12O&IC'12JD!AR>"#5B[TZVO;9()4=
M8XR&3R9&B*D=,%""*M44 1P01VT0CB7"]3DDDGU)/)/N:DHHH **** "BBB@
M JCJO_'JO^^/Y&KU4=5_X]5_WQ_(T 2Z?_QXQ_C_ #-6:K:?_P >,?X_S-6:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JCJO_ !ZK_OC^1J]5'5?^/5?]\?R- $NG_P#'C'^/\S5FJVG_
M /'C'^/\S5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^;=6
M^,/Q)\,:]=+J^EP1P><RI!<6C*@7/&QP1NX[Y.:Z#1_VDM,EVIK.A75L>ADM
M9%E'UPVTC\S0![E17&:/\5_!&M[5M]?MH9#_ ,L[O,!SZ?/@'\":["*6.>)9
M89$DC895T8$'Z$4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *HZK_QZK_OC^1J]5'5?^/5?]\?
MR- $NG_\>,?X_P S5FJVG_\ 'C'^/\S5F@ HHHH **** "N;UW6;Z#5X-,L9
M+>WD9(Y3+,A?<&E5-JKD=,Y//0\>HZ2N8\7BUF@BBO+.Z.V6)H;JWB9V0F0!
M@I0$JV/SS@9- %J]\0/INF0O>01I?2N\20F7:A*DY<LP^5,#=D]B.IIS:O+9
M^'I-3GFM+UB1Y(L\A&+$*J[BQS\Q^]Q].*QX8=2BDT35]3M[B<VXFBD BWS(
MCD>6[*N?FPH#;1GGZTIT2YGT35VMX'3[1?"\M;9QL/RE3T_A+%2<''49[T :
MIUJ?3+F>WU<PMLM&NTEMT*@JOWUP6/(R.<\YZ#%):ZM?I=:>NHQP+'J*GRA$
MI!A<+N",23NR,\@#D=.:H:AI\GB>]N)4AG@@33I;5&N(FC+2R8Z @' VC)Z'
M/&:EB2XU:]T1'L[BW_L[,MR98RJAPA0*I/#\DG*Y&!UYH U]7U%["&!(45[F
MZF6"$-]T,<DD^P )]\8JM#K3VW]IPZGY?FZ?$)WDA0JLD9!((4DD'*L,9/0<
M\U3U2=]1NH9(+*[$ND7JR.DD17S8R&4M'_>')/OM^E1OI<NN2:]=>7)!'>VB
MV=OYR%&( ;+%3@@;F[\\'VH N6NKWT=SIXU*.!8M14F(1*087"[MC$D[LJ#R
M .1TYJ&'Q!=M!::I)'"-,NYQ"B!2)4#-M1RV<$$XXP,;NIQ4*PSZS<Z-%)9W
M%N+ &2Z,L950_EE JD\/RQ.5R,#KS56&QNI=$TSPZ]K.DMK<1F:4QD1>5&^X
M,'Z$L , '()YQB@#M**** "BJW]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C0!9H
MJM_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0!9HJM_9]K_SR_P#'C_C1_9]K_P \
MO_'C_C0!9HJM_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (T 6:*K?V?:_P#/+_QX
M_P"-']GVO_/+_P >/^- %FBJW]GVO_/+_P >/^-']GVO_/+_ ,>/^- %FBJW
M]GVO_/+_ ,>/^-']GVO_ #R_\>/^- %FBJW]GVO_ #R_\>/^-']GVO\ SR_\
M>/\ C0!9HJM_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XT 6:*K?V?:_\\O_ !X_
MXT?V?:_\\O\ QX_XT 6:*K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XT 3R11S1M
M'*BO&PPRL,@CW%<AK'PK\$ZYN:Z\/VL<C?\ +2U!@;/K\F ?QS74?V?:_P#/
M+_QX_P"-']GVO_/+_P >/^- 'C&L?LVZ3-N?1]<N[5NH2YC69?ID;2/UKCY?
M@_\ $OPG*T^@WAE .=VG7IB8CW5MN?IS7TO_ &?:_P#/+_QX_P"-']GVO_/+
M_P >/^- 'S.GQ5^*7@]UBURUDE13@#4K(KD>SKM)^N376:/^TGI\FU-:T&X@
M/0R6DHD!]]K;<?F:]J?3+.1"CP!E(P022#7,ZK\*_!.L!C=>'[57/_+2#="V
M?7*$9_&@"+1_BWX'UK:L.O6]O*?^6=X# 0?3+8!_ FNRAGAN85E@E26)N5=&
M# _0BO%M8_9NT:XW/H^M7EFQY"7"+,OTXVD?K7%W/P5^(GAJ5I]#NTN,<AK"
M[,+X]PVW\@30!]0T5\J?\)_\2_!KA-;L9I(E.!_:5FP4_1UVY^N375:/^T'I
M+[4UKPW-$>\MG/O!_P" MC'YF@#Z!HKSW1_B?\/-9VK'K$-K*?\ EG>;H<?\
M";Y?UKM+>#3KN%9K9HYHF^Z\<FY3]"#0!>HJM_9]K_SR_P#'C_C1_9]K_P \
MO_'C_C0!9HJM_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (T 6:*K?V?:_P#/+_QX
M_P"-']GVO_/+_P >/^- %FBJW]GVO_/+_P >/^-']GVO_/+_ ,>/^- %FBJW
M]GVO_/+_ ,>/^-']GVO_ #R_\>/^- %FBJW]GVO_ #R_\>/^-']GVO\ SR_\
M>/\ C0!9HJM_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XT 6:*K?V?:_\\O_ !X_
MXT?V?:_\\O\ QX_XT 6:*K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XT 6:*K?V?
M:_\ /+_QX_XT?V?:_P#/+_QX_P"- %FBJW]GVO\ SR_\>/\ C1_9]K_SR_\
M'C_C0!9HJM_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0!9HJM_9]K_SR_P#'C_C1
M_9]K_P \O_'C_C0!9HJM_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (T 6:*K?V?:
M_P#/+_QX_P"-']GVO_/+_P >/^- %FBJW]GVO_/+_P >/^-']GVO_/+_ ,>/
M^- %FBJW]GVO_/+_ ,>/^-']GVO_ #R_\>/^- %FBJW]GVO_ #R_\>/^-']G
MVO\ SR_\>/\ C0!9HJM_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XT 6:*K?V?:_
M\\O_ !X_XT?V?:_\\O\ QX_XT 6:*K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XT
M 6:*K?V?:_\ /+_QX_XT?V?:_P#/+_QX_P"- %FBJW]GVO\ SR_\>/\ C1_9
M]K_SR_\ 'C_C0!9HJM_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0!9HJM_9]K_SR
M_P#'C_C1_9]K_P \O_'C_C0!9HJM_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (T
M6:*K?V?:_P#/+_QX_P"-']GVO_/+_P >/^- %FBJW]GVO_/+_P >/^-6%4(H
M51@ 8 H 6N8O=:U*7Q(VF6#VL(@D166="S3;HG?L1M7Y0,C)S],'IZX_Q6(9
MK^UW6=_%>Q2D6]U:0LSNOEL0%8 C[W!5O0GIS0!L7]]J2:0+R$6UHZP"61;I
M6<;B/N<%2#GC/N.#2W>KSP:982?9O+OKYXXDAD.1&[#)W8ZA0"??&.,U0NG2
M\TRWT[7])N+JY>V61VBMC)'YN""%=<A&SW.!SUI)]-OX=$T*68/<W>FRQR3A
M3N9AM*MC^\0&S[X]Z -/3=0GEOKO3KWRS=6P1_,B4JDB.#A@"20<A@1D]/>M
M2L+289+G7M0UAHI8H98XX(%F0H[*N26*D @$M@9YX^E;M !1110 4444 %4=
M5_X]5_WQ_(U>JCJO_'JO^^/Y&@"73_\ CQC_ !_F:LU6T_\ X\8_Q_F:LT %
M%%% !1110 4444 %%%% !1110 Q(DC+%1RQR23DFGT44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7":]\5=*T+Q%>:)_8VNZC
M=68C,[:?:"5$WKN4$E@>A]*[NO%W_P"2O>.?^W#_ -)ZY\35=&DYI7L1.7+&
MYO?\+FL/^A0\8?\ @M7_ .+H_P"%S6'_ $*'C#_P6K_\74-%>3_:L_Y5^)S?
M6'V)O^%S6'_0H>,/_!:O_P 71_PN:P_Z%#QA_P""U?\ XNH:*/[5G_*OQ#ZP
M^Q-_PN:P_P"A0\8?^"U?_BZ/^%S6'_0H>,/_  6K_P#%U#11_:L_Y5^(?6'V
M)O\ A<UA_P!"AXP_\%J__%T?\+FL/^A0\8?^"U?_ (NH:*/[5G_*OQ#ZP^Q-
M_P +FL/^A0\8?^"U?_BZZKPAXOL/&>E3W]A;WENL%R]K+#>1A)$D4 D$ G^\
M.]<?7END6U]-J'B%K7Q!K>G(-8N08K"]:%"<CYB!W[9] *]/+:M3'5'3BDFE
M?<SJXZ%"#J5=$K;:[GU%17SE]AU?_H=/%?\ X-'H^PZO_P!#IXK_ /!H]>]_
M96)[+[SB_M_!=W]W_!/HQE5U*L 5(P01P17*ZQ\-/!FN;C>^'K+S&ZR0)Y+D
M^I*8)_&O'?L.K_\ 0Z>*_P#P:/1]AU?_ *'3Q7_X-'H_LK$]E]X?V_@N[^[_
M ()T>L?LX:%<[GTC6+VR8\A)U69![#[I_4UQ=S\$_B%X9F:YT"_2<CD-8W;0
M2?B&V_H36C]AU?\ Z'3Q7_X-'H^PZO\ ]#IXK_\ !H]']E8GLOO#^W\%W?W?
M\$RA\1OBSX+(76+>YDA7I_:5F2I_[:+@G_OHUT^C_M*0-M36_#\B?WI;*4-G
M_@#8_P#0JS#8:LP(/C/Q40>"#JC_ .%8D_P]TVZF::XO]2EE;EGDF5F/U)6C
M^RL3V7WA_;^"[O[O^">VZ/\ &/P+K&U5UN.TE/\ !>H8<?5C\OZUVUK=VU[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZK_ ,>J_P"^/Y&K
MU4=5_P"/5?\ ?'\C0!+I_P#QXQ_C_,U9JMI__'C'^/\ ,U9H ***CN$EDMI4
MAE\J5D(23 .UL<'!XXH DHKBWL?%<5S96<OBT+<7".S,+"(H-H&57@%CS[<
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M0-YJDL4_BW+\O )_.NSK(UC3M0O"IL;Z*$;HRT<\1=?D<-N&""#Z]0< <=:
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M/MG_ $[7'_?NK-% %;[9_P!.UQ_W[KQX/YGQ;\;MM9<_8.&&#_J*]JKQ=_\
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MWGP2_P"20Z%_V\?^E$E>!G/V/G^A]=PU_P O?E^IZ!1117@'UX4444 %%%%
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M]'KSCP]_Q^>(O^PU<_S%?5\*_P"^2_PGEYO_ +G+UC^;-NBBBOTD^+"BBB@
MHHHH **** "N\^"7_)(="_[>/_2B2N#KO/@E_P DAT+_ +>/_2B2O SG['S_
M $/KN&O^7OR_4] HHHKP#Z\**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBH;N[MK"UDNKRXBM[>(;I)9G"(@]23P* )J*Y__A._
M!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8?_BJ .@HKG_^$[\'_P#0UZ'_
M .#&'_XJC_A._!__ $->A_\ @QA_^*H Z"BN?_X3OP?_ -#7H?\ X,8?_BJ/
M^$[\'_\ 0UZ'_P"#&'_XJ@#H**Y__A._!_\ T->A_P#@QA_^*H_X3OP?_P!#
M7H?_ (,8?_BJ .@HKG_^$[\'_P#0UZ'_ .#&'_XJG)XX\)2.J)XIT1G8X55U
M"(DGT'S4 ;U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 <Z-5&GV&J:K<31II]O+((X4C"L65B&R>Y9\XZ=LYS6;IYU
MYK&TUG5+U9%NKB(G3F@78B.X"X/7<N0V?;\:L0>'[#7[^XO[RS:.)+M]L*W3
M&.5XV*>8R8 !.W_'.:VKW3H9;VVO;B]GC6"0&*/>JQAC\HR".2<X&><GC% &
ME1110 51U7_CU7_?'\C5ZJ.J_P#'JO\ OC^1H ET_P#X\8_Q_F:LU6T__CQC
M_'^9JS0 4444 <_XDO;"VN=.2[TB\U&?>TUN+2(.T93&6ZC Y'MZUDZ4VFR^
M+89H?"^IV=Q*LCFXNHV5$8]2JABH)R<GCK[UNZQ)JS:A9VFEW%K 9(Y))&GC
M+\*5 P 1_>JO!8ZN=6LY-5U>W=(F9HX8+4Q^8VTCEBQZ DX[XSVH Z&BBL+6
M->N+*_CT^QM8Y[DK'(YFE*(J-($'0$DDD]N.O/0@&[15*#4D?3&O9XG@"%E>
M-L%@RL5(&.O(XQUXJE:^(X)O"ZZ[+"\43*6$0.YB=Q4*/<G _&@#:HK(AULQ
M3S6^J0)9RQP&Y&V7S%:(?>.=HY'&1CN,$TVSUR2:YM([JS^S)?(7M6\S<6P-
MVUQ@;6V\X!(X/- &S15+4]173;='\LRRS2+##$#C>[=!GL.I)] :@M=95A?)
M?1K:SV*AYU#[U"$9#JV 2, ]@<@T :E%8UGKDDUS:1W=G]FCOD+VK>9N+8&[
M:XP-K;>< D<'FHX?$?FM;W#6H73;F;R(;GS,L6R0I*8X5B, Y)Y&0,T ;M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>+O_R5[QS_ -N'
M_I/7M%>+O_R5[QS_ -N'_I/7#C_]WE\OS,JWP,V****^7//"BBB@ HHHH **
M** "O./#W_'YXB_[#5S_ #%>CUYQX>_X_/$7_8:N?YBOJ^%?]\E_A/+S?_<Y
M>L?S9MT445^DGQ84444 %%%% !1110 5WGP2_P"20Z%_V\?^E$E<'7>?!+_D
MD.A?]O'_ *425X&<_8^?Z'UW#7_+WY?J>@4445X!]>%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7G_QM_Y)#KO_ &[_ /I1'7H%
M>?\ QM_Y)#KO_;O_ .E$= ',_P#"+^'O^@%IG_@)'_A1_P (OX>_Z 6F?^ D
M?^%:U%?&>TG_ #/[W_F>7S/N9/\ PB_A[_H!:9_X"1_X4?\ "+^'O^@%IG_@
M)'_A6M11[2?\S^]_YAS/N9/_  B_A[_H!:9_X"1_X4?\(OX>_P"@%IG_ ("1
M_P"%:U%'M)_S/[W_ )AS/N9/_"+^'O\ H!:9_P" D?\ A1_PB_A[_H!:9_X"
M1_X5K44>TG_,_O?^8<S[F3_PB_A[_H!:9_X"1_X5S/Q!T'1K+P-J-Q:Z3803
MIY6V2*V167,J X(&>A-=Y7)_$O\ Y)]JG_;+_P!&I6^'J3=6-V]UU?\ F7!O
MF6I[Y1117UAZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117/
MWOB"Z76CI^GV,<_DR*D[23;"2T;.%08/.%ZG [>X .@HK+EU*]ELHKG3M.$X
M>(2E9YO*.",[1A6RWY#WJ/\ X2&"31+/488G<WA1((6X9G;L3VQ@DGT!ZT ;
M%%9^G:DUW/<VEQ"L%Y;%?,C5]ZE6&596P,@\CH.0:T* ..L/#EOJ$M\\M_J]
MO,+R<M%'<O$H!D8@J/0@@Y%69/!D0:"2+4]3=XIXI0MQ=LZ':X8Y!Z\ _C6Y
MJFJ6VD61NKHN5W!%2-"SNQZ*H'4FJ\>O6CPZ=,Z2PQ:@J^0\@ &YAD(<$X;
M^G;- &I1110 51U7_CU7_?'\C5ZJ.J_\>J_[X_D: )=/_P"/&/\ '^9JS5;3
M_P#CQC_'^9JS0 4444 <IKNC:=)K]E*XU)[BYW1^5:3.H RN9&.X;5'&<=<C
M@FGQ:9H^C>)-.B87<ES.LAM7FN7E564?-PQX.T]?KTK9U+3Y;PQ36MT;2[AS
MY<P0.,'&593U!P.X/ YKD[:6W'CBP_M#7(]5U+,D<,-N@CCM1L8LQ )R3C&"
M<\^U '=UR?C :86@>XN_L%_$\1@NB0ORF0;@,\/C&XJ>G!KK*:\:2+M=%8 A
ML,,\@Y!_ C- '-65QK>J:;879M;24(79A-*\'F$$A) NQN"/FP>Y![5CZ9!>
M77POM@( 6A=)D2%RS2*DNX\8&#P>!GM7?T4 <9JT0\3W]PVF3+-#%I<\/FQG
MY3+)C"9]?EY';C/6IDN8]:OO#T5HQ+V9,]VO>#$978_HQ+8P>>">U=;10!RV
MLZA:7MU:SVLWF_V1J"_;%4',0*LI)XY W9R., ^E036KZ]-XCN;&026]Q8K:
M6\J'Y97 <D@]QE@,].OI76)"$D>3)9VX)/IS@?09-24 <@9X]=NM!@M'.^US
M-= ?>M_W13:_HV6Q@\\$]JIP_O\ PYI/AY21J4%S$L\/\4:QON9SZ*0O![Y&
M.M=W10 4444 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/-Q_W\H^Q_P#3
MS<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_]/-Q_P!_*/L?_3S<
M?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/-Q_W\H^Q_P#3S<?]
M_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_]/-Q_P!_*/L?_3S<?]_*
MLT4 5OL?_3S<?]_*\>">7\6_&Z[F;'V#ECD_ZBO:J\7?_DKWCG_MP_\ 2>N'
M'_[O+Y?F95O@9L4445\N>>%%%% !1110 4444 %><>'O^/SQ%_V&KG^8KT>O
M./#W_'YXB_[#5S_,5]7PK_ODO\)Y>;_[G+UC^;-NBBBOTD^+"BBB@ HHHH *
M*** "NU^"UMYGPDT-O/F7/G\*^!_KY*XJN\^"7_)(="_[>/_ $HDKP,Y^Q\_
MT/KN&O\ E[\OU.W^Q_\ 3S<?]_*/L?\ T\W'_?RK-%> ?7E;['_T\W'_ '\H
M^Q_]/-Q_W\JS10!6^Q_]/-Q_W\H^Q_\ 3S<?]_*LT4 5OL?_ $\W'_?RC['_
M -/-Q_W\JS10!6^Q_P#3S<?]_*/L?_3S<?\ ?RK-% %;['_T\W'_ '\H^Q_]
M/-Q_W\JS10!6^Q_]/-Q_W\H^Q_\ 3S<?]_*LT4 5OL?_ $\W'_?RC['_ -/-
MQ_W\JS10!6^Q_P#3S<?]_*/L?_3S<?\ ?RK-% %;['_T\W'_ '\H^Q_]/-Q_
MW\JS10!6^Q_]/-Q_W\H^Q_\ 3S<?]_*LT4 5OL?_ $\W'_?RN!^--MY?PDUQ
MO/F;'D<,^1_KXZ]'KS_XV_\ )(==_P"W?_THCH SZ***^)/*"BBB@ HHHH *
M*** "N3^)?\ R3[5/^V7_HU*ZRN3^)?_ "3[5/\ ME_Z-2M\/_&AZHN'Q(]S
M^Q_]/-Q_W\H^Q_\ 3S<?]_*LT5]>>D5OL?\ T\W'_?RC['_T\W'_ '\JS10!
M6^Q_]/-Q_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['
M_P!/-Q_W\H^Q_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_
M]/-Q_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/
M-Q_W\JPJ[5"Y)P,9/4TM% !7%>*9=.@U>"[AOAIVJQ/M+L,^:@C8CY#]\9.W
M(YR2*[6FM&CLC,BL4.Y21G:<8R/3@D?C0!R6J>,;*STZSMM3N!I]]>0*\RA&
M8VX(YX )#=<9_'IR^[FM+C2M"U/3HW&FV=VK<(5Q%M9-^.N!D'GMDUUE% '/
MZ05O_$NIZK;N)+-H8K>*53E9"NXL5/<#<!D<=?2N@HHH R=>>WBAM)9KJ*VF
M2X!MWF4E-^UN&QT&W=SD8K"L_#FLWCZ1%JEW8C3=,*20I9EF:9U&%+%@,#Z>
M];FOZA-IR6,EOIQOY9+D1K$N P)1N03P.G7T)JC9:9K4^H17MQ);:5"K[VM+
M/YS+GJ)&.%)]PN?0T =+1110 51U7_CU7_?'\C5ZJ.J_\>J_[X_D: )=/_X\
M8_Q_F:LU6T__ (\8_P ?YFK- !1110!Q%[H6IW-U,WB*]OK[3\G9%I_R1[?2
M2-?G;\-QK1\,6VBPZ'I/E16B7 "CY  _G^60P;'.[&[(//6NFJC<:197.I6F
MHO"!=VS$I*H 8@J5*D]QS^8% %ZBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\7?_DKWCG_ +</_2>O
M:*\7?_DKWCG_ +</_2>N''_[O+Y?F95O@9L4445\N>>%%%% !1110 4444 %
M><>'O^/SQ%_V&KG^8KT>O./#W_'YXB_[#5S_ #%?5\*_[Y+_  GEYO\ [G+U
MC^;-NBBBOTD^+"BBB@ HHHH **** "N\^"7_ "2'0O\ MX_]*)*X.N\^"7_)
M(="_[>/_ $HDKP,Y^Q\_T/KN&O\ E[\OU/0****\ ^O"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_ .-O_)(==_[=_P#THCKT
M"O/_ (V_\DAUW_MW_P#2B.@#/HHHKXD\H**** "BBB@ HHHH *Y/XE_\D^U3
M_ME_Z-2NLKD_B7_R3[5/^V7_ *-2M\/_ !H>J+A\2/?**^<OL.K_ /0Z>*__
M  :/1]AU?_H=/%?_ (-'K]"_LK$]E]YR?V_@N[^[_@GT;17SE]AU?_H=/%?_
M (-'H^PZO_T.GBO_ ,&CT?V5B>R^\/[?P7=_=_P3Z-HKYR^PZO\ ]#IXK_\
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M(*29[XR#C.,^U2PZ(]S_ &I-J7EB;48Q Z0L66., @ ,0"3\Q.<#J..*VZ*
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MVTD-U"%N)+)8EC)D7!+*21_7I0!Z!1110 51U7_CU7_?'\C5ZJ.J_P#'JO\
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M@ K.OO\ D8/"7_8P6?\ Z&:T:SK[_D8/"7_8P6?_ *&:X\=_NT_3_(]'*O\
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M,T ;3ZQ8K9QW2S--%)DIY$;2LV.ORJ">._''>I+?4K*ZT_[?#<QM:;2QES@
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M5[Q)G[5H6['D_P!HIOSTSL;;_P"/8_'% &K9WUO?Q-);NQ"-L=71D9&ZX96
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MJWP,V****^7//"BBB@ HHHH **** "O./#W_ !^>(O\ L-7/\Q7H]><>'O\
MC\\1?]AJY_F*^KX5_P!\E_A/+S?_ '.7K'\V;=%%%?I)\6%%%% !1110 444
M4 %=Y\$O^20Z%_V\?^E$E<'7>?!+_DD.A?\ ;Q_Z425X&<_8^?Z'UW#7_+WY
M?J>@4445X!]>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 5YQX>_X_/$7_8:N?YBO1Z\X\/?\?GB+_L-7/\ ,5]7PK_ODO\
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M #[3!_SVC_[Z%'VF#_GM'_WT*/LT'_/&/_OD4?9H/^>,?_?(H /M,'_/:/\
M[Z%'VF#_ )[1_P#?0H^S0?\ /&/_ +Y%'V:#_GC'_P!\B@ ^TP?\]H_^^A1]
MI@_Y[1_]]"C[-!_SQC_[Y%'V:#_GC'_WR* #[3!_SVC_ .^A1]I@_P">T?\
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M /M,'_/:/_OH4?:8/^>T?_?0H^S0?\\8_P#OD4?9H/\ GC'_ -\B@ ^TP?\
M/:/_ +Z%'VF#_GM'_P!]"C[-!_SQC_[Y%'V:#_GC'_WR* #[3!_SVC_[Z%'V
MF#_GM'_WT*/LT'_/&/\ [Y%'V:#_ )XQ_P#?(H /M,'_ #VC_P"^A1]I@_Y[
M1_\ ?0H^S0?\\8_^^11]F@_YXQ_]\B@ ^TP?\]H_^^A6!XZN(6^'WB4":,DZ
M5=  ,/\ GDU;_P!F@_YXQ_\ ?(K \=6\*_#[Q*1#&"-*NB"%'_/)J /!-&_Y
M 6G_ /7M'_Z"*O51T;_D!:?_ ->T?_H(J]7UU/X%Z+\D>'+XF%%%%62%%%%
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M2<#&3ZTZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(3B1(Y Q0^A Z?C0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /(K7G_ /_0UK'$?PI>C-*7QKU/7:***_'C4**** "BBB@ HHHH *Y/XE_\
M)/M4_P"V7_HU*ZRN3^)?_)/M4_[9?^C4K?#_ ,:'JBX?$@HHHK]M/S0****
M"BBB@ HHHH *SK[_ )&#PE_V,%G_ .AFM&LZ^_Y&#PE_V,%G_P"AFN/'?[M/
MT_R/1RK_ 'VEZ_YGT;1117QI^F!1110 4444 %%%% !115.[U;3[">&"[O8(
M)9CB-)) "W^<?GQ0!<HJ"ZO;2QB$MW=0V\9.T-+($!/IDU."" 0<@T %%%%
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M\_\ R**//NO^?/\ \BBK-% %;S[K_GS_ /(HH\^Z_P"?/_R**LT4 5O/NO\
MGS_\BBCS[K_GS_\ (HJS10!6\^Z_Y\__ "**//NO^?/_ ,BBK-% %;S[K_GS
M_P#(HH\^Z_Y\_P#R**LT4 5O/NO^?/\ \BBCS[K_ )\__(HJS10!6\^Z_P"?
M/_R**//NO^?/_P BBK-% %;S[K_GS_\ (HKBV\#W1\7ZYK_G_P#(4^S_ +C8
M/W7E1[/O;OFSUZ#'O7>T5%2G&I'EEL)I25F<=_PBMU_?_0?XT?\ "*W7]_\
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M?\__ /Y!'_Q='_"KKK_G_P#_ ""/_BZ]2HI_7J_\WX(7U:EV/+?^%777_/\
M_P#D$?\ Q='_  JZZ_Y__P#R"/\ XNO4J*/KU?\ F_!!]6I=CRW_ (5==?\
M/_\ ^01_\71_PJZZ_P"?_P#\@C_XNO4J*/KU?^;\$'U:EV/+?^%777_/_P#^
M01_\75'6/@]=:KI<UE_:GE>9M^?[.&QA@>F\>E>P44I8RM).+EH_0:H4T[I'
M'?\ "*W7]_\ 0?XT?\(K=?W_ -!_C78T5XWU##_R_BRO8P[''?\ "*W7]_\
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M'_Q5>CT4?VEB?YOP0?V+@?Y/Q?\ F><?\*[NO^?O_P AC_XJC_A7=U_S]_\
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M1');L-PCX^4[@01P.<9'8U>L[2"PLXK6V39#$NU5SG]>Y]Z )Z*** "BBB@
MHHHH *HZK_QZK_OC^1J]5'5?^/5?]\?R- $NG_\ 'C'^/\S5FJVG_P#'C'^/
M\S5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)N]?ALID\^TNEM6D$7
MVO:IB#$X /S;@,\9VX]Z??:Y;V,\L7DW$Y@C$MPT*@B!#G!;)!/0G"Y.!TK-
MUG6-'N;S^S;O4K2*&W=9+E7F4,S*=RH%SD\@$X],=^(X+B.RU#Q2]TX4$)<
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M^Q XK1HH S?^$>T0S>=_8^G^;NW;_LR;L]<YQUK2HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *HZK_P >J_[X_D:O51U7_CU7_?'\C0!+I_\ QXQ_C_,U9JMI_P#QXQ_C
M_,U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *I:M=O9Z=))%@SOB*$>LC':OZD?AFK
MM8.HV\VIZ[;VMWI#3Z5$K,9)#&T;R$<$H6R0!N[=3[9H I^#BVGR:EX>FE>6
M2PFWQN_5XY/F!_/.:4^*KZ*]O["?288[Z!$:WA%V3]J#''R'9T]^QZXY(AFT
MB?1_&%I?:)H?^AM;M#=BW,42D$Y4A2PRP(YXZ4FKV6K:@)-4@L)X=4LI@+!/
M,B*LG\6[Y^C<YR>.,#KD T;W5##K6BVEYI*--<EMMQO5E@<*20I(W$XXSA>#
M^%3PZW+=74ZVUHLL$-R+9V6;]XK;@"2FWA1USG)],<UEZ@-8O]5T"[_L*X06
MLCR7(\^$[-RE<#Y_F]?I[\!-0T2YN=8AO;73S::@+D%KZ"951X0W(D7.6)4=
M,'MR.E '5R()(V0\!@17$ZCX=T:U\4^&[2+2[,0LEPLBF!3YFU!@MQ\Q]S7<
M5S6L0ZA)XKTB[@TNXGMK(2^9(DD0SO4 8#.#QCG('MF@ U,V/ANUL[>+1TGM
M+B^0*HVB.!V88(!YZY(P/Q'%$6I:M)XXN-/,-L;2*V5P//8':S$;L;.6XZ<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 51U7_ (]5_P!\?R-7JHZK_P >J_[X_D: )=/_ ./&/\?YFK-5
MM/\ ^/&/\?YFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 51U7_CU7_?'\C5ZJ.J_\>J_[X_D: )=/_X\
M8_Q_F:LU6T__ (\8_P ?YFK- !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!'X@D5P/_"M/"/\ T"/_ "9E_P#BJY<1BH4+<R>IG.HH;GOE%>!_\*T\(_\
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MD]21S6FDVL^'/A^]S(T9N[;<XCNB9<1EOE0L&'(!'.30!U[,J*68A5 R23@
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MR^Y?YGT[17@OPJTJRTKXK7EC9P^7:RZ$SR1%F96;ST&3N)[<?G7H2++X3O\
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MH3XFU,:;;3+;VCRG4_L$Y)95/[S;N4<XS[GCWH ZZBN6NM;U>VAUL?Z"TFF
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M87,I#I8SSF6QA>0.8X2!CD$X!Y(&>*Z.@ HHHH **** "BBB@ HHHH ****
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MZ:FI(9R9#%<K;8\LL2V2I8AL$GTK4GBN'L6BBG1;@IM$LD>X9[DJ"/YU8HH
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MFKWRW0M6WP6\4/E1*_\ ?(+,21VYP/2MRBK&9%EI%S:^(;_4WO(I([M47R1
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MN36E10 4444 %%%% !1110 4444 %8K:'/:ZE<7NDWJ6K71#7$,T/FQNPXW
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M\HG.=C[AM!/."".N,5L444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W**P_[0NO\ GK_XZ/\
M"C^T+K_GK_XZ/\* -RBL/^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#<HK#_M"Z
M_P">O_CH_P */[0NO^>O_CH_PH W**P_[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\
M* -RBL/^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"
MZ_YZ_P#CH_PH W**P_[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -RBL/^T+K_GK
M_P".C_"C^T+K_GK_ ..C_"@#<HK#_M"Z_P">O_CH_P */[0NO^>O_CH_PH W
M**P_[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -RBL/^T+K_ )Z_^.C_  H_M"Z_
MYZ_^.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W**P_[0NO\ GK_X
MZ/\ "C^T+K_GK_XZ/\* -RBL/^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#<HK#
M_M"Z_P">O_CH_P */[0NO^>O_CH_PH W**P_[0NO^>O_ (Z/\*/[0NO^>O\
MXZ/\* -RBL/^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#<HK#_M"Z_YZ_\ CH_P
MH_M"Z_YZ_P#CH_PH W**P_[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -RBL/^T+
MK_GK_P".C_"C^T+K_GK_ ..C_"@#<HK#_M"Z_P">O_CH_P */[0NO^>O_CH_
MPH W**P_[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -RBL/^T+K_ )Z_^.C_  H_
MM"Z_YZ_^.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W**P_[0NO\
MGK_XZ/\ "C^T+K_GK_XZ/\* -RBL/^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#
M<HK#_M"Z_P">O_CH_P */[0NO^>O_CH_PH W**P_[0NO^>O_ (Z/\*/[0NO^
M>O\ XZ/\* -RBL/^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#<HK#_M"Z_YZ_\
MCH_PH_M"Z_YZ_P#CH_PH W**P_[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -RBL
M/^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#<HK#_M"Z_P">O_CH_P */[0NO^>O
M_CH_PH W**P_[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -RBL/^T+K_ )Z_^.C_
M  H_M"Z_YZ_^.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W**P_[0
MNO\ GK_XZ/\ "C^T+K_GK_XZ/\* -RJ.J_\ 'JO^^/Y&J/\ :%U_SU_\='^%
/,DNIKA0DC[ESGH!0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )\ ^8# 2(  A$! Q$!_\0
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M+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C5FB@"M_9]K_SR_\
M'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K_P \O_'C_C5FB@"M
M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/+_QX_P"-']GVO_/+
M_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:* *W]GVO_/+_ ,>/
M^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\ C5FB@"M_
M9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V?:_\\O\
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M_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\ SR_\>/\
MC5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_ !X_XT?V
M?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH K?V?:_\
M/+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C
M5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'C_C1_9]K
M_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH K?V?:_P#/
M+_QX_P"-']GVO_/+_P >/^-6:* *W]GVO_/+_P >/^-']GVO_/+_ ,>/^-6:
M* *W]GVO_/+_ ,>/^-']GVO_ #R_\>/^-6:* *W]GVO_ #R_\>/^-']GVO\
MSR_\>/\ C5FB@"M_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XU9HH K?V?:_\\O_
M !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XU9HH
MK?V?:_\ /+_QX_XT?V?:_P#/+_QX_P"-6:* *W]GVO\ SR_\>/\ C1_9]K_S
MR_\ 'C_C5FB@"M_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C5FB@"M_9]K_SR_P#'
MC_C1_9]K_P \O_'C_C5FB@"M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (U9HH R
M-0@CMO+\E2N[.<$^U%2:O_RQ_P"!?THH M:?_P >,?X_S-6:K:?_ ,>,?X_S
M-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN$\4^+
M[U=?M_#6A%%OIF59+A@&$6>< >PY.>U=#!X<2.#$NIZK-<$<SF]D7GU" [!]
M,4 ;5%8/A^/5;>^U2VU2^:\\MT^SR,@7,9!QP !G.03[5I?VMIHO/L9U"T^U
M9QY'G+OS_NYS0!<HJK>:E8Z<J-?7MM:A^%,\JIN^F3S4;ZSI4:P,^IV:K.,P
MEIU D[?+SS^% %ZBJMSJ=A921QW=];022?<6655+?0$\TEYJNG:<R+>W]K;,
MXRHGF5-P]LGF@"W15 :WI+31PC5+(RR@-&@N$W.#T(&><U>)"J68@ <DGM0
MM%5;34]/OV=;.^MKED^\(95<K]<'BHQK.EF\^QC4K,W6[9Y'GKOW>FW.<T 7
MJ*K6NHV-\\B6EY;W#1G#B*57*GWP>*2;4K&WNH[6>]MHKB3[D3RJKM] 3DT
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M6555OH2>: +5%(CK(BNC!E89# Y!%58=5TZYNFM8+^UEN$SNBCF5G&/4 YH
MMT450UK5[;0M)GU&Z)\N(?='5B> ![DT 7Z*Y_2;2\U;3!?:O<7"272ATM[>
M9HE@0\@ H02W3))]NE<)\/KF^U;Q1=V]_JNI3PV\;.B->R 9#@#.&Y^G2@#U
MNBBJ]W?V6GQB2]NX+9"<!II @)^I- %BBHX9XKB%98)4EB895T8,#]"*@CU7
M3I9Y(([^U>:(XDC692R<XY&>* +=%5KK4;&Q,8O+RWMS(<()I53<?;)YJOJ<
M%Q>VADTV],-U%DQLIW(S?W77H0>GJ.U &C16+X9\01^(=,,_E^3<PN8KF$G_
M %;CK^%;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9
MJ_\ RQ_X%_2BC5_^6/\ P+^E% %K3_\ CQC_ !_F:LU6T_\ X\8_Q_F:LT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >.0J^F_&G-X<>
M9=.49N 0ZG9_,"O8ZPO$/A/3?$8C>Z$D5S%_J[F$[77OC/<9J6"QUV*-8GUJ
MVE0<&1K'$I'U$FW/_ ?PH A\:7]QIOA#4;JU)698PJLO5=S $_@#7#1VT(^!
M[R^6OF&3S=V.=_G;<Y]<<5Z.NCVITZXLIS)<I<@^>\S9:0D8)., < =, 8XQ
M7/CP-*-#.@_VNW]D&7>$^SCS@N=VWS,XQGG[N: .<UB]GU+X,6MS=EGFWHN]
MN2VURH.?7 ZU1UC2K&/X3:=?"W0W;,F9VY?!)XSUV^W2N]U[PFNJ^'(-#L[I
M+&TBVC_4F0D+T ^8?B><U0O/ ]Y>>$[7P^^LQK# ^?-%G\S ?='W^,9//?C\
M0#E/$>G6@^%VE:B85:]D,6ZX?F0C:1C<><8 XZ<5=\7$S?"719)#N<" ACU^
MX16]?^"+N_\ "MEH+ZQ$L5LV?,%F=S@#Y1]_C&3]>.G?)\=Z?+I'PWM-/FN4
MN#!/'&DBQ^7E0&QQD\XH SM;T#3(?A197\5I&EV$AD,X'SL6P"">I'/3H,5'
MXHUR^E^'OAZ*61\7@/VAB?\ 6*F  3[\'\*Z2T\-W/B+P3H]E-J?E6!ABD>-
M8 9#@?=#YP!_P$GCJ:W-8\):;K&@1:0RF&& #R'3K&0,#Z\=?6@#'N] UN\U
MO1M4LXM,L5L@$817+OYD7'R_ZH<8SCZUS?B.UBN_C#9V\RYBD\H. <;AMZ<5
MVV@^&;W2H8K>\UV:_M(,>3 85C5<=,G)8@=AG'3CBJ-_X)NKWQ<GB%=7BCEC
M93'$;0LH X )WC/UXH YO18(K#XSW=M:1K#!M<>7& J@&,-@ =LT:Q<ZOX.\
M2ZG=WEBFH:/J<F9"ZY!7LN>Q .,'@UTMKX)N[?QBWB,ZO$\SN2\7V0A2I&,
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M]B* .EKBOBG_ ,B8_P#U\1_UKM:YSQ7X;O/$UG]B&I0VMIN5ROV4NY(S_%O
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ME=O3WSC\:M7&S[3X1^R!?O';MZ>5Y)S^'W?TH Z.ZNH;.W>XN)!'$N,L?<X
M [DG@#O3+._M[^)I+=R0C;75T9&1NN&5@"#@@\CN*RO$F?M6A;L>3_:*;\],
M[&V_^/8_'%9>J_:/M_BS[(#_ ,@R/.W_ )Z;9/UVX_2@#I+/6+"_G,-M.7?:
M77*,H=0<%D) #CD<KD<BB/6+"6^^QI.3-N*#Y&",PZJ'QM+#!R <C!]*P;S_
M %OA3["%W9;9MZ>7Y!S^'W?TJA'G_A M!\L#[3]KM\>OF>;\_P"/WL_C0!W=
M%%% !15;_3O^G?\ \>H_T[_IW_\ 'J +-%5O]._Z=_\ QZC_ $[_ *=__'J
M+-%5O]._Z=__ !ZC_3O^G?\ \>H LT56_P!._P"G?_QZC_3O^G?_ ,>H LT5
M6_T[_IW_ /'J/]._Z=__ !Z@"S15;_3O^G?_ ,>H_P!._P"G?_QZ@"S15;_3
MO^G?_P >H_T[_IW_ /'J +-%5O\ 3O\ IW_\>H_T[_IW_P#'J +-%5O]._Z=
M_P#QZC_3O^G?_P >H LT56_T[_IW_P#'J/\ 3O\ IW_\>H LT56_T[_IW_\
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M[_IW_P#'J +-%5O]._Z=_P#QZC_3O^G?_P >H LT56_T[_IW_P#'J/\ 3O\
MIW_\>H LT56_T[_IW_\ 'J/]._Z=_P#QZ@"S15;_ $[_ *=__'J/]._Z=_\
MQZ@"S15;_3O^G?\ \>H_T[_IW_\ 'J +-%5O]._Z=_\ QZC_ $[_ *=__'J
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ML><]?NC'Z4 :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F:O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH M:?_QXQ_C_ #-6:K:?_P >,?X_S-6: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,
MU?\ Y8_\"_I11J__ "Q_X%_2B@"UI_\ QXQ_C_,U9JMI_P#QXQ_C_,U9H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,S5_^6/\ P+^E%&K_ /+'_@7]** +6G_\>,?X
M_P S5FJVG_\ 'C'^/\S5F@ HHHH **** "N;UW6;Z#5X-,L9+>WD9(Y3+,A?
M<&E5-JKD=,Y//0\>HZ2N8\7BUF@BBO+.Z.V6)H;JWB9V0F0!@I0$JV/SS@9-
M %J]\0/INF0O>01I?2N\20F7:A*DY<LP^5,#=D]B.IIS:O+9^'I-3GFM+UB1
MY(L\A&+$*J[BQS\Q^]Q].*QX8=2BDT35]3M[B<VXFBD BWS(CD>6[*N?FPH#
M;1GGZTIT2YGT35VMX'3[1?"\M;9QL/RE3T_A+%2<''49[T :IUJ?3+F>WU<P
MMLM&NTEMT*@JOWUP6/(R.<\YZ#%):ZM?I=:>NHQP+'J*GRA$I!A<+N",23NR
M,\@#D=.:H:AI\GB>]N)4AG@@33I;5&N(FC+2R8Z @' VC)Z'/&:EB2XU:]T1
M'L[BW_L[,MR98RJAPA0*I/#\DG*Y&!UYH U]7U%["&!(45[FZF6"$-]T,<DD
M^P )]\8JM#K3VW]IPZGY?FZ?$)WDA0JLD9!((4DD'*L,9/0<\U3U2=]1NH9(
M+*[$ND7JR.DD17S8R&4M'_>')/OM^E1OI<NN2:]=>7)!'>VBV=OYR%&( ;+%
M3@@;F[\\'VH N6NKWT=SIXU*.!8M14F(1*087"[MC$D[LJ#R .1TYJ&'Q!=M
M!::I)'"-,NYQ"B!2)4#-M1RV<$$XXP,;NIQ4*PSZS<Z-%)9W%N+ &2Z,L950
M_EE JD\/RQ.5R,#KS56&QNI=$TSPZ]K.DMK<1F:4QD1>5&^X,'Z$L , '()Y
MQB@#M**** "BJW]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C0!9HJM_9]K_SR_\
M'C_C1_9]K_SR_P#'C_C0!9HJM_9]K_SR_P#'C_C1_9]K_P \O_'C_C0!9HJM
M_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (T 6:*K?V?:_P#/+_QX_P"-']GVO_/+
M_P >/^- %FBJW]GVO_/+_P >/^-']GVO_/+_ ,>/^- %FBJW]GVO_/+_ ,>/
M^-']GVO_ #R_\>/^- %FBJW]GVO_ #R_\>/^-']GVO\ SR_\>/\ C0!9HJM_
M9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XT 6:*K?V?:_\\O_ !X_XT?V?:_\\O\
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M_/+_ ,>/^-']GVO_ #R_\>/^- %FBJW]GVO_ #R_\>/^-']GVO\ SR_\>/\
MC0!9HJM_9]K_ ,\O_'C_ (T?V?:_\\O_ !X_XT 6:*K?V?:_\\O_ !X_XT?V
M?:_\\O\ QX_XT 6:*K?V?:_\\O\ QX_XT?V?:_\ /+_QX_XT 6:*K?V?:_\
M/+_QX_XT?V?:_P#/+_QX_P"- %FBJW]GVO\ SR_\>/\ C1_9]K_SR_\ 'C_C
M0!9HJM_9]K_SR_\ 'C_C1_9]K_SR_P#'C_C0!9HJM_9]K_SR_P#'C_C1_9]K
M_P \O_'C_C0!9HJM_9]K_P \O_'C_C1_9]K_ ,\O_'C_ (T 6:*K?V?:_P#/
M+_QX_P"-']GVO_/+_P >/^- %FBJW]GVO_/+_P >/^-']GVO_/+_ ,>/^- %
MFBJW]GVO_/+_ ,>/^-']GVO_ #R_\>/^- %FBJW]GVO_ #R_\>/^-']GVO\
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M )8_\"_I11J__+'_ (%_2B@"UI__ !XQ_C_,U9JMI_\ QXQ_C_,U9H ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY3!;R2B-Y2BEMD8RS8'0>]244 <WXBU"Q?3+*/4-#U"\2\.4@AA#21.!GG#
MJP&>0>QYK(T)]+L-=M4L_#6K6D]VS1-=:@IPJA6; )9N>.G'Z5M^)+O4(YK.
MST^_MK"2X$A6:= V]UQMC )QEMWZ5E:5>WSZMI9NO%,5VLQ=39I:I'('"$E6
MP21C!S[@4 =K1137D2-=SNJ@D+ECCDG 'XDXH =1110 4444 %%%% !1110
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MI7(V[G.3N;;QD #D\5'!X<\HV]NUWOTVUF\^&V\O#!LDJ"^>54G(&!T&2<4
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M_P"_=6:* *WVS_IVN/\ OW5FBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %0WEU'964]W-GRH(VD? R< 9/\
M*IJPH['5K2ZN[O4-::^T_9(19+8H"!U !'+8'&.] #-)U^]O;@"ZT](H)I D
M+Q3;RN8A( XP.H)Y&>>/<W-5UN+2[NPM3$TLMY<+" #@(#GYC^7 [\^AKF=
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M"OHRO _AI_R3[2_^VO\ Z->O,S.35)6?7_,PKNT36_X1?P]_T M,_P# 2/\
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MHHHKI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L[5=-EOECEM+Q[*\ASY4ZH'P#C*LIX(.!Z<@<U
MH'@&N2T_QI/-I]O++X=UN61HP6>&U!1CCJN6Z'M0 ZSM+JV\1VK:]JT]Y.2R
MV*K;".'=M)8_*3\VW/WL=\9KK*Y-M?;4]:T>W.C:K9@7+/YEW $0XADXR">>
M?T-=90 4444 9FK_ /+'_@7]**-7_P"6/_ OZ44 6M/_ ./&/\?YFK-5M/\
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ME'V/_IYN/^_E6:*^8/NBM]C_ .GFX_[^4?8_^GFX_P"_E6:* *WV/_IYN/\
MOY1]C_Z>;C_OY5FB@"M]C_Z>;C_OY1]C_P"GFX_[^59HH K?8_\ IYN/^_E'
MV/\ Z>;C_OY5FB@"M]C_ .GFX_[^4?8_^GFX_P"_E6:* *WV/_IYN/\ OY1]
MC_Z>;C_OY5FB@"M]C_Z>;C_OY1]C_P"GFX_[^59HH K?8_\ IYN/^_E'V/\
MZ>;C_OY5FB@"M]C_ .GFX_[^4?8_^GFX_P"_E6:* *WV/_IYN/\ OY1]C_Z>
M;C_OY5FB@"M]C_Z>;C_OY7AGPT_Y)]I?_;7_ -&O7OE>!_#3_DGVE_\ ;7_T
M:]>7FG\%>O\ F<^(^$ZRBBBOG3B"BBB@ HHHH **** ,[PQ%YOQND7>Z?\4X
M3E#@_P#'RM>L?8_^GFX_[^5Y5X2_Y+A+_P!BV?\ TI6O7J^LP?\ N\/3_,]&
ME\"*WV/_ *>;C_OY1]C_ .GFX_[^59HKJ-"M]C_Z>;C_ +^4?8_^GFX_[^59
MHH K?8_^GFX_[^4?8_\ IYN/^_E6:* *WV/_ *>;C_OY1]C_ .GFX_[^59HH
M K?8_P#IYN/^_E'V/_IYN/\ OY5FB@"M]C_Z>;C_ +^4?8_^GFX_[^59HH K
M?8_^GFX_[^4?8_\ IYN/^_E6:* *WV/_ *>;C_OY5FBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH :Z[XV3<5W C*]1]*P&U6\T.&.VO-(NKF) $2X
MT^(.I4="4!!0^P!'H:Z&HKBY@M(&GN9HX8E^])(P51]2: ,)->GU1@EAH%\9
M4.4FOH1#$AP1G).X]3]T5NVT4D-NB2S--(!\TA &X]^!T'M2K/"\KQ)*C2(
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M0?\ D7=,_P"O2+_T 5H5^VTOX<?1?DC\\K_Q9^K_ #84445H8A1110 4444
M%;OP=_Y'#QO_ -N'_HN2L*MWX._\CAXW_P"W#_T7)7D9O_ 7K^C/H^'?]ZE_
MA?YH]?HHHKY@^Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KP/X:?\ )/M+_P"VO_HUZ]\KP/X:?\D^TO\ [:_^C7KR\T_@KU_S
M.?$?"=91117SIQ!1110 4444 %%%% '!ZS_R5!/^P*/_ $<:T*S]9_Y*@G_8
M%'_HXUH5^K\/?\B^'S_,^0SK_>ODOU"BBBO=/&"BBB@ HHHH *S]>_Y%W4_^
MO27_ - -:%9^O?\ (NZG_P!>DO\ Z :SJ_PY>C_)FU#^+#U7YH]L\"?\D\\-
M?]@JU_\ 12UT%<_X$_Y)YX:_[!5K_P"BEKH*^%/U<**** "BBB@ HHHH *PX
M-#?3;VYU*/4M6O7*NRV<UT&BR><*I  ]!SQ6Y10!Q&CHR>*93H]O>6]H]P3=
MPR0-%"J^4I! 8##[S_#U')XQ39]-E71]8T)K"=[JZNGEMYUA)1M[;E<R=%*]
M\D'CC/%=S10!AZBPU.WU#P\8KE9GLR%N)(B(I"1CANY!(R/>J*PSZS<Z-%)9
MW%N+ &2Z,L950_EE JD\/RQ.5R,#KS73B)!(9,?.>,DY_+TI] '%PV-U+HFF
M>'7M9TEM;B,S2F,B+RHWW!@_0E@!@ Y!/.,4MQ97<6CZMX?CM9VEO;B4P2K&
M3'Y<K9+,_1=N6R"<G' .:[.B@#"UG9<6K^'A!<@W=H\<=QY9,2G:0 S=CQG'
MM52)+C5KW1$>SN+?^SLRW)EC*J'"% JD\/R2<KD8'7FNE,2&42$98# R>GT%
M/H XRXLKN+1]6\/QVL[2WMQ*8)5C)C\N5LEF?HNW+9!.3C@'-63%/HEWJZ16
M=Q.MZJ/;&&,OEQ&$*L>B_=!RV!SUXKJJ* *&B6!TO0[&P9@S6\*QL1T) YQ^
M-7Z** "N;\3^4E[I<LFCOJC%I(UB"JRKE02?FX!^7@_7UKI*Q-=:^N+BSTRQ
MO18FYWM)<;0S!5QE4!XW'=U[ $T 9%O+$->TI1X1.GEIG N72-=O[M^!L/?W
MX_'&.RKF[6*XT+5+&Q?6;B_2[+KY5UM:1<*6WA@ =O&"#G[P_'I* "BBB@#,
MU?\ Y8_\"_I11J__ "Q_X%_2B@"UI_\ QXQ_C_,U9JMI_P#QXQ_C_,U9H **
M*CG@CN;>2"9 \4BE'4]"",$4 4-6LKV5X;S3)8$O8 RJMPI,;JV,J<<CE5.1
MZ=.:S+6WUJ?5[2YU^YT^".)V^RVMH6)DD*,,L6ZX7=P/Z51U[_A#YKS3](U5
MX$CLD8HC3%!& %4(>^"#D<_PU%IEGX*B\0Z<VBF W@9RIMIF?'R'.X'(VXSS
MP<X]30!W-%%<=XNEDBU2T%[+<0Z2PC DBD:-%E\U<^8RD$?+T).,Y[XH [&B
ML6XB,&A[KV[O+B&/<VZT+^;(N?DYCP>!C..O4G&:S$U:XM_ ,%W%?"YN)BL,
M5P?F*[Y-HSZLH/.>I'- '6T5R>H:A)X8O)XTFFN(&T^6Y1;B5I")8\?Q$DX8
M,..@QQBI(GN-*O-$=[R>?^T28KD2R%@7*%PR@\)RI&!@8/3B@#J**QO$%W+%
M_9]G#(T37UTL#2*<,J8+-@]B0N,]LUGOJDFAR:[;>9)/'96BWEOYSL[#(8%2
MQ))&Y<\G/)]J .IHKEEFGT:XT::2\GG%_F.Z$LC,"_EEPR@\)RI&%P,'IQ56
M&_NH]$TWQ$]U,TMU<1^=$9&,7E2/M"A.@*@@Y R<<DYH [.BBB@ HJM_:%K_
M ,]?_'3_ (4?VA:_\]?_ !T_X4 6:*K?VA:_\]?_ !T_X4?VA:_\]?\ QT_X
M4 6:*K?VA:_\]?\ QT_X4?VA:_\ /7_QT_X4 6:*K?VA:_\ /7_QT_X4?VA:
M_P#/7_QT_P"% %FBJW]H6O\ SU_\=/\ A1_:%K_SU_\ '3_A0!9HJM_:%K_S
MU_\ '3_A1_:%K_SU_P#'3_A0!9HJM_:%K_SU_P#'3_A1_:%K_P ]?_'3_A0!
M9HJM_:%K_P ]?_'3_A1_:%K_ ,]?_'3_ (4 >5>+?^2X1?\ 8MC_ -*6J]6=
MXGFCG^-T;1MN \. 9QC_ )>6K1KYK,O]X?HCAK_&%%%%><8!1110 4444 %9
M/BC_ )%'6O\ KPG_ /1;5K5D^*/^11UK_KPG_P#1;5=/XX^J_-#CNCF=!_Y%
MW3/^O2+_ - %:%9^@_\ (NZ9_P!>D7_H K0K]MI?PX^B_)'YY7_BS]7^;"BB
MBM#$**** "BBB@ K=^#O_(X>-_\ MP_]%R5A5L_".XB@\8>-O-;;N^PXX)_Y
M9R5Y&;_P%Z_HSZ/AW_>I?X7^:/8Z*K?VA:_\]?\ QT_X4?VA:_\ /7_QT_X5
M\P?=%FBJW]H6O_/7_P =/^%']H6O_/7_ ,=/^% %FBJW]H6O_/7_ ,=/^%']
MH6O_ #U_\=/^% %FBJW]H6O_ #U_\=/^%']H6O\ SU_\=/\ A0!9HJM_:%K_
M ,]?_'3_ (4?VA:_\]?_ !T_X4 6:*K?VA:_\]?_ !T_X4?VA:_\]?\ QT_X
M4 6:*K?VA:_\]?\ QT_X4?VA:_\ /7_QT_X4 6:*K?VA:_\ /7_QT_X4?VA:
M_P#/7_QT_P"% %FBJW]H6O\ SU_\=/\ A1_:%K_SU_\ '3_A0!9HJM_:%K_S
MU_\ '3_A1_:%K_SU_P#'3_A0!9HJM_:%K_SU_P#'3_A1_:%K_P ]?_'3_A0!
M9KP/X:?\D^TO_MK_ .C7KW/^T+7_ )Z_^.G_  KPSX:?\D^TO_MK_P"C7KR\
MT_@KU_S.?$?"=91117SIQ!1110 4444 %%%% '!ZS_R5!/\ L"C_ -'&M"L_
M6?\ DJ"?]@4?^CC6A7ZOP]_R+X?/\SY#.O\ >ODOU"BBBO=/&"BBB@ HHHH
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M9II6N/-5.$E+[P0/0-CCT%;M% &"=$GU*ZN+G5Q I>T:S2.W<L K?>8D@<G
MP,<8ZG-%II%^]WISZC);M'IJD0M$26F<KMWL"!MXSP">3UXK>HH Y^YM=2U2
M:7S&LU:SNDGL9(BQ!QD%),]\9!QG&?:I8=$>Y_M2;4O+$VHQB!TA8LL<8!
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M5K5D^*/^11UK_KPG_P#1;5=/XX^J_-#CNCF=!_Y%W3/^O2+_ - %:%9^@_\
M(NZ9_P!>D7_H K0K]MI?PX^B_)'YY7_BS]7^;"BBBM#$**** "BBB@ K=^#O
M_(X>-_\ MP_]%R5A5N_!W_D</&__ &X?^BY*\C-_X"]?T9]'P[_O4O\ "_S1
MZ_1117S!]T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7@?PT_Y)]I?_ &U_]&O7OE>!_#3_ ))]I?\ VU_]&O7EYI_!7K_F<^(^
M$ZRBBBOG3B"BBB@ HHHH **** .#UG_DJ"?]@4?^CC6A6?K/_)4$_P"P*/\
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MBRR7<9B:8N -H4\D @'/M]*["@ HHHH S-7_ .6/_ OZ44:O_P L?^!?THH
MM:?_ ,>,?X_S-6:K:?\ \>,?X_S-6: "BBB@#G/&"6Z:6]U+?6UF_DRVZO<Y
M*LL@&0,<Y^4$8ST/%9/AV1O$OB"'5;O5M/G;3T9;>UL2_P I889VW@'IQTQ_
M78\13_9-2TFZ72YM0E#R1QI&%.PD [N3P<+P?KZU0NM3U2XU2QNE\+7R_9BQ
M+[HM[ J1L'S=,D$\_P (XH ["BLW0=2FU72EN[BW-O*99$,)ZIM=EP??CFM*
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5V]/?./QJU<;/M/A'[(%^\=NWIY7DG/X?=_2@#H[JZAL[=[BXD$<2XRQ]S@
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M]'&M"OU?A[_D7P^?YGR&=?[U\E^H4445[IXP4444 %%%% !6?KW_ "+NI_\
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MBY=F"+G.U 20@SCA<#@41Z-I\-]]L2WQ,&9Q\[%%9OO,J9VACDY(&3DU?HH
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M_(S_ /Q5'_"(:%_SX_\ D9__ (JC^S:O=?U\@^MP[,^K:*^4O^$0T+_GQ_\
M(S__ !5'_"(:%_SX_P#D9_\ XJC^S:O=?U\@^MP[,^K:\#^&G_)/M+_[:_\
MHUZX[_A$-"_Y\?\ R,__ ,578_#3_DGVE_\ ;7_T:]>%G>&G0HQYNK(G6C4C
MH=91117RA@%%%% !1110 4444 <'K/\ R5!/^P*/_1QK0K/UG_DJ"?\ 8%'_
M *.-:%?J_#W_ "+X?/\ ,^0SK_>ODOU"BBBO=/&"BBB@ HHHH *S]>_Y%W4_
M^O27_P! -:%9^O?\B[J?_7I+_P"@&LZO\.7H_P F;4/XL/5?FCVSP)_R3SPU
M_P!@JU_]%+705S_@3_DGGAK_ +!5K_Z*6N@KX4_5PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S-7_Y8_P#
MOZ44:O\ \L?^!?THH M:?_QXQ_C_ #-6:K:?_P >,?X_S-6: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#R'Q;_ ,EPB_[%L?\ I2U7JH^+?^2X1?\ 8MC_ -*6J]7S
M69?[P_1'#7^,****\XP"BBB@ HHHH *R?%'_ "*.M?\ 7A/_ .BVK6K)\4?\
MBCK7_7A/_P"BVJZ?QQ]5^:''=',Z#_R+NF?]>D7_ * *T*S]!_Y%W3/^O2+_
M - %:%?MM+^''T7Y(_/*_P#%GZO\V%%%%:&(4444 %%%% !6[\'?^1P\;_\
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M\]H_^^A1]I@_Y[1_]]"C[-!_SQC_ .^11]F@_P">,?\ WR* #[3!_P ]H_\
MOH4?:8/^>T?_ 'T*/LT'_/&/_OD4?9H/^>,?_?(H /M,'_/:/_OH4?:8/^>T
M?_?0H^S0?\\8_P#OD4?9H/\ GC'_ -\B@ ^TP?\ /:/_ +Z%'VF#_GM'_P!]
M"C[-!_SQC_[Y%'V:#_GC'_WR* #[3!_SVC_[Z%'VF#_GM'_WT*/LT'_/&/\
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M!_SQC_[Y% !]I@_Y[1_]]"C[3!_SVC_[Z%'V:#_GC'_WR*/LT'_/&/\ [Y%
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MZ.-:%9^L_P#)4$_[ H_]'&M"OU?A[_D7P^?YGR&=?[U\E^H4445[IXP4444
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M%N]FG7<WG7%MY>69N"P5\\*Q'(P3R<$9J2\T.66ZNI;.]^RK>HL=R/*W$@#
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MT*_5^'O^1?#Y_F?(9U_O7R7ZA1117NGC!1110 4444 %9^O?\B[J?_7I+_Z
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M% 'D/BW_ )+A%_V+8_\ 2EJO51\6_P#)<(O^Q;'_ *4M5ZOFLR_WA^B.&O\
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M]%075[:V,8DN[F&WC)VAII @)],FIP00"#D&@ HJ![ZTCNTM'NH%N9!E(6D
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MCG'8<5-8Z#;V-Q%*)KB;[.ACMDF8%8%/4+@ G@ 98DXXS0!J4444 5O/NO\
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M/#OV [=RD9QNYZUWE%-8'#IW4?Q8>QAV/+[#X8W5CIUK:?;M_D1)%N\H#=M
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MHJS17*=Y6\^Z_P"?/_R**//NO^?/_P BBK-% %;S[K_GS_\ (HH\^Z_Y\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9(+"0RLO(&]EV _7:2/I0!;_ +>A6_M[:>TNX%N6VV\\B+Y<IQG'!)4D9QN
MZ4EWK\-E,GGVETMJT@B^U[5,08G !^;<!GC.W'O5"76=&U+6K=7U*T*6<W[J
M(3*7EG/RC"@YPN3]2<]!R:SK&CW-Y_9MWJ5I%#;NLERKS*&9E.Y4"YR>0"<>
MF._ !TM%("& (Z'FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,S5_^6/_  +^E%&K_P#+'_@7]** +6G_ /'C'^/\S5FJVG_\>,?X_P S5F@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** $95=2K ,I&"",@BL^#0-&MITFM](L(
MI4.5>.V164^Q XK1HH @>QM)+M+M[6!KE!A)FC!=1Z!NHJ"ZT72KZ;SKS3+*
MXEQC?- KMCTR15ZB@"I)IFGRV2V4EC;/:)C; T*E!CT7&*FMK6WLX%@M8(H(
M5SMCB0*HSSP!Q4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH S-7_ .6/_ OZ44:O_P L?^!?THH M:?_ ,>,
M?X_S-6:K:?\ \>,?X_S-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,U?_EC_ ,"_
MI11J_P#RQ_X%_2B@"UI__'C'^/\ ,U9JMI__ !XQ_C_,U9H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKYK\>Z79ZQ\7
M?$ZW\33B 6BQ R,-@,"D@8/KS6-_PB&A?\^/_D9__BJ[J6!J58*<6K,YYXB,
M)<K/JVBOE+_A$-"_Y\?_ ",__P 51_PB&A?\^/\ Y&?_ .*K3^S:O=?U\B/K
M<.S/JVBOE+_A$-"_Y\?_ ",__P 57H7P,L[>UUCQGI\4?^AK]CQ"Q++\R2;N
MN>M85\).C'FDT:4Z\:CLCVNBN*\-@:%KCV2@1Z?J3S26ZCA8YD=@R#T!4 _@
M:$ABU+Q_97UQ&DJ/:2O;!UR%5'4*PSW)+,#Z,*Y#<[6BN?T?5-7U*\NEEBL8
MX;2]>WE52Y8J$!!4^N2,Y'3TQSO.B2QM'(BNC JRL,@@]B* '45RW@FPL[6V
MU&2"UABD^WSQ[D0 [0_"Y]!Z5I:WJ%Y8FV%NUK#'(6#W%P"X4@?*JQAE9F;G
MH>W2@#7HKFK;6[Z^\,VVL">RL8Q&[7)F@>7E3CY0&4\X/!R>@I'U37+?3K*2
M\.GVTLY8R2O&Q$8_@01[]S.WL3C!'- '345R8\47\OA_1]2BM;;=>726\X=F
M&W+["5&,]CUZ>]=)9?:_LP^W& W&6R8 0I&3CKSG&,^^: +%%%% !17F7QNA
M2Z\.^'[.;<UO<Z_:PS(&*[T*R9!Q7(?\*T\(_P#0(_\ )F7_ .*KDQ&+A0:4
MD]3.=10W/?**\#_X5IX1_P"@1_Y,R_\ Q5'_  K3PC_T"/\ R9E_^*KF_M2C
MV?\ 7S,_K$3WRBO _P#A6GA'_H$?^3,O_P 56?>>$]$\.>(O"5YI-F;:X?7[
M2%G$TC90L<CYF/7 K2EF%*I-02=V5&M&3LCZ,HKD]8TK3KGQQI)N+"UE,T$Y
ME\R%6WE0FW.1SCM3+N!/#GBK1QIH,-KJ+O#/:(?W>0N0ZKT4COBO0-CKZ*Y_
M1]4U?4KRZ66*QCAM+U[>55+EBH0$%3ZY(SD=/3'.\Z)+&T<B*Z,"K*PR"#V(
MH =17F5O#H-O8ZQ;2:4&O'U&>"T:*UV$,3A%6; 52#VW?A73SW>KZ)HFAK-)
M#-</-!;79E4L6W$ D,".1ZD'- '1S316\+33RI%$@RSNP55'N32M(BQF1G4(
M!N+$\ >N:XOQ)=3WNC>*;*]CMI$LHT>W98R"-RD@G)/S#U&*NZAJ^I:2MNMS
M#97-K=PND: ,I1Q&6"L3G<I (R /I0!TT4L<\22PR+)&ZAE=#D,#T((ZBGUR
MSZW>6GAS0+JTM+-5NVMXI(^46,/CA%';GUX]ZT]*U"[GU+4[&\\AFM'39)"I
M4,KKD @D\CZ\^U &M1110 445\F>&/#&D:OX?MK^_M6GNIC(TDK3/ECO89.&
M]JZ<-AI8B7) XL;C:>#IJI43:;MH?6=%?,7_  @_AS_H'?\ D>3_ .*H_P"$
M'\.?] [_ ,CR?_%5W?V17[K\?\CR?]8L+_++[E_F?3M%?,7_  @_AS_H'?\
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MBBB@ HHHH **** "BBB@#,U?_EC_ ,"_I11J_P#RQ_X%_2B@"UI__'C'^/\
M,U9JMI__ !XQ_C_,U9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#S_P 0_"+1?$?B.\UR;5=;L[J[">:MG<I&AV*%'!0G
MH/6LW_A16B?]#)XI_P# Y/\ XW7J5%4IR6B8G%/='EO_  HK1/\ H9/%/_@<
MG_QNC_A16B?]#)XI_P# Y/\ XW7J5%/VD^[^]_YBY8]CRW_A16B?]#)XI_\
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M.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W**P_[0NO\ GK_XZ/\
M"C^T+K_GK_XZ/\* -RBL/^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#<HK#_M"Z
M_P">O_CH_P */[0NO^>O_CH_PH W**P_[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\
M* -RBL/^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"
MZ_YZ_P#CH_PH W**P_[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -RBL/^T+K_GK
M_P".C_"C^T+K_GK_ ..C_"@#<HK#_M"Z_P">O_CH_P */[0NO^>O_CH_PH W
M**P_[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -RBL/^T+K_ )Z_^.C_  H_M"Z_
MYZ_^.C_"@#<HK#_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W**P_[0NO\ GK_X
MZ/\ "C^T+K_GK_XZ/\* -RBL/^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#<HK#
M_M"Z_P">O_CH_P */[0NO^>O_CH_PH W**P_[0NO^>O_ (Z/\*/[0NO^>O\
MXZ/\* -RBL/^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#<HK#_M"Z_YZ_\ CH_P
MH_M"Z_YZ_P#CH_PH W**P_[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -RBL/^T+
MK_GK_P".C_"C^T+K_GK_ ..C_"@#<HK#_M"Z_P">O_CH_P */[0NO^>O_CH_
MPH W**P_[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -RBL/^T+K_ )Z_^.C_  H_
DM"Z_YZ_^.C_"@"SJ_P#RQ_X%_2BJ4D\MP1YK[MO3@"B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139912705619552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Titan
                                            Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000910267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139912706306480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_eecd--PvpTableTextBlock_zokMnNwYvDDa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48F_eecd--PeoTotalCompAmt_hecd--IndividualAxis__custom--MarcRubinMember_zb9PTTugUDMi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48F_eecd--PeoActuallyPaidCompAmt_hecd--IndividualAxis__custom--MarcRubinMember_zyTLWXt8iYr1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_487_eecd--PeoTotalCompAmt_hecd--IndividualAxis__custom--DavidLazarMember_zeQ4Sn5qD5d9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48A_eecd--PeoActuallyPaidCompAmt_hecd--IndividualAxis__custom--DavidLazarMember_zK1VV4ZtkjS" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_489_eecd--NonPeoNeoAvgTotalCompAmt_hecd--IndividualAxis__custom--NonpeoNeosMember_zxmyzcLNq8Vk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_481_eecd--NonPeoNeoAvgCompActuallyPaidAmt_hecd--IndividualAxis__custom--NonpeoNeosMember_zKdB9k1jWSb3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_480_eecd--TotalShareholderRtnAmt_pp1p0_zuUngniIe0O4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_48D_eus-gaap--NetIncomeLoss_iN_di_zTaOqkwDPa7a" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Marc Rubin</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">David Lazar</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table Total for PEO<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Actually Paid to PEO<sup>(1)(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table Total for PEO<sup>(1)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Actually Paid to PEO<sup>(1)(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table Total for Non-PEO NEOs<sup>(3)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Actually Paid to Non-PEO NEOs<sup>(3)(4)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value of Initial Fixed $100 Investment Based on Total Shareholder Return<sup>(5)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_41C_20220101__20221231_znbrCC8VMLq3" style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 11%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">426,248</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">429,495</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">152,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">152,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">362,340</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">361,412</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">23.80</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(10,206,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_417_20210101__20211231_zffgTtjGCsR1" style="vertical-align: bottom; background-color: white">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">884,247</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">578,213</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0024">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0025">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">877,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">578,101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,776,000</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, our Chief Executive Officer was Marc Rubin through August&#160;15, 2022, and <span id="xdx_90E_eecd--PeoName_c20220101__20221231_zpyuwU9gIcOc">David Lazar</span> was appointed as our Chief Executive Officer
and PEO effective as of August&#160;15, 2022. During 2021, our PEO was <span id="xdx_901_eecd--PeoName_c20210101__20211231_zEZd6b8XPPO5">Dr. Rubin</span>.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote [Text Block]</a></td>
<td class="text"><p id="xdx_89C_eecd--AdjToPeoCompFnTextBlock_dU_zl1jCVARzBw1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="color: Black; vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: left">Dr. Rubin</td><td style="font-family: Times New Roman, Times, Serif; text-align: center; color: Black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231__ecd--IndividualAxis__custom--DrRubinMember_zG110hp46Jd2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: center">2022<br/>
($)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center"/><td style="font-family: Times New Roman, Times, Serif; text-align: center; color: Black; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20210101__20211231__ecd--IndividualAxis__custom--DrRubinMember_zldepVNpw2x5" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: center">2021<br/>
($)</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_407_eecd--PeoTotalCompAmt_zH5lMcttZHef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; width: 76%">Summary Compensation Table Total</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">426,248</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">884,247</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr id="xdx_404_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--LessValueOfStockAwardsReportedInSummaryCompensationTableMember_zY4F59RZtUKe" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Less, value of Stock Awards reported in Summary Compensation Table</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57,782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(490,003</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_zgIUbimHVpBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year-end fair value of outstanding and unvested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0042">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_zYTu7ReRvemk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, fair value of outstanding and vested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,514</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,534</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_zVmjFqLtLqla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year over year change in fair value of equity awards granted in prior years that vested in the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,515</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0049">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eecd--PeoActuallyPaidCompAmt_zeRelyPvOOh6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Compensation Actually Paid to Dr. Rubin</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">429,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">578,264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</a></td>
<td class="text"><p id="xdx_89E_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_zhis3nIMML1h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Dr. Beebe DeVarney</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231__ecd--IndividualAxis__custom--DrBeebeDeVarneyMember_zicVLX58oPB5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20211231__ecd--IndividualAxis__custom--DrBeebeDeVarneyMember_zCR4hKdeKSia" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eecd--NonPeoNeoAvgTotalCompAmt_zuhcUsHISAjh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Summary Compensation Table Total</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">362,340</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">877,644</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--LessValueOfStockAwardsReportedInSummaryCompensationTableMember_zGW2SaH2LeI3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Less, value of Stock Awards reported in Summary Compensation Table</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(54,340</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(490,003</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_zn9jgIw2qh65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year-end fair value of outstanding and unvested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0062">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,486</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_zEa43MqiDtJk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, fair value of outstanding and vested equity awards granted in the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144,534</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_zAIgOQo0ZcW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Plus, year over year change in fair value of equity awards granted in prior years that vested in the year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,515</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0069">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zBgo2N5WKxE6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Compensation Actually Paid to Dr. Beebe DeVarney</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">361,411</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">571,661</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</a></td>
<td class="text"><p id="xdx_898_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zMcmachOcSRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="img_001.jpg" style="height: 332px; width: 500px"/></b></span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income [Text Block]</a></td>
<td class="text"><p id="xdx_897_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zhmjZ1zaghXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img alt="" src="img_002.jpg" style="height: 319px; width: 500px"/></b></span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 23.80<span></span>
</td>
<td class="nump">$ 31.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (10,206,000)<span></span>
</td>
<td class="num">$ (8,776,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">David Lazar<span></span>
</td>
<td class="text">Dr. Rubin<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_MarcRubinMember', window );">Marc Rubin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 426,248<span></span>
</td>
<td class="nump">$ 884,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">429,495<span></span>
</td>
<td class="nump">578,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DavidLazarMember', window );">David Lazar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">152,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">152,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_NonpeoNeosMember', window );">Non-PEO NEOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">362,340<span></span>
</td>
<td class="nump">877,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">361,412<span></span>
</td>
<td class="nump">578,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrRubinMember', window );">Dr. Rubin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">426,248<span></span>
</td>
<td class="nump">884,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">429,495<span></span>
</td>
<td class="nump">578,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrRubinMember', window );">Dr. Rubin [Member] | Less, value of Stock Awards reported in Summary Compensation Table [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">(57,782)<span></span>
</td>
<td class="num">(490,003)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrRubinMember', window );">Dr. Rubin [Member] | Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">39,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrRubinMember', window );">Dr. Rubin [Member] | Plus, fair value of outstanding and vested equity awards granted in the year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">49,514<span></span>
</td>
<td class="nump">144,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrRubinMember', window );">Dr. Rubin [Member] | Plus, year over year change in fair value of equity awards granted in prior years that vested in the year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">11,515<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrBeebeDeVarneyMember', window );">Dr. Beebe De Varney [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">362,340<span></span>
</td>
<td class="nump">877,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">361,411<span></span>
</td>
<td class="nump">571,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrBeebeDeVarneyMember', window );">Dr. Beebe De Varney [Member] | Less, value of Stock Awards reported in Summary Compensation Table [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">(54,340)<span></span>
</td>
<td class="num">(490,003)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrBeebeDeVarneyMember', window );">Dr. Beebe De Varney [Member] | Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">39,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrBeebeDeVarneyMember', window );">Dr. Beebe De Varney [Member] | Plus, fair value of outstanding and vested equity awards granted in the year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">41,896<span></span>
</td>
<td class="nump">144,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ttnp_DrBeebeDeVarneyMember', window );">Dr. Beebe De Varney [Member] | Plus, year over year change in fair value of equity awards granted in prior years that vested in the year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">$ 11,515<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ttnp_MarcRubinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ttnp_MarcRubinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ttnp_DavidLazarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ttnp_DavidLazarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ttnp_NonpeoNeosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ttnp_NonpeoNeosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ttnp_DrRubinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ttnp_DrRubinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ttnp_DrBeebeDeVarneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ttnp_DrBeebeDeVarneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>titanpharma_def14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ttnp="http://titanpharm.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ttnp-20221231.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MarcRubinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:MarcRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DavidLazarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DavidLazarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NonpeoNeosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:NonpeoNeosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_MarcRubinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:MarcRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DavidLazarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DavidLazarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NonpeoNeosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:NonpeoNeosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrRubinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrRubinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrRubinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:LessValueOfStockAwardsReportedInSummaryCompensationTableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000910267</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ttnp:PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ttnp:DrBeebeDeVarneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-12-31">0000910267</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-12-31">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-01-01to2022-12-31">DEF 14A</dei:DocumentType>
    <ecd:PeoTotalCompAmt
      contextRef="From2021-01-012021-12-31_custom_DavidLazarMember"
      id="xdx2ixbrl0024"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2021-01-012021-12-31_custom_DavidLazarMember"
      id="xdx2ixbrl0025"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"
      id="xdx2ixbrl0042"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"
      id="xdx2ixbrl0049"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"
      id="xdx2ixbrl0062"
      unitRef="USD"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"
      id="xdx2ixbrl0069"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-12-31">Titan                                             Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <ecd:PvpTableTextBlock contextRef="From2022-01-01to2022-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_eecd--PvpTableTextBlock_zokMnNwYvDDa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Pay vs Performance Disclosure"&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_48F_eecd--PeoTotalCompAmt_hecd--IndividualAxis__custom--MarcRubinMember_zb9PTTugUDMi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_48F_eecd--PeoActuallyPaidCompAmt_hecd--IndividualAxis__custom--MarcRubinMember_zyTLWXt8iYr1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_487_eecd--PeoTotalCompAmt_hecd--IndividualAxis__custom--DavidLazarMember_zeQ4Sn5qD5d9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_48A_eecd--PeoActuallyPaidCompAmt_hecd--IndividualAxis__custom--DavidLazarMember_zK1VV4ZtkjS" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_489_eecd--NonPeoNeoAvgTotalCompAmt_hecd--IndividualAxis__custom--NonpeoNeosMember_zxmyzcLNq8Vk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_481_eecd--NonPeoNeoAvgCompActuallyPaidAmt_hecd--IndividualAxis__custom--NonpeoNeosMember_zKdB9k1jWSb3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_480_eecd--TotalShareholderRtnAmt_pp1p0_zuUngniIe0O4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_48D_eus-gaap--NetIncomeLoss_iN_di_zTaOqkwDPa7a" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Marc Rubin&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;David Lazar&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Year&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary Compensation Table Total for PEO&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation Actually Paid to PEO&lt;sup&gt;(1)(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary Compensation Table Total for PEO&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation Actually Paid to PEO&lt;sup&gt;(1)(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary Compensation Table Total for Non-PEO NEOs&lt;sup&gt;(3)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Compensation Actually Paid to Non-PEO NEOs&lt;sup&gt;(3)(4)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value of Initial Fixed $100 Investment Based on Total Shareholder Return&lt;sup&gt;(5)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Net Loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_41C_20220101__20221231_znbrCC8VMLq3" style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 11%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;426,248&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;429,495&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;152,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;152,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;362,340&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;361,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;23.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(10,206,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_417_20210101__20211231_zffgTtjGCsR1" style="vertical-align: bottom; background-color: white"&gt;
    &lt;td style="text-align: left"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;884,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;578,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0025"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;877,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;578,101&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,776,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31_custom_MarcRubinMember"
      decimals="0"
      unitRef="USD">426248</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31_custom_MarcRubinMember"
      decimals="0"
      unitRef="USD">429495</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31_custom_DavidLazarMember"
      decimals="0"
      unitRef="USD">152250</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31_custom_DavidLazarMember"
      decimals="0"
      unitRef="USD">152250</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31_custom_NonpeoNeosMember"
      decimals="0"
      unitRef="USD">362340</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31_custom_NonpeoNeosMember"
      decimals="0"
      unitRef="USD">361412</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2022-01-01to2022-12-31"
      decimals="1"
      unitRef="USD">23.80</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-12-31"
      decimals="0"
      unitRef="USD">10206000</us-gaap:NetIncomeLoss>
    <ecd:PeoTotalCompAmt
      contextRef="From2021-01-012021-12-31_custom_MarcRubinMember"
      decimals="0"
      unitRef="USD">884247</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2021-01-012021-12-31_custom_MarcRubinMember"
      decimals="0"
      unitRef="USD">578213</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2021-01-012021-12-31_custom_NonpeoNeosMember"
      decimals="0"
      unitRef="USD">877644</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2021-01-012021-12-31_custom_NonpeoNeosMember"
      decimals="0"
      unitRef="USD">578101</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="From2021-01-012021-12-31"
      decimals="1"
      unitRef="USD">31.00</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      unitRef="USD">8776000</us-gaap:NetIncomeLoss>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="From2022-01-01to2022-12-31">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2022, our Chief Executive Officer was Marc Rubin through August&#160;15, 2022, and &lt;span id="xdx_90E_eecd--PeoName_c20220101__20221231_zpyuwU9gIcOc"&gt;David Lazar&lt;/span&gt; was appointed as our Chief Executive Officer
and PEO effective as of August&#160;15, 2022. During 2021, our PEO was &lt;span id="xdx_901_eecd--PeoName_c20210101__20211231_zEZd6b8XPPO5"&gt;Dr. Rubin&lt;/span&gt;.&lt;/span&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="From2022-01-01to2022-12-31">David Lazar</ecd:PeoName>
    <ecd:PeoName contextRef="From2021-01-012021-12-31">Dr. Rubin</ecd:PeoName>
    <ecd:AdjToPeoCompFnTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89C_eecd--AdjToPeoCompFnTextBlock_dU_zl1jCVARzBw1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="color: Black; vertical-align: bottom; font-family: Times New Roman, Times, Serif"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: left"&gt;Dr. Rubin&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; color: Black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231__ecd--IndividualAxis__custom--DrRubinMember_zG110hp46Jd2" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center"/&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; color: Black; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210101__20211231__ecd--IndividualAxis__custom--DrRubinMember_zldepVNpw2x5" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; color: Black; font-weight: bold; text-align: center"&gt;2021&lt;br/&gt;
($)&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; color: Black; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eecd--PeoTotalCompAmt_zH5lMcttZHef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; width: 76%"&gt;Summary Compensation Table Total&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;426,248&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;884,247&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--LessValueOfStockAwardsReportedInSummaryCompensationTableMember_zY4F59RZtUKe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Less, value of Stock Awards reported in Summary Compensation Table&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57,782&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(490,003&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_zgIUbimHVpBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Plus, year-end fair value of outstanding and unvested equity awards granted in the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0042"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_zYTu7ReRvemk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Plus, fair value of outstanding and vested equity awards granted in the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_zVmjFqLtLqla" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Plus, year over year change in fair value of equity awards granted in prior years that vested in the year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,515&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eecd--PeoActuallyPaidCompAmt_zeRelyPvOOh6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Compensation Actually Paid to Dr. Rubin&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;429,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;578,264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrRubinMember"
      decimals="0"
      unitRef="USD">426248</ecd:PeoTotalCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrRubinMember"
      decimals="0"
      unitRef="USD">884247</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember"
      decimals="0"
      unitRef="USD">-57782</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember"
      decimals="0"
      unitRef="USD">-490003</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"
      decimals="0"
      unitRef="USD">39486</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember"
      decimals="0"
      unitRef="USD">49514</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrRubinMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember"
      decimals="0"
      unitRef="USD">144534</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrRubinMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"
      decimals="0"
      unitRef="USD">11515</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrRubinMember"
      decimals="0"
      unitRef="USD">429495</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrRubinMember"
      decimals="0"
      unitRef="USD">578264</ecd:PeoActuallyPaidCompAmt>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_89E_eecd--AdjToNonPeoNeoCompFnTextBlock_dU_zhis3nIMML1h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Dr. Beebe DeVarney&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231__ecd--IndividualAxis__custom--DrBeebeDeVarneyMember_zicVLX58oPB5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210101__20211231__ecd--IndividualAxis__custom--DrBeebeDeVarneyMember_zCR4hKdeKSia" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eecd--NonPeoNeoAvgTotalCompAmt_zuhcUsHISAjh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left"&gt;Summary Compensation Table Total&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;362,340&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;877,644&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--LessValueOfStockAwardsReportedInSummaryCompensationTableMember_zGW2SaH2LeI3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Less, value of Stock Awards reported in Summary Compensation Table&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(54,340&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(490,003&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember_zn9jgIw2qh65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Plus, year-end fair value of outstanding and unvested equity awards granted in the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0062"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39,486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember_zEa43MqiDtJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Plus, fair value of outstanding and vested equity awards granted in the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eecd--AdjToCompAmt_hecd--AdjToCompAxis__custom--PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember_zAIgOQo0ZcW6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Plus, year over year change in fair value of equity awards granted in prior years that vested in the year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,515&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0069"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eecd--NonPeoNeoAvgCompActuallyPaidAmt_zBgo2N5WKxE6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Compensation Actually Paid to Dr. Beebe DeVarney&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;361,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;571,661&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember"
      decimals="0"
      unitRef="USD">362340</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember"
      decimals="0"
      unitRef="USD">877644</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember"
      decimals="0"
      unitRef="USD">-54340</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_LessValueOfStockAwardsReportedInSummaryCompensationTableMember"
      decimals="0"
      unitRef="USD">-490003</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember"
      decimals="0"
      unitRef="USD">39486</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember"
      decimals="0"
      unitRef="USD">41896</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember_custom_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember"
      decimals="0"
      unitRef="USD">144534</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember_custom_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember"
      decimals="0"
      unitRef="USD">11515</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2022-01-012022-12-31_custom_DrBeebeDeVarneyMember"
      decimals="0"
      unitRef="USD">361411</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="From2021-01-012021-12-31_custom_DrBeebeDeVarneyMember"
      decimals="0"
      unitRef="USD">571661</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_898_eecd--CompActuallyPaidVsTotalShareholderRtnTextBlock_dU_zMcmachOcSRl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;img alt="" src="img_001.jpg" style="height: 332px; width: 500px"/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="From2022-01-01to2022-12-31">&lt;p id="xdx_897_eecd--CompActuallyPaidVsNetIncomeTextBlock_dU_zhmjZ1zaghXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;img alt="" src="img_002.jpg" style="height: 319px; width: 500px"/&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ecd:CompActuallyPaidVsNetIncomeTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZD]'DV=OG_/4#^-WOF?I,IG3U+\]??VCE?KBE6?O)V]/3B9GD\GMFXMCZ'3
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M;%!+ 0(4 Q0    ( ,]*LU:4.^(3[@   "L"   1              "  :\
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M2P$"% ,4    " #/2K-6 )[(7O\"  ")#P  #0              @ 'G$P
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,]*LU:7BKL<P    !,"   +
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4!08     "@ * (0"  "V&P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>28</ContextCount>
  <ElementCount>18</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>9</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="titanpharma_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://titanpharm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="titanpharma_def14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" original="titanpharma_def14a.htm">titanpharma_def14a.htm</File>
    <File>ttnp-20221231.xsd</File>
    <File>ttnp-20221231_def.xml</File>
    <File>ttnp-20221231_lab.xml</File>
    <File>ttnp-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "titanpharma_def14a.htm": {
   "axisCustom": 0,
   "axisStandard": 2,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 2,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://xbrl.sec.gov/ecd/2023": 46
   },
   "contextCount": 28,
   "dts": {
    "definitionLink": {
     "local": [
      "ttnp-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "titanpharma_def14a.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ttnp-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ttnp-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ttnp-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    }
   },
   "elementCount": 101,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://xbrl.sec.gov/ecd/2023": 6,
    "total": 9
   },
   "keyCustom": 0,
   "keyStandard": 18,
   "memberCustom": 9,
   "memberStandard": 0,
   "nsprefix": "ttnp",
   "nsuri": "http://titanpharm.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_def14a.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://titanpharm.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "titanpharma_def14a.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_def14a.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:PvpTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "menuCat": "Notes",
     "order": "2",
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "shortName": "Pay vs Performance Disclosure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "titanpharma_def14a.htm",
      "contextRef": "From2022-01-01to2022-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:PvpTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 9,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://titanpharm.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid to Dr. Beebe DeVarney"
       }
      }
     },
     "localname": "Additional402vDisclosureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToCompAmt": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "localname": "AdjToCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AdjToCompAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "localname": "AdjToCompAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "localname": "AdjToPeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AggtErrCompAmt": {
     "auth_ref": [
      "r69",
      "r80",
      "r90",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "AggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "auth_ref": [
      "r72",
      "r83",
      "r93",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AllAdjToCompMember": {
     "auth_ref": [
      "r103"
     ],
     "localname": "AllAdjToCompMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllIndividualsMember": {
     "auth_ref": [
      "r76",
      "r84",
      "r94",
      "r110",
      "r118",
      "r122",
      "r130"
     ],
     "localname": "AllIndividualsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllTradingArrangementsMember": {
     "auth_ref": [
      "r128"
     ],
     "localname": "AllTradingArrangementsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AwardExrcPrice": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price"
       }
      }
     },
     "localname": "AwardExrcPrice",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "perShareItemType"
    },
    "ecd_AwardGrantDateFairValue": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "localname": "AwardGrantDateFairValue",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AwardTmgDiscLineItems": {
     "auth_ref": [
      "r121"
     ],
     "localname": "AwardTmgDiscLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMethodTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "localname": "AwardTmgMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "localname": "AwardTmgMnpiDiscTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "localname": "AwardTmgPredtrmndFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "localname": "AwardUndrlygSecuritiesAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "sharesItemType"
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "localname": "ChangedPeerGroupFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CoSelectedMeasureAmt": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "localname": "CoSelectedMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_CoSelectedMeasureName": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "localname": "CoSelectedMeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "auth_ref": [
      "r69",
      "r80",
      "r90",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "localname": "ErrCompAnalysisTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompRecoveryTable": {
     "auth_ref": [
      "r66",
      "r77",
      "r87",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "localname": "ErrCompRecoveryTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "auth_ref": [
      "r73",
      "r84",
      "r94",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "auth_ref": [
      "r73",
      "r84",
      "r94",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "auth_ref": [
      "r73",
      "r84",
      "r94",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "auth_ref": [
      "r73",
      "r84",
      "r94",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ForgoneRecoveryIndName": {
     "auth_ref": [
      "r73",
      "r84",
      "r94",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "localname": "ForgoneRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_IndividualAxis": {
     "auth_ref": [
      "r76",
      "r84",
      "r94",
      "r110",
      "r118",
      "r122",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "localname": "IndividualAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingArrLineItems": {
     "auth_ref": [
      "r128"
     ],
     "localname": "InsiderTradingArrLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "auth_ref": [
      "r65",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "localname": "InsiderTradingPoliciesProcLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "auth_ref": [
      "r65",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "auth_ref": [
      "r65",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_MeasureName": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name"
       }
      }
     },
     "localname": "MeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "localname": "MnpiDiscTimedForCompValFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "NonRule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "NonRule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_OtherPerfMeasureAmt": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure Amount"
       }
      }
     },
     "localname": "OtherPerfMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "auth_ref": [
      "r71",
      "r82",
      "r92",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "OutstandingAggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "auth_ref": [
      "r74",
      "r85",
      "r95",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "localname": "OutstandingRecoveryCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryIndName": {
     "auth_ref": [
      "r74",
      "r85",
      "r95",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "localname": "OutstandingRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "auth_ref": [
      "r98"
     ],
     "localname": "PayVsPerformanceDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "localname": "PeerGroupIssuersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "localname": "PeoActuallyPaidCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoName": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "localname": "PeoName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_PeoTotalCompAmt": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "localname": "PeoTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PvpTable": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "localname": "PvpTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PvpTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "localname": "PvpTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "auth_ref": [
      "r66",
      "r77",
      "r87",
      "r111"
     ],
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDateAxis": {
     "auth_ref": [
      "r67",
      "r78",
      "r88",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "localname": "RestatementDateAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDeterminationDate": {
     "auth_ref": [
      "r68",
      "r79",
      "r89",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "localname": "RestatementDeterminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "dateItemType"
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "auth_ref": [
      "r75",
      "r86",
      "r96",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "Rule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "Rule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "auth_ref": [
      "r70",
      "r81",
      "r91",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TabularListTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "localname": "TabularListTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TotalShareholderRtnAmt": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "localname": "TotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TradingArrAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "localname": "TradingArrAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TradingArrByIndTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "localname": "TradingArrByIndTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrAdoptionDate": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "localname": "TrdArrAdoptionDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrDuration": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "localname": "TrdArrDuration",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "durationItemType"
    },
    "ecd_TrdArrIndName": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "localname": "TrdArrIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrIndTitle": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "localname": "TrdArrIndTitle",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "sharesItemType"
    },
    "ecd_TrdArrTerminationDate": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "localname": "TrdArrTerminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "localname": "UndrlygSecurityMktPriceChngPct",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "pureItemType"
    },
    "ttnp_DavidLazarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "David Lazar [Member]"
       }
      }
     },
     "localname": "DavidLazarMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_DrBeebeDeVarneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Beebe De Varney [Member]"
       }
      }
     },
     "localname": "DrBeebeDeVarneyMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_DrRubinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Rubin [Member]"
       }
      }
     },
     "localname": "DrRubinMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_LessValueOfStockAwardsReportedInSummaryCompensationTableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less, value of Stock Awards reported in Summary Compensation Table [Member]"
       }
      }
     },
     "localname": "LessValueOfStockAwardsReportedInSummaryCompensationTableMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_MarcRubinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marc Rubin [Member]"
       }
      }
     },
     "localname": "MarcRubinMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_NonpeoNeosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEOs"
       }
      }
     },
     "localname": "NonpeoNeosMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus, fair value of outstanding and vested equity awards granted in the year [Member]"
       }
      }
     },
     "localname": "PlusFairValueOfOutstandingAndVestedEquityAwardsGrantedInTheYearMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus, year-end fair value of outstanding and unvested equity awards granted in the year [Member]"
       }
      }
     },
     "localname": "PlusYearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInTheYearMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ttnp_PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus, year over year change in fair value of equity awards granted in prior years that vested in the year [Member]"
       }
      }
     },
     "localname": "PlusYearOverYearChangeInFairValueOfEquityAwardsGrantedInPriorYearsThatVestedInTheYearMember",
     "nsuri": "http://titanpharm.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net Income (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r101": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r102": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "vi",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r103": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r104": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r105": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r106": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r107": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r108": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r109": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r111": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r112": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r113": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r114": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r115": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r116": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r117": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r118": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r119": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r121": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r122": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r123": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r124": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r125": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r126": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r127": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "F",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r128": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r129": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "A",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r131": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "B",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r132": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "C",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r133": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "D",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r134": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Form 20-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "16",
   "Subsection": "J",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r66": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r68": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r69": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r71": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r73": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r74": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "iii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Form 20-F",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r76": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r77": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r78": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r79": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r81": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r82": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r83": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r84": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r85": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r86": {
   "Name": "Form 40-F",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r87": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r88": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r89": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r91": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r92": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r93": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r94": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r95": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r96": {
   "Name": "Form N-CSR",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r97": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r98": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r99": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001829126-23-003606-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001829126-23-003606-xbrl.zip
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M*!WQ^'Z>%\WV+FXE?U[](\(%SJ:.D<)E=3BUQMP<5$G9O_^:W6-RBI\3ZS/
M(J07:^.Z)WM6,")]$!V?X>*E0W,OB:K%=>>*"H=23-AV9-A;,!\D-2HJ>; T
MU]\]KZ1P%"LU,BL8)DNS$D649-LQMREW*"Z27<N7RG2<$6/:9N3 Z&^9SFA(
M4#:X,8=1,Y@5Q>8AXTB7S&KE_OK&'OB )X'&&;A5M#2 6?$AI:0\Y)IM=]>^
M#*/^2)%KPF:9;A2E&3J@5#:<=5!;KLSVO/;) /WU^JMG>\PYHDD*#G"1\@DV
MQWA"HDWECY]WEED.=F<K&%>6"[ %.U?TOXS78K@6T K.6-C>*0J2CF<+[0NR
M@[CNL*9%RM<+-,-I967L+(<I'F%N:/LJ+L677&F_KCSE1>F#NJL/G<X36*AH
ME9@]E\W<=S(@XM*V5@E9\+0C'*_4L2Q98,7._]SWVMKML,7^_AM71<H(BL2O
M8EW,TV2;3G/8I0%R8_F,E<;)+_1'>C]\0XN04!T B%VZ+L=5/'@T1'GC'L>-
M[J[V&@=?A1?A+%Q5#8#W(9K V_9AT09<-L;PCR+L5<9B<M-:XB!5B/]-5A8C
M?L(P:<F%L9Z&&QV01=)!CD*C,/K[^>UCZ&2;C<NT19OSHJ/"UG[[I?,$\ID%
MY<,UTJ]#Y-C;.\/6!25:F".[F"NL6-!\#Q*OV^,/1EH%U#+R>NY_+3[5:9($
M>_/9B9C*-)['].@]Z%K;ZQ"YVJT:*! LR&KQPA8F\]M+M(70GOHMA3-*S[1/
M,M#P'T]/C\29'O"F/Q(F/*N!&%(YOX,)'ONN.\WS"+:[PJI2"$RTZBI'Z_&_
MS\Q&N]:./=_MLLSK)O"T806U"ALE-K1XHIX)DFIW0UUMHU\]LE'2QL,C\*UC
MUCL(W)JCK1ABVXMH'R9N.&KME-5]NT_846!Q'P$L7L^E+\+P;^F8,_EV1@25
MF]B[F9PG%INBY0_39@R]H>TRMG#I8JZ:NK]XYT6$#19C7&[F5)_!%RU-)>ZG
M!^T,Q\1B/MX+MI'3M%L%#5_FS:?<-2:WY/6+48L;PM=X""6/\9P'])J]A71,
MIRS@U*,M6EOXCDX>W[%'LEZA0G)1? W0";4]UN(/TE_"U#Z(Q[!ZG?6=WQ9S
M$@"G#JRQ5OBR=NZ(YG#<=D_)P%%#S4F:O[L$.=SOKL(7:!2H5G^?,6[)5VD0
M+6W R&KXV)"K2]LU%NUP5X+JDB[U.O/0^@5%?B3Z\T=O0H<>?L.B6[$"?R@(
M&6D^H[LU5.;SZAS#2M_9*.H<HSD)"VUB6_5T'[7MJX7RMK!7*D=\=@Y&YN,Y
M2I^@988$VPETI_QI6FY9]@RMZ<W" B:=8H7;V%PA@;G>Z:>G=[T%(6_GCVZ,
M-FQ7(X -/JV61L*@N&\ R@?(F>:F!]]"],'82A]FH6BTG?BAY:I?%PU^W^CI
MQ@-"-\L)G\1:E;LU6=LD+WL>T+^05>WJ;&H2Q8.][0/L(02CS*&B$E\?I/<"
M;H3\:;5$CVR7H+RPB5'1[W1:57<EB/%,;A >EKOL8(HLDXVZV#<>N=CK5([2
MCXE""]!8VQBQG' Z+\Y/^X48DLQQP0$/IK2W,ATMDDO,L3L'OZ)XV[D:)"R+
M%>U+D'J!9/</EI^IZ3_D793<X4<+[8W+.IB /ZYSWD( EQS5.A1-$\*@ &N'
M7$\#URIF8K%OTW32!*3\<@QC18W+!:\&KT@\4S;5+SW+RW!EG#*LW!D^,;X*
MA_6[#"R'I@+-4*,L+?,YXK$=JV5"O)'=5^X>Z>CN(65*3=69'?Y\['HM*MEF
M'\/?8,.&#](/7KVXQG 4)OA(T3(KO&>Q:WR/]_Q.O&.1FOH"WLT.\%/5[-(^
M$97#6K?5*H)7)=K?0*P\URVGD\F-^8#UYOC-S3@/<K4M<I9G+!T0E5/F. 5U
MN,3Y_.D^,]S7?%9Y+)^3,\^PO+3&_WMW7LB1A-%"D(T !^$$^ F 3';]ICSB
M_+[D$V\)1+]_:K[T/84-VVHG([0Q\$2'ND58/<#2*%3I?>LPX9QB7]5 %3,"
M&-.@(SG0F?>[&]\UEE;I:_?EA?M#0BI8'BBDKJF@> F]JCP:AZ?X!<MW04$&
M4I1EBB1M+]P)=@?8EX:BD%U&]ZY(,Q-C-&PAYM$BAN_V<9L&!N F>B.1[NF;
M O9!<AVK/FJ67E29]1\@F>4E-@>S@HZHM[\&"1/S1(/?T\VR2GG0.H+>@A=I
M0U]>4(:-B&4+/K0ODW@=XA[AEOP&L$$ 5I7%4*X;TR6<4QQ35%2*!,TOPZ'+
MH& +%]_V,7&"EZ*VW@:!5*0AXL8,SFMRUV*LJ2,>-Z/A%,DMY^=I>WW3#F_"
M+I2H383ZEP@%.^CJS).O6+=S>$G29Z A2UI\MULHO5F4XD6/H\^Z&D\VO?&M
M42"=H9D(8((' :3>VMCFE!B2]LF4>15CKRT#FCE^&)Q>@ DL;\>-IA#2C;UU
M85AR<.Z\\7)6X//W#>5^&B^L!$_6R@E.*X<!#'.W/*WTFD2/1MMCF4H_O535
MCB5\W4,L?TO11TQO9Q*HY5H;'&BW9PF+&J]RU?:&<;>%\CD,"-$[E4?/,;U%
M>V2&' EO>@A6E!17C(QX?%%V.%=D),828GILDF![7JU2S]QB#_)S4/;J8EJQ
M+M:X&4%5;B<ML1TX-U2+ZYRJ=/\E-&1+3%QMYJR9; :R8"(HN ?PF;0E$5B3
M:$Y.=7B5.YW-?,7&C; -J0F@/$M!#VTJ)R05]BN1(\@\(W^G2+TO<E>@PFXF
M"0%T&KP?*7,5%1^'4Q_JQI=/X;R+/F=)=WC,_P@MZ,& ;3\.S4GA,QU^DX-C
MLQAU?;E;LRD6[Y<GFRBQK)0$S[<W-=R2WV6,&Y26C9:!2C6T9!EOO$(UPZ9L
MD27@VO;#FO,6 K]OA#1;+*X!AI_6X5,WE$CN%[:ST_CXSLF)K]L3;NJ8!-92
M@SX8E52&G.[LY2OMK;R8XTHXZ=R0H1EW[/#F6#_$*"AU/(\XHLW3='_5%*N4
M5NQ=WW*<@C=/7EZU6$@NMR1BX5@[LN;W.ES#CDAB5<F1BFI T;4@JRGF4C<U
MY4/IYSA*T8E9-,)31<6E=-JJSC.PGT:,;)U6[O1'!=D[-;=K>9K66BLEJ@#N
MA 2WY:F8EB10V<'X)S;+Q)6>6,;PRQHZ**TP2J@Y,%$H"FU  /2GH=>>"& G
M6#= N^%C+;/]4N52A:4BJX5ILEM*&4=;48B6RW+R$Z!J8?Z"Q"'Y\DQI58..
MX< X9NGB;K6O@67VPS4J)M5._;I$]\,@NDJ&3:TYT/!>J>5]=G'WSH((#!P2
M-DQN4K>K#G"F:FA+Y.161764?RZ;BDY7O6QFD!Q.8^.%'8%GRPU@P4$DE,B%
MH8U<^&[*FCMU!5&:/]MG9NJP)&F<%=N3#;-Y<G_':Q834+5HZ'GN(,,!3-O\
MP#PN?WAV9AJ5?5BP-CMM0 TWFA$6X145L*2$J@N-5P[<6]?TYV2T_$!?+(JW
M'F&X@@ 2GF%Q+0LYBG&V\LL5RG/DIE(02P>1"=CZ$C2F?!OP(ERR&',X+XU4
M+'<GY-P)OO79H\AO.N2!B)IN_N)R(=3S9/:Y2\;GQ*&91R@*0<(W,T.7!X1V
MGT%56ISGJ,KYK7/S5Y.9&"PL@]Y=\A]WZ'))T-+^4^8W/S55"QBNIV*_O'RF
MDZ]DP(OP2)L3)EG!LUS>9YC2X8N)S)+.EMQSL@+7JQ3$W,EVF>\'ZGDT3_Y^
MJ<C*\,5'7A1'])]AQ,U)^DOOPTG[>)X4#>V,CRB5R]Y62<R-C-R26TFV5V=)
M00W\![;LK8;#K8;]T!7STS\I?A"]^D_+H.;EO]MA8_FQJH5LK"(J$VP.,2$B
M,>&98<%%CTADH6P4@L\4N66.J$35@NW@S-\JM2K+=,0?6WQZT,*>%X"J>NRC
M"'FW-R H:NS-:WVEG+99?E-/1R]M6K'-P%'-L]5Q45)4/V-$]%&F^1F/[J3.
M!_97C'*L#/0%F$IS:&4\3^J+*H=#,L*H'94$>C7$3]Y0QF)"YK"R:%D9-$)4
M#[3D[_NY?UA*VJ#K'LYYY>F[X(D!./!K)GY),20_XC(]T& ,3G]%^,@?6%A8
M.!'DG1;3;X;;XY>NSILY=G,'/+/1P $$5^RJ: +7:M77$8#YP!D7;'Y'*W'5
M;9FU(JO>%CJ6&YQL=A ZB7J]7&&MQ-HE="6^OXFT[[%1?J=]6]O;(4SM+V$)
M ):=$N#\16-^>KYU6*OJ#K5%;CH#@V,+*R#9A!4^HZ;^@><L']=)-'F7=#XI
M]OLTY'#'2S"O3GT79'UH,HF" ,(,7:<1@!A_U^5N!Y(]4U+1:XB0_Y3=?FGU
M*M6C;$&V=]XT=D+:(5)$V^3$\Y[!S'<MV[ ZFZ@"5 F#,_T))(0HQ:/>NL(K
MFI-?X]:PEU@K<7;^\J0O& :N;FL21F-->4U8A^KQ]%T@ %!=<KNW2#5+FO>-
M^Q67SM<B"&!Y%)(%&6F BTF0FWZ=WYP_V4< H<KP1 2@B)Q[IX!&6NZ_=9#Y
M]084X\#\/W4 _=LMSS#B_L7R7RS_Q?(_S7+LM;,E=5$-S?(74Q0+#@30*NR4
MZ!(=V7,GMOX@Y*XM9=/M*F"74F5B>Y"8CS5\/-^JM,]-3+/%<KA/$"85^RK+
MK7G9KL*@I&B[@]Y;8)\O'I?:L"K.^$'Q/B&I)<OTA.UW HJ90S6ZHSF1NW5F
MD3L]H#@C+-8*JGY/+@V>C+A0OW1/3%G+<0O'H]ZAR,]G!U4#/1.%@NO;3_W[
M"8F@W,,8/)L'2NB&[#7>0SZ^I,2$-,\P=D&Z(WQ0P_BG5<?+P>4UKF\JQ6R/
M4315/RP.Y6A=ERB-6GE]'R]F"=PH&*$O?NM_#EK4<O@M&-.JP\74KP^O@G6_
M"A=>N17"EB]N 3%*2*U0(CW6FGF?V@A2*^W@CHNXDM_BJXFY)FWTU^YS5,-P
M)_@13AS_'2T;]!PJJM/-A" Z"^E (#O.Z).;]9F#TU9TO).K?!C7?%8A1+.(
MC4L)MX77@E$Q4X/2\(&8).DE"VIB=(Q)UH7_'#_^7;32"-X@B0WNU@2\!(*W
MO#UBMUJ4$OHL,3NFB^QVFBB$IKPC;IK0<&"A%@Y)4"F;DK,R7;A@]DRB1V1]
M[L5%:PE*CJIV:']P?S4IV?(UKI0UU8T=C9XJ)R>QR<\12H"=NVH<"ZI?4O#K
MK'[C\K<&N]^KG%Y]3-B5D,/F":% \WGLQI^,?SY-/$^":0(2(56SKNV.G:)<
M6?&)C%3?^,="A/_*5EQ&2&!6G=B8M"3TR*HGSUZ8K>&>7@(JRL+R!(W#4IEI
M"MYD*3Z_Z[!QA9'A^X?HSVO-#6A)OX91VKG<'OM8)SQU-GD[BM8@R%_IKO3[
M'-H'SWSOCY&BT-R4L;P9PM1\*L08X2DG&KEG_N0_BW#^?V_W0W*10N?"H7#I
MPM]F'2"?A03<09#08S[C7+,_[8K_%YO!184:M.60N>76Z?#6I391TSIW!@5Y
M4#:%Z!L;Z3V1E;5J?-!9Q C35%R_G^,;-RIV0PV9"?S2T-Y!K"IE;>/00[VF
M6W-C%1.[J6$(H$>DMM%^\W@!U!BW0Q\MM*3Q.IPQV%]UR =K0PH0_Y^V]O\Z
MP!T_X1B_P>?"VT/%OKMB&*+"UJEG8Z;*_W7%H5])C) N/:/ H&UIW)0^\*A_
M8S?ZKO_6W%VGAX8HOI_0<PV.^S$5 ,VZ0[3-:D-.5W0S3]9:.9P8<^*,U9X'
M%RIH3DKZPG'VYD>34#<%1==\SI?A*Q]%W^FWWB]8Z@!SP68\!?-<7H^F13X>
M.Q5Q_]!7&7</^.C1&2(3O9.;''\#S9)J??N)@WSLB8)._H(#3.J@MJS<]MM5
MII+2(MN+!!I'JGV)6UF:R4^KDN;5'Y3W2-?(60YFWV_PM'EYQ"TT(+3!)6>1
MJY<YGE0=9,/F%IC,\CB#4IMC(4A.I)BG$RU\)"XUV^S()>ELZ86_RVT%8:T7
M%N_CN(>[0KR];?B#D@)$C3,_</!9S!+1]2_-PT2X9V(-[J<VD][(.+B*L*NB
MI'5-P??44W;'?B6KK+NV9>1[<]Z!JXL1!N"<M]\O%1Z9AIBUY%QX627?3%SQ
MNY$7'B9[1XZ1)A?/\(3F^,6IW+QRM;\L6T%KM=16YR:CE,?W3B-VT'D (VSW
M\H5U9D^!7*&.JYTD[6[:Y/1%I_)[E.(V16SJ^ 91D#E099$[+V.?%?Q$D)Q=
M2N[]+U+M_I JY0A8<5A+#6BEL,3XDL-H$\R]9WOC]G,FB;XRFG(;2<%E-.KJ
MA!>L>)=]_<&DT<[D2XU4'$%%4<_@&A)?E0A[2*(Z&[?[5/W;MW1(GAYL3_5'
M3,U(&W]J?ZS[PKKR@=>[;V@ C:]K.PM::=J/<I3<OU(>\PM&^8N5.(,_X,=?
MK,3A_0%7_DHESB_HYG_I4*+A,KR6--F%U'C<WSH99M3OY'FP'BA65174@BUH
M@A$ .[ND3\GVT2M0!]_H7QN8CBO/JZ_ZZ72RS 3'KE:V_.=QHTM#2X;3 G&]
MMPB ^(J952EECDI":#9+]_/G4$?+JDM[/7D$\%>X@7BRVO0"=0D=/VJ71;Q0
M\>9CI:^BZZ^1NUR9T$B'#[MYQ*MH#EK=%L.+COB <CXU;7L1=Y8UPK;R,!0P
M8D GEN7KW6JX<462ARF@"RI3!Q\-XP^6>]J],SE,P2Z%?/3"&B_/$SZMJ\V"
M:\RAH6"-L'M#4"V*_5VL7FN\BF+Z4*4NC4<X&'AH:7!F-50@(!Z:KZM1M,+4
MS-9SLFP&RK=U!F-XT;N8JR4_JI$/LKO5O-,,/<>O.$(?Q!KE5>]./DB^DC^P
M>#>^8QS!) B:4GM#>DWKM+X=J:,6"I/<Y"SC*\3O(]IG3X U(0#O<JZ+.. 2
M,_!X%K0$:>DS,>_(>V1Q#P%$.\>G=ESAU.N-U\B[\&Y7JED8AYC&[]7:6:F<
MW![$V/IGL)M_#?6OH?Z;AE(C>\BB2@F\N@%HKG$ZYC_1(^:/?77V[3VCE%$B
M+N]TFO..]-B%1&?7P A65@&X39^J<-=98[[-G31#:U;S8>]>O=9-,F^&?1O5
M.IS-/N"-WKRY7 9NIU19>AZJ!OFF1ON2^#J&K-"R^/);>>?< <S8U\R3M37;
MZR&,_H_"J;]US8:D2C#/4R[S/=P</GY:,5)V?7=I:W4W6L8T/RC\HO*VGV.G
M]("]SX"FW,DTU$'AAL;;F=G-X@[&1<6UUZ6Y!K!6S(%ZL0TT)851YNC+?<6Z
MH[ZQ;S+'],]SZ 4%7^$PTOBC&YZ<YS]I'GX=L:X[RN<?^#(U6G#!Q_AA2'<5
M4V 8-GHYINORIE;I?S8Q_%W#DXW@;I-ALY,3NIO\=RP/J^,4>J@.EW(2Z9HF
M?Y_:2W<T9N I3S9E>CQ7\XGX)5W <$WUH3,"B*A;3H;9((!AM_76,0<SH4QW
M(B&[]K7S*PX+PDM2T=<(P'<, 2QM( "_/B3Q," (?*#9<*7S2,H5/%4"5X4F
MS+_T_-"P:/\2,IBZ3'A%7H@ *&3^[.ZM6RSPL>2CPE;Q;S 22//:-P20^J@=
M!&77@W.$0K7'02<L+BT(  .)[-M&>96O<\&K>N\]7Y_=_?-100=5>>"-9X<!
M<%QU!/ QVS0=I@;I;KAYV;*C@ !PXUK@?H24D(4R"+1ZJ_;.$HR0:E-E_KO6
MG%8>!:<%FT#XNW#&9SCHJ)!:D0F0KE:&EIY"MHM?OH=D_F8GW\<P_6]UIL\2
M0C_[S)=[ H5*[+DJM,HC@7*9GKU;RZD/"3)UB,NG]CREI#Q6SVCUX %*9 A@
M86@#1H 4^5%6( (X,#W=AQCINW/6+L'GFYPASE<D&^VJCO<;R1C0B9K(NK=!
M^*)4!58"]73%Q]1Y8<P1*Y<1GYD/"VE_S^+$,P I6NI(&P3*ZP8N+A*+F0--
M0SGV]Y"Z='#KV%E,U=[S9'A95VS0*3=F++DCOGFM@ QLZ/ [+L;&58.<PW9"
M^ 9.@W)0_^E+$DWP:Z3^-QP.]>#X=*'?MA# B; +<BS,4)DS->9B6 L,@C%[
M/7_P-/60>FG MU-'?VY-5CWK+"KV/F0W;2$9MC&AA S;8?RCXU=@>HB;UKU'
M)G#@.P(8S'WPW;P76YSG4!G+ER ; 2R^C+P2&['Z8E; >7K/R$IC)58C=#0J
M'<9*,NFY>-W@NP??AS*7(\V(\@HWSU)U?+GT$_*%;U':GAH<P<NF-6>G=1M+
MIK2E;'$=(I@)L@[)CJ(&6N0QE4ZTMC]/CS\K $O<!^%=\1RV[0>P72DM?HS"
MM0.9:^E2WM4)Z;1/3/\:(6Z^6NB7(UEH6B&&=U?<GUU ;K<^6KPJK5Z'3AQ:
MM9#$9\K)6*%TB3UE_0@!6&+B((#ZW,PA!&#V6$1%ZP!&N"]OQ \Y;$=::^[G
M7;&SP 4'2! <8^PL>QPC(1\!L.T;<!ELS3N?%LP-7XX\\U8R<L3H9<X(ZZ15
M6F)!=?NQ&/V/;K_;8\H=^]O*PD,6F2*F7OCKW5=[2/P4K:RHJ6DY$(@(7)KK
M:+/5GM3H61JLH,#>Z66C9^'WB=)%,1BH )*^YSZ;VIIR?N\P7P$-WW]NS<U7
M#N.6J=QECZSX-CU1U)$/.+Y0E@)(_T C6]I' $SN'>"S1020<;K[9W1+* )P
MCNDYYLX_X-$/9"F,$3U(^UW%>J'@P?F5E\M'>(LZN%<]?2+!Q1T.%I5" *]S
MD]=8MZ#JUT=ZBZ*U\]?]ND57DQ52I.J;S&U^O_>NSLGH#2MA&WIGAP@@DU@=
M2V>]B?."49CBNA:R^3AJP01LL'X)TFG1.SI?O4SR&7TUP9?G(7804E>Y10<J
M"I_."^]8%4( /G<)MW78R19 NB[C13 AJ-V^_:9FU%G2>EH]<Y 7%C[RQ:B3
MN!XP= BCKZVW7"90L(EO:VGSU<X7 #^,<+.:!6VU:=GZ(QQG^84_7-YARQ%7
MCY\'::0RS/#+@E"9ZTS"[KCY@ [8\TF%J_ &Z-=+U*H^@T9QDHD*6GF)HMCI
MO%R*F#O(YRB@/DW!HP4MZ_DX>GYU-#!@A?2(? ]RN:Q@O9RP-<J>-'^&L\/)
MOI<JQNBKZGC55'AW'&RBAZ=KY<D!ARG:#\F12(/1_)$VE1M0!\595B"P=TS9
MBC[G:'!,B<U?NW8!G8\!GGQ2'I6B6H<?FVC,N;:XI[-4/*W/W@]<EU&!H:<.
MM\"[]UBFXB8"AAKJV#^UV9Y(#\#])$"20[K.Z5=6!QR%95HJ$<UJ/T#R-^3T
M[_!7/RU8:WDQ<OI2]%KX<NJ(<W^ZNYAS#2<%U^$/6M3?97V_FS/J7W];5O)F
M^BTBJY;^:>]V$$5YX)[OG-QCZWM2[,5<T6\(WLYEI'D+-1"9DW-^T9#)-G7S
M6]*ER;C9?$LV >_8'^,EWA&A09^AJ5+F=XOR')/%?,UA]W+3N.UG*G[/\KZC
ME]AW*(*?3!\RS:72C#NY>5Z7O8M!?5BBZ%-1O?SF%4E0^?YP<6GN]/I8:8GC
MTN>"<?VM-\-C#&&"#Y^4XS!0"IVC>HMHLGRI_7!KSUD5W:^'QDX1N))K X3_
MR-).K0X"6"ET68?/@$^2ZM)^(BMM$<#>T867L6H]YAME*;*C]:2?M+A.1X=4
MXP 1Y+OY^D7@B=MQ*"&D8_U]PPZ?_56;I]X-I(W+7S''Q". JIYQ<#S_1EK@
M-2/TV^]G<L'Q0LQ5!"TN? Y\DO9D8;L6RH0 & ,>(H"*T&N6B%J\]1T/9(#<
MKK2 ZUXUJ RRI 4>$!;^Y S73T/17+3T9AS%,-N=K8HO) V1XT[@7TY(2@&N
MF$4P$:C:N?UFC/.415(@C0+E%?7:#T/WK[].OM)+5SI+Q%(KJS:$Y=,$6W,N
M?H?,JYZTD:(<K5\Q-E")WK3UBDLHWSP/GD%=XSD-,T'BD?Q9T-FG*IV<?!>O
M>^ Z]H0V+@0 O%F'7Q:FYN*^/-#S+[ON>#&X8Z53W3WHPWQ]]F ^'["K!G>
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M?$WISR^##CY"W>'>FB9P5!DX6;X4W3"D%WX.?]T+BP7_=*GW2G+0P8(3S5R
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MO"4Y=E (6VEH=G5M@"74&5R46 6R% XK??P)H>UZX6JY)N/P\A^O:5]<L2Y
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M0M#E#Z=R_F@:ZQ?N1/W_2OV ^@$W8$F.X8?A^$6N-N^'S$_^/B"J[W/8*/&
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MNMS^Y>^5+K&X0"\\EXP 45"5TB:=!9LH6YQC C_@H I3E2)1G@7;+#?.9F[
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M+8=V8=/EJ[GP^E5C&5OC#4(GN,63AR$/O(->^!,(8^@-+.?63["<J5 &1-N
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MYT],0.@8&-A8V"1W[I!P/B!_P/EO7_ .  \=R0>\"0;1 $AX(# >"-X-4 $
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MJ4JAL"T:5327.$4KX:9#CR=]%__9U[.H9RS2=%;/0XZEM=C7#4LX]#,#F]B
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MG5'N?C\"+8,>J_MZKT,D^:F$B#JH,_.=)[)[9%:CG*X-0MLHP[6HB/UO<][
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M C4C4.08*)-VN$@^'$BY/8!VI5QP0G[_#(&Q7QMT+9TB38@=XHL=EEDSG"?
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M]7O-C<Y-D*1-175<'L]0.'A '=-$6118\C[R7;LT176\O4T=?SAO:MP@0+4
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M:(.P5DE-F)<OSQQ^+U@I/S??A+V=*\,9B_;9YV:6]!F)W($MS'Q !$U8?8,
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MU?4F0Q1]U>V&I2S'V#0V#[O*KD%O'G=;U?7@4G*S9>(T2FU9]D=<..US)6E
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MJL1[$<%:"F&E]-*>V=1+6 FVTL:H)7],]#)6NP) M6'V5P!?JDG"AD.D!J$
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MUCP/%(ED]=!*(Z%P&:&WOX2_V'RE^:)?F#(A([$B[];2Q%=SP!+++1X=7.%
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M*#-L,F2EQ_AB7S"PFL.W9..9.)/2?OOF8V4L_!ML8GQ*,*+1&.W]70>TB2M
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MHEF,VIO9^EWS:[IZ,*4#?A48@2><\4L]/)&?SB:ZM'Z$6?WKX;VQ T;PJ*<
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MUGOR26N?7F31@E2[@;;_"M!  NSA2,-I2(<B(+(5T#3NMQ>C^C.8 \M]3?S
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MJB3<<+D-D/A/-\6R'XQ:^26^*^RQB5?O^2!6-EFC%S)ERFIN^9TM?2G<N9&
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MQ,!:B2*9">O;W3D<=-X+(W:4\0$5O>;JMZIHQER:YE> L 70(!?(]=OE!%0
M],K*IXPO4;E%Z93(WZ&YI'47?I"O[+@8")CYQ<RJ/5R AAT# >N<7+R&B00]
MTZ\Z!_N(.P@!U'?3R1,2; 77(4B5Y!>Z[P]'M0=>[G-= 2B2<;/6(+' ^;3:
M=U< H6E<!.P-$@(8_WV/F0P@!F:8#XD\8E*+5S^K&*#!<6-!GP%(<;6I.)$I
M5%OC;<NGD1JUO&>(TW68PAI],#MLM,R^[_!N0;N()26KF8-,JHB@MW; SSA
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M_\*/+'?/'XW;H^A-$11-AH)^(AC^M.,P N:S;UTY_2/K;RLXEJ.>#-X(!^0
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MA,%Q*'> $6*U=\YM[<<< $3ETD.N?>YX2?4FL >CP.G%7#Z]  "JFS>[@#6
MA7MQ"4B"U5.YS70N8OC.$MFJ@&S>@J*[$-5A6NU0H@:;A^IE"H2S6<MO*6L4
MP)(<E7$7)*KDE"Z-8UM8BA('M"U/N9SCT+ $#:&3.("3>YB[%TZ* 89 D7LX
M]6QKT32VQE@3WA\[:",:$>#F^E6=+9Z:*^-2C:[D 9#R+ <UX17X*.\"M12*
M<[:4O2Q2I,>7K_:6*[//E3+->LG$ J\EH![>#N@4 H4[7%BZ-\DHJ6:=Z9J@
M2G06XXHK$Z>XJKZ<YP8*W?(Q3K;69851D?KZ^CI7BAHY43SV64D&U3/%>)\C
M 36(%AXAO"G.\%7+EC'ES,"&'GIVO2;NU4H*?KQ/!Z:T,C7YJRC5*U$N8V#+
M4K?U"*C8-P"1:UMB=H#(DS>-&?@>@N].N M!\%V3,KD'@:/CSO7\&]S>U%=0
MK=C4B230;JNTDP.6JE86P"V\08FR/MX (7\!&V'DI.P17[9N:'S8"Y,)OR)V
M,:?6ME:$B4/L^W;,> 9TDBE:VP7R4/7/VVQB+N9REXBS7R ?PPK^> =L]?TQ
M.O "X$YA8J4B$=K$Z3 5S%!XD[CJ.[N2&,_J*OK3K6% 1XW=R %C.LO$PQ1K
ME&,BK?9I*PZ,T">J$&IX :K7TQYR= ( -",_2.X;<@EGJ)=B<@;/5!=?40 H
MQD_Z)^E- /UHC'4)C;V08XMDRCUV(WGVMMTP8<UGQ:FBK/UD1^!8E&GRF(=R
M;8'05TN4_7J6FMDEI;LC/.KR>Q/=Z$#U<*A6ON&@9[!6JM)6$P?4]D$*Z9 @
MN[7O@FJFPZXG0X@_5"Y7*[<)YJ7@!TO$VDQD!9VQ@&BNAWYB_22\A_$WO!6!
MDX?96BI"89,ZHF0:\EH^'GVJNT&E]ZG?*%@7-HABK[#T<FB#T8W+1N?N$J/I
M75$?FTL=];%61GW\5-3'(K62V3L]/SL];U]TJI7/I]\ZYR?MD[W.$NO2<PH[
M-==D-X ?.IR2M8CK6"*A3TW7Z%S0O6K'0<#UP]%0"!STIH(8E2XGH#>;:1G@
M\+WXU0?%="C:=='^#CI##>1Q8 VMD=B5WNK%WU=.39QA[KLXJHL]L#CDI"9^
MLU#]Q*"?72E[4NS+;Q;(\DFM6CD;UO?K-=$)'%M\#J3T>C*XK(E]Z\KIBTY=
M'%E_HR_VN*X^.K;L RMP+4_"//SNKQ:N_KPNCNT3JP>_!W5L91/!G-=B#S\^
MCH.^KP<]L= )A=Z=8RNPQ7G<<SP Y!C&$OM!G3_@[T']P4QWM=!T:OX69Z.(
M)JK#KEK04$!^(%>3.*D9'1^4SX\:AE)P&@5F\4F =26Q!RG&7%%>(:<3);68
MR;B27E]UG7QP4U<G,.:$ 51?!KS%S429)1WQRO"3.>%!::X>WKJ:=2D6<SU+
MQ%/)1Y0Z;M/D^I!ZLRA?;'I\.E,X=383"Z$$_90C8SAIS\60L,3E?]+N[K?_
MQ5X&9&'86SBYD[6 $?RE+V+?5RL_PJWSO/@1>"_?V!G\]Q6QDD4(:OC8TVK:
M/GJQ0C2MX10#YT:\;>=:&ZMHI95ECN?(U:0S:]!E:M2M_6Q-.F5,V\ WK'$(
M0.F?WI!-:%2CFU%CCNS&"-VY"*7WSS<;"4@\MK;0FZF%;NZQ*P=@B/7@B<O
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M$@"*GU_Z7&%\9-TX(^=OXNB&WGZ%B@YWO]'042E/G2.6K)&WJEJY#TK T?J
M8'8<2BH+E:ZVK],"5*L(ZH6A,P7@^TN*&:N!.:'VS2/>A4L('" 06&T_9B,
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M=YP(.=BLV%A>F=DXD^J+-;7IP"(QO<%!%\#O5*D^I3EU7F'1:;'%:PP42;#
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M)E7H6(B]4+II^Q,-- R1%41UL?\@%U:U@HZPF@$9>M5"YT;=?C%3][_KUGW
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ME JCZ =KMX5UAW'OOZ#N405&7S>RPSKE08#)HTE#*\JC5!-SC<O ;%8-NF0
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M@:8&8/P58Z3 I"X.(R0PQU.M0M/*MK;-A8^IF5;@WTP2^,'<55T%J'FV:BM
M)92S30D+".^.G@L%E'DGW4V14;[<.6X-U3&B>U%:B@WG:#E>2#\$V'J=>T]Q
MAZFZ^%V5+O*P3K,5<M/TGG0=>2753;67-"-4A<'4 >,E<@][PMJH[?;Q*AJO
MON$K*@@<>Z0?ZW.& ^"K6<27:/;0X="/457&BL3)(#!N[.'(=!>M,8<"+/5!
M&#?<QJUPM9*Y%N8]X5:VV.[,P -UZGCD4R>>1+BD/6/UK;,5*CPC#W4(%&D9
M&)]@2<G.YFPI^T&]6B%YP^('J 9.*>E%D$@V_I8<9#IP(A,N$<C5!$MF-#A6
M@29.H)UC:/GI"GQ8^"PD%L*V8!:I&2>!8:GZ@Q?#. C[%C"+7V-/JKZI.U38
M?@VGWWG?: BK/JJ+MYWNQ4I-.($Q)PSP5^P',?6Z S.5*$SWY""@0?0RU"6^
MSME22$TT8LL!%ZWQ&,/FE(2R,$ATE;K54CM#X)(H,S5:W2EEJ2U?5M*F+V&G
M;^1M)'YQ[D".?"SI3[7ZU10%I?MPT-X$8W7JL+)(U=+DUCY6P-=X!H(:WF?;
MCL=6$D_5"_ "D9M94N#.T %8X4-%.F8W\)HPFS%*I:!H^4*]"@*IB%GP<7 ;
M19QLZ(QA<T<^.;DGTYW&_2+O34DL/[F41^]N>Y_N4&5[VWG#0#BXCXZN641E
MS90NW>Y?U<7'=P[5J7N[T5I!31YI^\#G!F&H@>_^!Q3E:Q5; %)7]$#$.7_%
M4AR&@04:+<8,<A<-9#@.K.UOU>D47;9 Y[9,:HH*;+$12A<[J@97U!:;@R.S
M351!*E]+D-#8RYO:LU*L(NP']F;E/KK!V \L=;5WF$0>AN)_K=$879M)*]<C
MBFC$" WT)0,(N!I^:H]T=QO]R#CHE14X?@PJO7,%[!E7I5K'Z)ZOJ+J&Z")V
MPB$KO[]:P.^-3NM;?/.GMY@5ZG[:5NY(7F+Q1A6G@9-^5ANSIS<&]OPL#L:@
MG>\ZH#3#M$=1'Q0/[/DF ]BCWYS(O](WB/C=BGA[TN[NM__U[J+=[;P79V>[
MJ*.  0%Z/5URA!1=:NO6=?TKC/?FWB<A(MZJ[5ILW@36F+@_QMV"TD^J3!2/
ML/ KQHJBF6%1NV'RK ?Q)4DP5-T0.4ALG<"+:1,@V)0-)?#:<):N_K35J(LS
MV.^ KS2MJ%:T<W P87Z+N(6>6@L<=" CM+] 33N6?><2#I W++,GQ_N?N[0G
MP+6<D2INBTL!>0-Z(';,N:3F>I'ONR$(\#[]UI>(I(P>^*85 5K]C6<_XGZ^
MV 1G3*)3[:[:A,Q:F^MJ!Z:W)K<)@@2KQAGTX43 ;K&'GX6%"CW2*YGNDO8T
MKM3-C %7/:()RTV($IM%@V"NL?0-(Q51K E(*G)*J./:#[[7Q# UY+*$1WP!
MFPU11R7  TTT(+31++\,T4;3G"%]%Z]>%%= !O.URU6ET_>Q^+#NNLQ=;4)C
M;\ALI2MR7-@$K5$36ZH5!%N5.38BUGO8XAH-=SA'4([HH&K&VKGK#N]!S_*^
MXPR!CR61K<@ 7D=8ISUZ%/.JP;JBH0.:?X\XQ:1: 88<#X"GQ(&^T0_]073-
MP>0)$!B^#<P?-:T<QT U$4V5W7J[7A/ MP'1/"!EF,.UXKY$=HVJF.C8/BI?
M=L@(]X<$)>O*$E\]AWI+11/LGDU2X@_8&X($\.GHJ+X[<UQ6+K_ N($:M3NT
M%)[! AQQ#(P/U$>@/M>5EX2,R$UAGB]^7WRQL'XF.G+X_&EEJ;SA2 @5OZ;,
M(WY0[()VW0Y#'S97>8(\<MM2GRN0#-(+%44 "1&U*T> 1K1CH$W83M(L?T6I
MFNG4E $CH1N0N3 N,@"7N+*\&0,&)SVEL%8\]M:6Z?%+/!H,74<!L6H0#1*;
M*99X!*.?.#Q0XP 2"NS#KFR(]*H;E6WT%#5&3; WA:Q&>C.[M94W*63&D44B
M%3$(IDS@ R="B$))Y>O#[V#Z,H,WO#W94Z'Q2^U[SI;":ESB_T2,GG: :FT.
MY-\FZ'/_]:GZ.^>+ 1X?R%Y@*BR-+4:ZY'HD3%K6(J+=VK96JS&@RSE(-*=@
M&1BR#05\=\C]ZGI2>L58)OC=;.- $(P[=;'/+!2E%:@0W(&0&%0<8NX0CZR$
MI>-5*UJ2A#:0"AP(MGE#L:U$.2P%AL#.V*BY&*S8MC *!<FTQN,#P8R0QW!;
M[=#I@3B*)J2H^DG?/F7" GWU8SM*1F=5(2-NSN5E#'+-AQ';@X'EH#[)OC$&
M3'U8+^K<BTMLK:O%XX65P:.(&\HX\-6"PRAQQV82 U$.D+"9F":\#BZF8>%C
M]%*3^,LNFC:D.X(_?W.5T]T&*Z(F/KO6C9]^ ?(8N-;WFE+. DI3NB!]DL#
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M'N7O<)1CWA?5W3TXIM7E@B!Q>"^. D=Y3<)X/'9E-KMDQF):%%^9-8:F>15
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MZR,L2)62= J;;=A.!U@UH1M1=N)YDDFE+O*GX.MI*S#-=6,(S2+QN%NVOZH
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MUU&1.6@KX:"%C92;O]RN(ZG'\A/JG4:-?>;(13 6X]'#@"D>^7]F#+J1>SK
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M=?9 C>4E#5#5[4NDS;Z60E5K;M>V[J^JE0ZU$I 2D)\BI'GA9TNDB\T-#I2
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M4P=(_"WKCN2VGKI%95%O4*XK1J]S]NR,GI?40GV,[=NOI#NI5RO8)U4/2+/
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M1LT'0,HX0&S#&@\HBI>]B^UB]&<^DUX(YUBM[$H/F$84+N8REHC.?@<BZ_M
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M:TBWRKLVMO":R!E;K\O4G5,>U"'41#NJ6FE?!E*22;68:UDB?DHN/>!HKN)
M:"DW=X#A@<%(%-M'RO7)X$].4%CZ )G/I+3(#(H<8$3=/?0G@(V,!G5HN<I*
M_I^U%GFSF>=* S/2@9$# '/G6G9&J3LT/M\OQ=878]$359PSRLK=][XKO7"_
M_S3YJWF8 N_EC0O1^X]5>"1J'?HP<K>MCS5XZ]&/>F=S:^?#_\_>NS<U;FQ[
MP_^[RM]![YSD%-0C"#:7&9+L5'G DY P0("9)/NIIZ9DNXV5D25'%QCGT[_K
MTMUJR9(O8,!X=&J?#+9UZ<OJ=?VMM4IBQ \:]5*K#KD_O0W\!%23'[]S?]KF
M*.&\_T='63L10&VQE:L?%250BJ)N*%CG8(VB0\Y,^)"ZU(-PBJYA+S:>#C['
M1X4LE'H7UKMD5M3!6>*KDQ&J53( -G")V_C,M9A=V:!&C.E( G?K.M' 0E_[
M(N.0)393SQ[:$Z"RZIB#^"=QXS$&-X#/X-J-,MXTA1,P,0+W87B%%#\?)ZA8
M7L7RUI?E78-*\<."O(YL'ND1 $Z9TV,,_6C@8- OO@NVQL()27VQP*PALZ[#
MOG1\$'MC*6*^R#@D*Y'<;6QA=!18)@5HX'$P]<D01)R.7;Y3/P:5.3!BK2,G
MB18<"0P V2=8>+!3_' <U,]!T+,N:50V&>W(10/?9ZN7M4?'.M*AAR,C)@)C
M6704')IP0J$-27@?13?TCD2;MHS4*E$%PT;&&WN"(L,;[J85P6J%%/5P_<5W
M!28^5'$4%^2-$GJX0(9HH05J-"78P887PYL=5*&MT(GACR!4=^+FL.A:4 :B
MG*,GPZ/UJVBAS]]>ME"VT9K89$1ON+>;M#8Z8HSQ'^'!4B"!:N &C6>Q@>B
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M78$FW(_W:PCTR.FLR_$#SY>L_4+:.:W2QCVN6YDR=@YFZU]+ZSZ%D)X<=,Z
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MD<);^6BD14NS=)0['^-KF"I<N&H6@B7A1FQ8/#&W_$&=>R\L8RMT%TCB_]$
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MOI?E.:.HP$)A1QS< */NJ]X?JO!Q*W5$>>.2(XA^3)F>D#;D9H=>!J/T9M>
M@7$10XELVMVQ>LZ8IL'>7YEO@$AJE0(QN=JVK%L*/"-U5,]<JJ):<%DOLC+9
ML@=^6BQ!/90J&-"3*3?)3[]4+"%2CA;<>QTEX'DP7##-W<TO=,5#5FPJQ5F@
MI5QD7I9 4M>0N(9W0647E:>6$C_1L81[(F:*680\%HLY,2:.S5<A*.4DLO'V
MF?B,_?7&9S0K?,;7@<_(2/V]G<.6!B:@U&?^*%-?J*59E&8MS=7C !4.:@J%
M.8]<"EGE&/<QH.U( #NW&<E: V48=1QF#D!MP(E=$]S.26G:>J(<JTSI0Z.\
M,]:^G+X<M@H@D^%%:=$4=LZW:NY2"2M,X!I;P@D]5Z6)Z0MM6:09KY/)LE(%
M<8<9D+0N5D\Q1:&JT<$7V&PWUZA=U\4L2ZY59795EIK.E,O&MZ>M>+V6KL3T
MCIST]#2)+=L/A+JFN;J"_7 D,R7X(FI",77/"?4X8SMG4,TS2J]U9![<X+&
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MW_SGU<XK^@S7==7GA:<K3<XN;#76Y@"=7?[U QS?7CS I^Q\^XJLJ!_C4+T
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MK6Z<)GZCH"IJ0*XP@/+HT^&."/+7$;Z JQB B\')88" .W@VC.%;BF*:/<U
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M>G)T@KFUYV?6V_8OK=-WJB( UQ2 #\<GE^TCS/3_L1-:WR$CEO_24]0'607
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M.4*='OY\?W%]^M?_M]1]77T[[87,!3;VZ/P,K*</[>-Z#7>1[2#<6C;4)%^
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M5MI9]ZS8UK.KZ\L/I 1^7Z]=!Q3#Q-A=02T/XF?4V9'.DDWIA4+"8>DK'5I
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M;S4.WQS8=" Y*74;KNB#$H(Q$1F8IN"BU)$CT<UJ2/"4 N[#)"U8@M"3AW2
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M'$-/K7/PTDK-P:4_UM+LU/^3\^961P2HN@/B9&K_3,"N-;'!1)*CA1 "?([
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MW_;6KX7 V#Y@#3@8D$,3KH0C9)TF^@ 4,>#GG.+SQJI$^D;'C9\J&51ROG/
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MVSB&9X"_GB<%7"7B CU7/V95P:O.3X&:&*S'ANZ7]P%W0+7;R*-@:%A#S49
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M=GJ69N ?^)'OM^P&/"33,+Z%BRG$-;IRB(F2U9'C92L[;[UT-:3JY<M10,#
MMQ2XKQ*^])B.;KS_>5A=Q$V,L3)6T2L*N0YPHY05K.K%+&! X/9=SG<H7D)T
M!Q%1EW,38ZR<5?2*<JX#W"AG!:MZ.3/88'QU#^ZN[LF^GF/<4D_7 .:>8!FQ
M[>.+G:NA990:#RX^>N?JN6=[:QC\=X)X;XBBN54[;ZJU):65-[8J)ZV7M8I1
MO:@9)B%T 6,**!(=4# FHO=COTVO&TB(Z%>ZGSU2Y+\,7ST<D >X1)B]W(SB
MQV2Q\/"F3&CB32.HK@'>ZM%8E?$^H1=US-O<61?J^\50ES9W>@A6W"U ,R <
M@]0SP)EKP.JXS'E5_,+]OELMXR@AOT,/7\7!M1?B[ [<)U3T*H?Q?!@'7^,5
M)(SIU1])2#<I_2_8B\5]F3Q#;J]^*-[["L8>DOW<FN*A>5_W;CQ$>XFI_E#Q
MBQR"#8,-8!R &;O0]A%#VVL!]@,DV=4 %)<#7OKPS=,+\F>//D/AS,23IKPI
M3V]\P-[!L='GZMUN1.5Q>K-7=YZB]PI%_O#HGQF7GA@>T/T*8O[SXIE% D=Q
MZ=Y([\,8AT@8D,FS1],;UB-1[>5RQK/6'F]:(X7MX5KN/(G[#5"=W !B%TU_
M\\5E^:-7?7"53^B27U_8$O:T>C1_I T^O)?X5PBG\!(^>3B&&UVWB11HL/M$
M0[34C2)!N2%2'359MXI @TL(4OQ^.U@"&*8=+.R7;0<+^^/[!=?W<$HH]GQ:
MBTMRWH0>E+2X#!HGK9>^BE&]T 4&?,M1I@OZ$OD)[]V9,(^2"*JG316SC%1>
MRN5S3A2RA%#CP<X@@&,,%_!53%D:>H#SD LLIGSJEB0*.<Q4@>M(Y@4OPS@A
M  VQNA!2*-ABQ4PZ*XJX8'K$7C2* [C^%]PHXVK@S&I"0;,JBAK((57(F2ED
MD8&!0 ,&MY0+BBEREQ[5)84:SG1VD-*LIXD*R EAZ)@I$T<*!@P-.-RP,(:,
M0\!Y7$?>7!)2[;PI(4AIY0*HG'2BX&6,&L-M.09PD*UBOH3$Q^&2#W3HXJC
MC!>ZA&2C[$L8MR30)*960@EK>)A]O%J*<2[)V/'VE*G!]3J9?%P]/VZ]@"5D
M&AU(W@:L"*_-9P@O^+H"<!D2/T(DP1!\$Z:FYU+DE"=P37]E#E\T894PIHN]
M0:]>_@7 *2'467501"H#P"V!,#6MB OT""/H4QC<0H\K4_+.J,&94H:69JX.
M*<@)A>B8-3N)%DLOWH#< F0F^WM]5*N#7S*X6D,_H>$*WL]FH0\QN8YU]4<'
M&U.JZ4P_5U"K@1-JZLJR,3>3VX'"$.26A^ :(1HCRNLC:S71&$+\!:-D.2(D
M:569%FTL7[53+C*7&NJ$IMKY-;(9LP#"!&0V;N@H'1H,BH#T.M*BC66W=LI%
MCE-#G=!1.[]&ODLMP%9/;NAH#)%8P2@FS2[J V-2A+EZ1TIM6]=43CNA"SFG
M1IUR=0\$K#H!<[A 24S-E__0IXD719NQ%P9:&4B!!M6@(5H2A03EBC;4U&02
MR=& PQV0BIA<SZ+@3/3I1HDTNFQ!3;6R@*$)<T(N>FZ:10T3!+AZRGIQ(]7<
MH7@LUE8-5_.6G*.&&GNI:B%;O$LI<$YHJ(6<9E4;&*X@]N;0F3Q5#D5$4:I*
MVS4DM; A)0UUF:(D<.>$I>;815]5954RGKTD5X37,=6I\4837AOM2MI3@9W0
M5Q>&^G5]9:U5-.9")DPG\?(9O8+3D)!D(4;#+L/9#&+(BEJONKX.3,EPM\!R
M7?:S=D*H.U%N3)9)YU477L#6#=CZ<:,15Z_MGXAH(3P^>Q@^HRB ^('JNZ)Z
M.C W]K)+8-M!F3[63DAW)\JR81Q%^EZ1HZSU6'()'B!-<.R6@N\@'<4^6F@'
MC+N9V5.K.@BU1ILVCBI32;2G'ID?D#IR2X&-D=-^2M29VU-D>U!J9:IM'55H
M*^&>2E6.CUO4K20_/)%B#$0GV<Z6IM3:,Y1<J!W-G-!H/ZYU>2HS]Q,IC6&Y
M58O>TV>(=ZI %9;VZDYM*.IJ4VKFA!K[<>U960I73M20WC2)/'P3$MHZ U&#
M-58+MM$MZCT5T EMM;%KU&TI'G #^W,3)?6TO$-;!;28,R7=UW*4&SK14>N<
M "T-T^=YNZM:6BV,3Q_KII\6N!-"ZL91,Y7,I+AF'IF*N!(RF'O>,E-81$E^
M9"NU[,#WXGW[!I'Z;H0*C DY:>EQ 4D!9B0C_9) ^XU3#95M.RK^RF%_ T-*
M<3A-J,A6%+'&#X;&JZ'&6ZZ\[I'#K,VBE]0R,HP358N&6.<I]%8RE&B#\T4?
M6F5(4::$H:&8ZT("<4(6:EYU5:3O0N75-U9EL=V15:J'ZFGSN]HV%5 ^YT31
M2PCUV-+6UJ12Q0*KXHS!::.R153982<*N,I%-A/4PIHH_3HY*ZOC-&OB7%L)
MU[[^S>9R-Q1_8>W0C$%I+;9VO5L'(X,3ZCH&4)I3UV+AA&PZTY3-K/LR'(Z+
M7%^RM=D?.@R"D'/PHK^?G*VV"\/U,^I:;<RU$SK2WS8>6@R<D%E7ECUZX5FS
MH[S77[K5G^E9=1ASA@_0YQO0;53[/,AAQF;(:4@6\^ D&">$HR'6F-.&,8HA
M2@A3B-BM%-:6L.1.+.T1\0 )]2@4.Y>PGXJO;DA1IJ2BH9@K10)Q0BAJ7G6=
ME)"LWJ 0+\(X%0@W?*<O<KQ!&V5*DLW#VN$VU*(B+9--'>N<?A0$^PG)=+MG
M/J=99:GH]Z@!C+5HI,2*YDOEK!-*D%)J]'_,YUCTNX,B[3C0"Y+39NVL#0F)
M=CZ_$FJX7:(D6VN;-'!.B*6%G+*-4A-+9F[SQ>F1OHRQ?X\G!%\1&BX$LUM(
MGU&@TU$W,U.:ZA-$KJ\N-DYHK0?1NN[2[S*-<>A#@#"8/#Z K0N0^K IOO(7
M0-H2F09K;%BGC6XQN*,".B&H-G:-@9[29U3<3("E,.X0_1T6;3FHK<2ZF5EH
M,;4&(6E'*6V<T%P/HKW;7,PA8![!UJ7-.NV:W1#&,N]U&,6!8FA#!32E-SW1
M7&%RE!.:TE*KJR@#%[U!AZ#T)70+8R,U\I<)G*"K-1<U__9./$/L)O%73'DR
M[&5M25!=0E*H3&?JHO0Z\&W3(P@2,=LJ\\*_@E3R<V@GK\K"? I1).K=^]EO
M: $O."V\N?%>NRM5[\*F7+L$I].LSMY9X78@W56]A2NN7^X,9-X <^>0B"]#
M\@>K^,-9Z&>13[SUKS"&LY"2[D)N=V-3S%V#U FZS8>SHNY(O*NPZ^ZXOIE#
MD'MT0]LL>;!HLGA'BR7_*A8C/ VCD&YT;T([^K&D[GYA*N3=S8F+^N[%O+T=
M7'+'55UWZ$C_4/O[E YLH8>HY;U*C71"<JWT=)U$KKQC28+HU+_8 %N43WL/
M8PWIJGRZ]S$6N==^QV)Y>!A!<H?H _\V+2[J8EU2[6-L8_"^6T"RH7R]I1,*
M[$U7.\S//(ANQLQ'>4Z1O2F/XNO(%Q$BK+E[&R]#/K].-1=-!S;6P=U*N.C6
M5B*=T%8KO487=OHA:V'!OU4]"1?BK>+V;CPJ?<6([&6*VB[+,@7A";N 9+J:
M F-R6::47GE99@5@73,Z5E*IB(_=VIF2EG)<S M9Z\;/U%BC=8J.;J5*D0&M
MJZ,+.X5*P@5O+]5J$>LYB<?1.H%$B32N'/TT$07,+=5TF@Q2U8SUN1\Y^3&&
M <6+.)!\(%6#,RT3*<VZ2"H@IR0B8Z85"#<HC:=S,YNIZ"(F 6Z32!UH(PDU
MB<HRT!;EE$JDU-ISSP6*21A ;%LHOZ'7;01=DH_*P+1P],3K I*CG1*2EJ).
M4(> F39592]-%2TR]LH67",Q@^G)BQ0UD19M;/ER.^5B.;,:ZH2>VODUECO7
M&L/"$LP0KO8F\BW0H<7:2MI[T%IEM5G9[\G15UYZ$R<4UYWG&SMY+&X$*(U1
M/;"FAUO5G&)P38=U5V7Z ;:N\K(]Z"9X?HT#'&WFC]!/<$A#J)A3H\$:E96.
M;D53,J [@M*PD[>YF %D%KPAOS6R-(6?$[I:8U^L5E%%6 (8%4B#6$45Q5EW
MI%"G)"__JS7$?LCJ$P&U4>)?L)>NW+[V0BP:9:J(9$BC&E!3K8BA"7-'%4IN
M<GD(>+H\GANDC6;#*JG6:9O;%RJT>O$<S\>^+*>T&9C23#?BN73T:"<4U(EB
M74C-#+,!MQY^@31;EIA^KOJ0[R/HF]]F=((]L0P.XU_Y_";5Z+D<9FP[; W)
M8C-L"<8)U6B(-3;"3J& 8;DF^,P+UIJ=;LH-6CM[N&R#4&S?4@>8EX9LTY;J
M6<?DH!D#EPC!SF#X+<71!.(%N9]-<,#HZ'IH=&!C77^MA(N>/R72"9VTTFOT
M^[%6"@Y9#2&LQ/3\IHJ,5QN<N;ICI7;>7*4AH;6M,THGG9""C%%C6T+S_1P%
MK4E(%8V&*L!X\5:(-<I7G'6K@,N4&CF!GS,]^S>)X.G)],=3GJX"M*10-0*M
M1!J;UZNG6DSBE<.<D(&>6V-Z+D,##A^<5MH)F:7YG6Z[BT4'-KBS;4?)J)%.
MJ*:5GFP'6[?$D]9_XMKJO?]D(+,914:PFE7*""?$H:35W-<>+6UMX5>6[P0O
M8MHER92!-G),DZ@LQ6Q13LA!2ZUK@IED&S[:SC%:J6BPEC*,6C!*H!.::6/7
M)[U8DT[^"MVVP:P"9S;/*&A64\W$P;UD=<P:KS-VMXU-J5XF6#!0QK(%F)5
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M@'(  .JZ   +              "  0    !I;6=?,# Q+FIP9U!+ 0(4 Q0
M   ( ,]*LU;W$;0:\((  %7.   +              "  :ER  !I;6=?,# R
M+FIP9U!+ 0(4 Q0    ( ,]*LU:]4F-48QP! !\1"0 6              "
M <+U  !T:71A;G!H87)M85]D968Q-&$N:'1M4$L! A0#%     @ STJS5F^M
MN(1<!   _A,  !$              ( !61(" '1T;G M,C R,C$R,S$N>'-D
M4$L! A0#%     @ STJS5DZ/XG'W!   6R@  !4              ( !Y!8"
M '1T;G M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( ,]*LU8[+?U34!$
M ('<   5              "  0X< @!T=&YP+3(P,C(Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    " #/2K-6@>1 FA@-  !&J0  %0              @ &1+0(
K='1N<"TR,#(R,3(S,5]P<F4N>&UL4$L%!@     '  < O@$  -PZ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
